Note: Descriptions are shown in the official language in which they were submitted.
WO 2023/031103
PCT/EP2022/073922
- 1 -
TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDER1VIAL
ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-
CARBOXYLIC ACID
TECHNICAL FIELD OF THE INVENTION
[0001] The present invention relates to a transdermal therapeutic system (TTS)
for the
transdermal administration of guanfacine to the systemic circulation, and
processes of
manufacture, method of treatments and uses thereof
BACKGROUND OF THE INVENTION
[0002] The active agent guanfacine (also known as N-(aminoiminomethyl)-2,6-
dichloro-
benzeneacetamide, C9H9C12N30, CAS No. 29110-47-2) is a sympatholytic drug used
to treat
hypertension and attention deficit hyperactivity disorder (ADHD). It is a
centrally acting
alpha(2)-adrenergic receptor agonist. It has the following chemical formula.
0 NH
NANH2
CT
[0003] Currently, guanfacine is commercially available, e.g., in the form of
immediate or
controlled release tablets comprising from 1 to 4 mg guanfacine. The tablets
are suitable for once
daily administration.
[0004] However, the oral administration of active agents has disadvantages,
e.g., in terms of
patient compliance. Furthermore, it is not possible to quickly terminate the
therapy, e.g. in light
of overdosing or signs of intolerance, once the prolonged release tablet has
been ingested.
[0005] Therefore, a need exists for a transdermal therapeutic system for the
transdermal
administration of guanfacine. In particular, a need exists for a TTS, which is
suitable for multi
day therapy with a single application thereby improving patient compliance.
OBJECTS AND SUMMARY OF THE INVENTION
[0006] It is therefore an object of the present invention to provide a TTS for
the transdermal
administration of guanfacine. In particular, it is an object of the present
invention to provide a
TTS for the transdermal administration of guanfacine providing a skin
permeation rate which is
sufficient for achieving a therapeutically effective dose.
[0007] It is a further object of the present invention to provide a TTS for
the transdermal
administration of guanfacine providing therapeutically effective amounts of
guanfacine for at
least 24 hours, preferably at least 72 hours, more preferably about 84 hours.
In particular, it is an
object of the present invention that the therapeutically effective amounts are
provided over the
whole time period, wherein the TTS is applied to the skin, allowing an around
the clock
treatment by exchanging the TTS after a certain application time of, e.g., at
least 24 hours,
preferably at least 72 hours, more preferably about 84 hours.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 2 -
[0008] It is a further object of the present invention to provide a TTS for
the transdermal
administration of guanfacine, wherein the fluctuation in guanfacine blood
plasma concentration
is reduced when compared to oral administration, in particular at steady
state.
[0009] It is a further object of the present invention to provide a TTS for
the transdermal
administration of guanfacine with a high active ingredient utilization.
[0010] It is another object of the present invention to provide a TTS for the
transdermal
administration of guanfacine which complies with the needs of a convenient
application in view
of size and thickness and/or which is easy and cost-efficient to manufacture.
[0011] It is a further object of the present invention, to provide a process
for the preparation of
the TTS.
[0012] These objects and others are accomplished by the present invention,
which according to
one aspect relates to a transdermal therapeutic system for the transdermal
administration of
guanfacine comprising a guanfacine-containing layer structure, said guanfacine-
containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer comprising guanfacine and
a mono-carboxylic acid.
[0013] It has been found that the TTS according to the present invention,
which comprises
guanfacine and a mono-carboxylic acid, provides advantageous properties in
terms of the active
ingredient utilization and the constant and continuous guanfacine delivery. In
particular, the TTS
according to the present invention provides suitable permeation rates and
suitable permeated
amounts of guanfacine over a time period of at least 24 hours, preferably at
least 72 hours, more
preferably about 84 hours.
According to certain embodiments, the invention also relates to a transdermal
therapeutic system
for the transdermal administration of guanfacine as described above, wherein
the guanfacine-
containing layer is a guanfacine-containing matrix layer comprising:
i) guanfacine and a mono-carboxylic acid; and
ii) at least one polymer.
[0014] In certain preferred embodiments, the invention relates to a
transdermal therapeutic
system as described above, wherein the guanfacine and the mono-carboxylic acid
in the
guanfacine-containing layer are present in the form of a pre-mixture.
[0015] In a more preferred embodiment, the invention relates to a transdermal
therapeutic
system as described above, wherein the guanfacine and the mono-carboxylic acid
in the
guanfacine-containing layer are present in the form of a pre-mixture, wherein
said pre-mixture is
obtainable by a dry-grinding method or a slurry method.
[0016] In certain preferred embodiments, the at least one polymer is
- a mixture of an acrylic polymer and at least one silicone-based polymer;
- a mixture of two silicone-acrylic hybrid polymers; or
- a mixture of two silicone-based polymers; or
- an acrylic polymer; or
- an acrylic polymer comprising a ¨OH group.
[0017] In another preferred embodiment, the guanfacine-containing layer
further comprises at
least one additive, preferably at least two additives selected from the group
consisting of
dispersing agents, permeation enhancers and solubilizers.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 3 -
[0018] According to one specific aspect, the present invention relates to a
transdermal
therapeutic system for the transdermal administration of guanfacine, said
guanfacine-containing
layer structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer,
comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount
of from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing
layer;
ii) a mixture of an acrylic polymer and at least one silicone-based polymer,
wherein
the acrylic polymer is present in an amount of from 20 to 55 % by weight and
the at
least one silicone-based polymer is present in an amount of from 20 to 55 % by
weight, based on the total weight of the guanfacine-containing layer;
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer; and
iv) olcyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight
of the guanfacine-containing layer.
[0019] According to another specific aspect, the present invention relates to
a transdermal
therapeutic system for the transdermal administration of guanfacine,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyethylene glycol Cg-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
[0020] According to a further specific aspect, the present invention relates
to a transdermal
therapeutic system for the transdermal administration of guanfacine,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-based polymers, wherein the first silicone-based
polymer is
present in an amount of from 20 to 55 % by weight, and the second silicone-
based
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 4 -
polymer is present in an amount of from 20 to 55 % by weight, based on the
total weight
of the guanfacine-containing layer;
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) olcyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
[0021] According to another specific aspect, the present invention relates to
a transdermal
therapeutic system for the transdermal administration of guanfacine,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer in an amount of from 65 to 95 % by weight, based on the
total
weight of the guanfacine-containing layer;
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) olcyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
[0022] According to a further specific aspect, the present invention relates
to a transden-nal
therapeutic system for the transdermal administration of guanfacine,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer comprising a ¨OH group in an amount of from 65 to 95 %
by
weight, based on the total weight of the guanfacine-containing layer;
iii) polyethylene glycol Cg-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
[0023] According to certain embodiments of the invention, the transdermal
therapeutic system
according to the invention is for use in a method of treating a human patient,
preferably for use
in a method of treating a human patient at the age of from 6 to 17. In
particular, the transdermal
therapeutic system according to the invention is for use in a method of
treating hypertension or
attention deficit hyperactivity disorder (ADHD) and/or as adjunctive therapy
to stimulant
medications in a human patient, preferably in a human patient at the age of
from 5 to 17. In
connection with these medical uses, the TTS according to the invention is
preferably applied to
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 5 -
the skin of the patient for at least 24 hours, more preferably at least 72
hours, most preferably
about 84 hours.
[0024] According to certain embodiments, the invention further relates to a
method of treating
a human patient, preferably a human patient at the age of from 6 to 17, by
applying a transdermal
therapeutic system according to the invention to the skin of the patient. In
particular, the present
invention relates to a method of treating hypertension or attention deficit
hyperactivity disorder
(ADHD) in a human patient, preferably a human patient at the age of from 6 to
17, by applying a
transdermal therapeutic system according to the invention to the skin of the
patient. In
connection with these methods, it is preferred that the TTS according to the
invention is applied
to the skin of the patient for at least 24 hours, more preferably at least 72
hours, most preferably
about 84 hours.
[0025] According to another embodiment, the present invention relates to a
transdermal
therapeutic system for the transdermal administration of guanfacine as defined
above, having an
AUC0_24h of about 10 to 600 ng*h/ml, preferably of about 20 to 400 ng*h/ml;
and/or having an
AUC0_72h of about 30 to 1800 ng*h/ml, preferably of about 60 to 1200 ng*h/ml;
and/or having an
AUC0_84h of about 35 to 2100 ng*h/ml, preferably of about 70 to 1400 ng*h/ml;
and/or having a
Cm ax to C84 ratio of less than 3.5; and/or having a Crnaõ to C72 ratio of
less than 3.0; and/or having
a Cmax to C24 ratio of less than 2Ø
[0026] According to a further aspect, the present invention relates to a
process for
manufacturing an active pharmaceutical-containing layer for use in a
transdermal therapeutic
system comprising the steps of:
1) combining at least the components
(i) a pharmaceutically active agent; and
(ii) at least one mono-carboxylic acid;
to obtain a pre-mixture;
2) combining
(i) the pre-mixture of step 1); and
(ii) at least one polymer;
to obtain a coating composition
3) coating the coating composition onto a backing layer or a release liner
to obtain a coated
coating composition; and
4) drying the coated coating composition to form the active
pharmaceutical-containing
layer.
[0027] According to yet another aspect, the present invention relates to a
transdermal
therapeutic system obtainable by the process according to the invention.
DEFINITIONS
[0028] Within the meaning of this invention, the term "transdermal therapeutic
system" (TTS)
refers to a system by which the active agent (e.g. guanfacine) is administered
to the systemic
circulation via transdermal delivery and refers to the entire individual
dosing unit that is applied,
after removing an optionally present release liner, to the skin of a patient,
and which comprises a
therapeutically effective amount of active agent in an active agent-containing
layer structure and
optionally an additional adhesive overlay on top of the active agent-
containing layer structure.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 6 -
The active agent-containing layer structure may be located on a release liner
(a detachable
protective layer), thus, the TTS may further comprise a release liner. Within
the meaning of this
invention, the term "TTS" in particular refers to systems providing
transdermal delivery,
excluding active delivery for example via iontophoresis or microporation.
Transdermal
therapeutic systems may also be referred to as transdermal drug delivery
systems (TDDS) or
transdermal delivery systems (TDS).
[0029] Within the meaning of this invention, the term "active agent-containing
layer structure"
or "guanfacine-containing layer structure "refers to the layer structure
comprising a backing
layer and an active agent-containing layer. The active agent-containing layer
structure comprises
a therapeutically effective amount of an active agent. Preferably, the active
agent-containing
layer structure is an active agent-containing self-adhesive layer structure.
Preferably, the active
agent is guanfacine.
[0030] Within the meaning of this invention, the term "therapeutically
effective amount" refers
to a quantity of active agent in the TTS sufficient to provide, if
administered by the TTS to a
patient, the desired pharmacological effect. With regard to guanfacine, the
term "therapeutically
effective amount" preferably refers to a quantity of active agent in the TTS
which is, if
administered by the TTS to a patient, sufficient to trcat, prevent or reduce
hypertension or
attention deficit hyperactivity disorder (ADHD) or which is sufficient for
adjunctive therapy to
stimulant medications in a human patient. A TTS usually contains more active
in the system than
is in fact provided to the skin and the systemic circulation. This excess
amount of active agent is
usually necessary to provide enough driving force for the delivery from the
TTS to the systemic
circulation.
[0031] Within the meaning of this invention, the terms "active", "active
agent", and the like, as
well as the term "guanfacine" refer to the respective active agent in any
pharmaceutically
acceptable chemical and morphological form and physical state. Preferably, the
active agent in
the present invention is present in the form of a "co-salt", meaning that the
active agent,
preferably guanfacine, is present in a pre-mixture together with at least one
mono-carboxylic
acid, such that a e.g proton transfer or the formation of hydrogen bonds is
possible, and
preferably at least partly a guanfacine salt of the mono-carboxylic acid is
formed. In other words,
the active agent, preferably guanfacine, may at least partly be present in
protonated from. Further
forms include without limitation the active agent in its protonated or
partially protonated form,
deprotonated or partially deprotonated form, salts, or cocrystals. Further
pharmaceutically
acceptable chemical and morphological form and physical states include
solvates, hydrates,
clathrates, complexes and so on, as well as the active agent in the form of
particles, which may
be micronized, crystalline and/or amorphous, and any mixtures of the
aforementioned forms. The
active agent, where contained in a medium such as a solvent, may be dissolved
or dispersed or in
part dissolved and in part dispersed. However, in connection with the active
agent, preferably
guanfacine, and the mono-carboxylic acid it is to be understood that any form
obtained in the
guanfacine-containing layer based on the pre-mixture of guanfacine and the
mono-carboxylic
acid is covered by the present invention, including, e.g., the option of the
guanfacine and the
mono-carboxylic acid co-existing without chemical interaction, i.e. proton
transfer or the
formation of hydrogen bonds, as well as the option of the formation of a co-
salt as described
above. Preferably, the guanfacine free base and the mono-carboxylic acid may
form together a
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 7 -
co-salt or any other type of acid addition salt, so that the guanfacine-
containing layer preferably
comprises at least partly a co-salt or any other type of acid addition salt of
guanfacine free base
and the mono-carboxylic acid. In other words, the guanfacine-containing layer
preferably
comprises the guanfacine at least partly in protonated form and the mono-
carboxylic acid at least
partly in deprotonated form.
[0032] When the active agent is mentioned to be used in a particular form in
the manufacture
of the TTS, this does not exclude interactions between this form of the active
agent and other
ingredients of the active agent-containing layer structure, e.g., when the
active agent is provided
in a pre-mixture with the mono-carboxylic acid such that a co-salt, or any
other type of acid
addition salt is formed, which may still be present in the final TTS. This
means that the active
agent may be present in the final TTS in protonated or partially protonated /
or deprotonated or
partially deprotonated form or in the form of an acid addition salt, or, if it
is included in the form
of a salt, parts of it may be present as free base in the final TTS. Unless
otherwise indicated, in
particular the amount of the active agent in the layer structure relates to
the amount of the active
agent included in the TTS during manufacture of the TTS and is calculated
based on the active
agent itself or the pre-mixture of active agent and the mono-carboxylic acid,
but not on other
forms thereof.
[0033] The active agent starting material included in the TTS during
manufacture of the TTS
may be in the form of particles. The active agent may e.g. be present in the
active agent-
containing layer structure in the form of particles and/or dissolved.
[0034] Within the meaning of this invention, the term "particles" refers to a
solid, particulate
material comprising individual particles, the dimensions of which are
negligible compared to the
material. In particular, the particles are solid, including plastic/deformable
solids, including
amorphous and crystalline materials.
[0035] Within the meaning of this invention, the term "dispersing" refers to a
step or a
combination of steps wherein a starting material (e.g. guanfacine) is not
totally dissolved.
Dispersing in the sense of the invention comprises the dissolution of a part
of the starting
material (e.g. guanfacine particles), depending on the solubility of the
starting material (e.g. the
solubility of guanfacine in the coating composition).
[0036] There are two main types of TTS for active agent delivery, i.e. matrix-
type TTS and
reservoir-type TTS. The release of the active agent in a matrix-type TTS is
mainly controlled by
the matrix including the active agent itself. In contrast thereto, a reservoir-
type TTS typically
needs a rate-controlling membrane controlling the release of the active agent.
In principle, also a
matrix-type TTS may contain a rate-controlling membrane. However, matrix-type
TTS are
advantageous in that, compared to reservoir-type TTS, usually no rate
determining membranes
are necessary and no dose dumping can occur due to membrane rupture. In
summary, matrix-
type transdermal therapeutic systems (TTS) are less complex in manufacture and
easy and
convenient to use by patients.
[0037] Within the meaning of this invention, "matrix-type TTS" refers to a
system or structure
wherein the active is homogeneously dissolved and/or dispersed within a
polymeric carrier, i.e.
the matrix, which forms with the active agent and optionally remaining
ingredients a matrix
layer. In such a system, the matrix layer controls the release of the active
agent from the TTS.
Preferably, the matrix layer has sufficient cohesion to be self-supporting so
that no sealing
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 8 -
between other layers is required. Accordingly, the active agent-containing
layer may in one
embodiment of the invention be an active agent-containing matrix layer,
wherein the active agent
is homogeneously distributed within a polymer matrix. In certain embodiments,
the active agent-
containing matrix layer may comprise two active agent-containing matrix
layers, which may be
laminated together. Matrix-type TTS may in particular be in the form of a
"drug-in-adhesive"-
type TTS referring to a system wherein the active is homogeneously dissolved
and/or dispersed
within a pressure-sensitive adhesive matrix. In this connection, the active
agent-containing
matrix layer may also be referred to as active agent-containing pressure
sensitive adhesive layer
or active agent-containing pressure sensitive adhesive matrix layer. A TTS
comprising the active
agent dissolved and/or dispersed within a polymeric gel, e.g. a hydrogel, is
also considered to be
of matrix-type in accordance with present invention. It is to be understood
that a TTS comprising
an active agent-containing matrix layer may additionally also comprise a skin
contact layer.
[0038] Reservoir-type TTS are not to be understood as being of matrix-type
within the meaning
of the invention.
[0039] Within the meaning of this invention, the term "active agent-containing
layer" refers to
a layer containing the active agent and providing the area of release. The
term covers active
agent-containing matrix layers and active agent-containing reservoir layers.
If the active agent-
containing layer is an active agent-containing matrix layer, said layer is
present in a matrix-type
TTS. If the polymer is a pressure-sensitive adhesive, the matrix layer may
also represent the
adhesive layer of the TTS, so that no additional skin contact layer is
present. Alternatively, an
additional skin contact layer may be present as adhesive layer, and/or an
adhesive overlay is
provided. The additional skin contact layer is typically manufactured such
that it is active agent-
free. However, due to the concentration gradient, the active agent will
migrate from the matrix
layer to the additional skin contact layer over time, until an equilibrium is
reached. The
additional skin contact layer may be present on the active agent-containing
matrix layer or
separated from the active agent-containing matrix layer by a membrane,
preferably a rate
controlling membrane. Preferably, the active agent-containing matrix layer has
sufficient
adhesive properties, so that no additional skin contact layer is present. If
the active agent-
containing layer is an active agent-containing reservoir layer, said layer is
present in a reservoir-
type TTS, and the layer comprises the active agent in a liquid reservoir. In
addition, a skin
contact layer may be present, in order to provide adhesive properties. The
additional skin contact
layer is typically manufactured such that it is active agent-free. If the skin
contact layer is free of
active agent the active agent will migrate, due to the concentration gradient,
from the reservoir
layer to the skin contact layer over time, until an equilibrium is reached.
Additionally, an
adhesive overlay may be provided.
[0040] As used herein, the active agent-containing layer is preferably an
active agent-
containing matrix layer, and it is referred to the final solidified layer.
Preferably, an active agent-
containing matrix layer is obtained after coating and drying the solvent-
containing coating
composition as described herein. Alternatively, an active agent-containing
matrix layer is
obtained after melt-coating and cooling. The active agent-containing matrix
layer may also be
manufactured by laminating two or more such solidified layers (e.g. dried or
cooled layers) of
the same composition to provide the desired area weight. Preferably, the
matrix layer is a
pressure sensitive adhesive matrix layer. Optionally, an adhesive overlay may
be present.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 9 -
[0041] Within the meaning of this invention, the term "pressure-sensitive
adhesive" (also
abbreviated as "PSA") refers to a material that in particular adheres with
finger pressure, is
permanently tacky, exerts a strong holding force and should be removable from
smooth surfaces
without leaving a residue. A pressure sensitive adhesive layer, when in
contact with the skin, is
"self-adhesive", i.e. provides adhesion to the skin so that typically no
further aid for fixation on
the skin is needed. A "self-adhesive" layer structure according to the present
invention includes a
pressure sensitive adhesive layer for skin contact which may be provided in
the form of a
pressure sensitive matrix layer or in the form of an additional layer, i.e. a
pressure sensitive
adhesive skin contact layer. An adhesive overlay may still be employed to
advance adhesion.
The pressure-sensitive adhesive properties of a pressure-sensitive adhesive
depend on the
polymer or polymer composition used.
[0042] Within the meaning of this invention, the term "silicone acrylic hybrid
polymer" refers
to a polymerization product including repeating units of a silicone sub-
species and an acrylate-
sub species. The silicone acrylic hybrid polymer thus comprises a silicone
phase and an acrylic
phase. Preferably, the silicone acrylic hybrid polymer comprises a silicone
phase and an acrylate
phase, i.e. silicone sub-species and acrylate sub-species, in a certain weight
ratio, e.g. from 60:40
to 40:60. The term "silicone acrylic hybrid" is intended to denote more than a
simple blend of a
silicone-based sub-species and an acrylate-based sub-species. Instead, the
term denotes a
polymerized hybrid species that includes silicone based sub-species and
acrylate-based sub-
species that have been polymerized together. The silicone acrylic hybrid
polymer may also be
referred to as a "silicone acrylate hybrid polymer" as the terms acrylate and
acrylic are generally
used interchangeably in the context of the hybrid polymers used in the present
invention.
[0043] Within the meaning of this invention, the term "silicone acrylic hybrid
pressure-
sensitive adhesive" refers to a silicone acrylic hybrid polymer in the form of
a pressure-sensitive
adhesive. Silicone acrylic hybrid pressure-sensitive adhesives are described,
for example, in EP 2
599 847 and WO 2016/130408. Examples of silicone acrylic hybrid pressure-
sensitive adhesives
include the PSA series 7-6100 and 7-6300 manufactured and supplied in n-
heptane or ethyl
acetate by DuPontTM (7-610X and 7-630X; X=I n-heptane-based / X=2 ethyl
acetate-based). It
was found that, depending on the solvent in which the silicone acrylic hybrid
PSA is supplied,
the arrangement of the silicone phase and the acrylic phase providing a
silicone or acrylic
continuous external phase and a corresponding discontinuous internal phase is
different. If the
silicone acrylic hybrid PSA is supplied in n-heptane, the composition contains
a continuous,
silicone external phase and a discontinuous, acrylic internal phase. If the
silicone acrylic hybrid
PSA composition is supplied in ethyl acetate, the composition contains a
continuous, acrylic
external phase and a discontinuous, silicone internal phase.
[0044] Within the meaning of this invention, the term "non-hybrid polymer" is
used
synonymously for a polymer which does not include a hybrid species.
Preferably, the non-hybrid
polymer is a pressure-sensitive adhesive (e.g. a silicone- or acrylate-based
pressure-sensitive
adhesives). A preferred non-hybrid polymer according to the present invention
is a "silicone-
based polymer", which, as used herein, is a polymer obtainable by
polycondensation of silanol
endblocked polydimethylsiloxane with a silicate resin. Another preferred non-
hybrid polymer is
an acrylate-based polymer, i.e. an acrylic polymer, which, as used herein, is
a polymer
obtainable from one or more monomers selected from acrylic acid,
butylacrylate, 2-
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 10 -
ethylhexylacrylate, glycidylmethacrylate, 2-hydroxyethylacrylate,
methylacrylate,
methylmethacrylate, butylmethacrylate, t-octylacrylamide, and vinylacetate.
[0045] As used herein, an active agent-containing matrix layer is a layer
containing the active
agent dissolved or dispersed in at least one polymer, or containing the active
agent dissolved in a
solvent to form an active agent-solvent mixture that is dispersed in the form
of deposits (in
particular droplets) in at least one polymer. Preferably, the at least one
polymer is a polymer-
based pressure-sensitive adhesive (e.g. an acrylic polymer). Within the
meaning of this
invention, the term "pressure-sensitive adhesive layer" refers to a pressure-
sensitive adhesive
layer obtained from a solvent-containing adhesive coating composition after
coating on a film
and evaporating the solvents.
[0046] Within the meaning of this invention, the term "skin contact layer"
refers to the layer
included in the active agent-containing layer structure to be in direct
contact with the skin of the
patient during administration. When the TTS comprises a skin contact layer,
the other layers of
the active agent-containing layer structure do not contact the skin and do not
necessarily have
self-adhesive properties. As outlined above, an additional skin contact layer
attached to the
active agent-containing layer may over time absorb parts of the active agent.
The sizes of the
skin contact layer and thc active agent-containing layer arc usually
coextensive and correspond
to the area of release. However, the area of the skin contact layer may also
be greater than the
area of the active agent-containing layer. In such a case, the area of release
still refers to the area
of the active agent-containing layer.
[0047] Within the meaning of this invention, the term "area weight" refers to
the dry weight of
a specific layer, e.g. of the matrix layer, provided in g/m2. The area weight
values are subject to a
tolerance of + 10 %, preferably + 7.5 %, due to manufacturing variability.
[0048] If not indicated otherwise "%" refers to weight-% (% by weight).
[0049] Within the meaning of this invention, the term "polymer" refers to any
substance
consisting of so-called repeating units obtained by polymerizing one or more
monomers, and
includes homopolymers which consist of one type of monomer and copolymers
which consist of
two or more types of monomers. Polymers may be of any architecture such as
linear polymers,
star polymer, comb polymers, brush polymers, of any monomer arrangements in
case of
copolymers, e.g. alternating, statistical, block copolymers, or graft
polymers. The minimum
molecular weight varies depending on the polymer type and is known to the
skilled person.
Polymers may e.g. have a molecular weight above 2000, preferably above 5000
and more
preferably above 10,000 Dalton. Correspondingly, compounds with a molecular
weight below
2000, preferably below 5000 or more preferably below 10,000 Dalton are usually
referred to as
oligomers.
[0050] Within the meaning of this invention, the term "cross-linking agent"
refers to a
substance which is able to cross-link functional groups contained within the
polymer.
[0051] Within the meaning of this invention, the term "adhesive overlay"
refers to a self-
adhesive layer structure that is free of active agent and larger in area than
the active agent-
containing structure and provides additional area adhering to the skin, but no
area of release of
the active agent. It enhances thereby the overall adhesive properties of the
TTS. The adhesive
overlay comprises a backing layer that may provide occlusive or non-occlusive
properties and an
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 11 -
adhesive layer. Preferably, the backing layer of the adhesive overlay provides
non-occlusive
properties.
[0052] Within the meaning of this invention, the term "backing layer" refers
to a layer which
supports the active agent-containing layer or forms the backing of the
adhesive overlay. At least
one backing layer in the TTS and usually the backing layer of the active agent-
containing layer is
substantially impermeable to the active agent contained in the layer during
the period of storage
and administration and thus prevents active loss or cross-contamination in
accordance with
regulatory requirements. Preferably, the backing layer is also occlusive,
meaning substantially
impermeable to water and water-vapor. Suitable materials for a backing layer
include
polyethylene terephthalate (PET), polyethylene (PE), ethylene vinyl acetate-
copolymer (EVA),
polyurethanes, and mixtures thereof. Suitable backing layers are thus for
example PET
laminates, EVA-PET laminates and PE-PET laminates. Also suitable are woven or
non-woven
backing materials.
[0053] The TTS according to the present invention can be characterized by
certain parameters
as measured in an in vitro skin permeation test.
[0054] In general, the in vitro permeation test is performed in a Franz
diffusion cell, with 0.9 %
sodium chloride solution with 0.1 % sodium azide as antibacteriological agent.
[0055] Further, in vitro permeation test may be performed in a Franz diffusion
cell, with human
or animal skin and preferably with dermatomed Gottinger minipig with a
thickness of around
800 p,m and an intact epidermis, and with 0.9% sodium chloride solution (32 C
with 0.1 %
saline azide).
[0056] Where not otherwise indicated, the in vitro permeation test is
performed with
dermatomed Gottinger minipig skin with a thickness around 8001.1m and an
intact epidermis, and
with 0.9% Sodium chloride solution as receptor medium (32 C with 0.1 % saline
azide). The
amount of active permeated into the receptor medium is determined in regular
intervals using a
HPLC method) with a UV photometric detector by taking a sample volume. The
receptor
medium is completely or in part replaced by fresh medium when taking the
sample volume, and
the measured amount of active permeated relates to the amount permeated
between the two last
sampling points and not the total amount permeated so far.
[0057] Thus, within the meaning of this invention, the parameter "permeated
amount" is
provided in p.g/cm2 and relates to the amount of active permeated in a sample
interval at certain
elapsed time. E.g., in an in vitro permeation test as described above, wherein
the amount of
active permeated into the receptor medium has been e.g. measured at hours 0,
4, 8, 16, 24, 32,
40, 48, 56, 64, 72 and 88 the "permeated amount" of active can be given e.g.
for the sample
interval from hour 8 to hour 16 and corresponds to the measurement at hour 16,
wherein the
receptor medium has been exchanged completely at hour S.
[0058] The permeated amount can also be given as a "cumulative permeated
amount",
corresponding to the cumulated amount of active permeated at a certain point
in time. E.g., in an
in vitro permeation test as described above, wherein the amount of active
permeated into the
receptor medium has been e.g. measured at hours 0, 4, 8, 16 and 24, the
"cumulative permeated
amount" of active at hour 16 corresponds to the sum of the permeated amounts
from hour 0 to
hour 4, hour 4 to hour 8 and hour 8 to hour 16.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 12 -
[0059] Within the meaning of this invention, the parameter "skin permeation
rate" for a certain
sample interval at certain elapsed time is provided in us/(cm2*h) and is
calculated from the
permeated amount in said sample interval as measured by in vitro permeation
test as described
above in 1.1g/em2, divided by the hours of said sample interval. E.g. the skin
permeation rate in an
in vitro permeation test as described above, wherein the amount of active
permeated into the
receptor medium has been e.g. measured at hours 0, 4, 8, 16 and 24, the "skin
permeation rate" at
hour 16 is calculated as the permeated amount in the sample interval from hour
8 to hour 16
divided by 8 hours.
[0060] A "cumulative skin permeation rate" can be calculated from the
respective cumulative
permeated amount by dividing the cumulative permeated amount by the elapsed
time. E.g. in an
in vitro permeation test as described above, wherein the amount of active
permeated into the
receptor medium has been e.g. measured at hours 0, 4, 8, 16 and 24, the
"cumulative skin
permeation rate" at hour 16 is calculated as the cumulative permeated amount
for hour 16 (see
above) divided by 16 hours.
[0061] Within the meaning of this invention, the above parameters "permeated
amount" and
"skin permeation rate" (as well as "cumulative permeated amount" and
"cumulative skin
permeation rate") refer to mean values calculated from at least 2 in vitro
permeation test
experiments. Where not otherwise indicated, the standard deviation (SD) of
these mean values
refer to a corrected sample standard deviation, calculated using the formula:
SD = i 2 nt 11(xi
i=1
wherein n is the sample size, {x1,x2,...xn} are the observed values and x is
the mean value of the
observed values.
[0062] The TTS according to the present invention can also be characterized by
certain
parameters as measured in an in vivo clinical study.
[0063] Within the meaning of this invention, the parameter "mean release rate"
refers to the
mean release rate in 1.1g/h (.tg/hour) or in mg/day over the period of
administration (e.g., 1 to 7
days) by which the active agent is released through the human skin into the
systemic circulation
and is based on the AUC obtained over said period of administration in a
clinical study.
[0064] Within the meaning of this invention, the term "extended period of
time" relates to a
period of at least or about 24 hours, at least or about 48 hours, at least or
about 84 hours, at least
or about 168 hours, at least or about 1 day, at least or about 3.5 days, or at
least or about 7 days,
or to a period of about 24 hours to about 168 hours or 1 to 7 day(s), or about
24 hours to about
84 hours or 1 to 3.5 day(s).
[0065] For a continuous drug treatment, the frequency of drug administration
is preferably kept
sufficiently high so as to maintain therapeutically effective blood plasma
concentration. In other
words, the interval between two dosage form administrations, also called
dosing interval, needs
to be adapted accordingly. Within the meaning of the present invention, the
term õdosing
interval" refers to the period of time between two consecutive TTS
administrations, i.e. the
interval between two consecutive points in time a TTS is applied to the skin
of the patient. Once
applied, the TTS is usually maintained on the skin of the patient for the
entire dosing interval and
only removed at the end of the dosing interval, at which time a new TTS is
applied to the skin.
E.g., if the dosing interval is 24 hours or 1 day, the TTS is applied to and
maintained on the skin
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 13 -
of the patient for 24 hours or 1 day. After 24 hours or 1 day, the TTS is
removed from the skin
and a new TTS is applied. Thus, a dosing interval of 24 hours or 1 day allows
a daily TTS
exchange mode in an around-the-clock treatment.
[0066] Within the meaning of this invention, the term "room temperature"
refers to the
unmodified temperature found indoors in the laboratory where the experiments
are conducted
and usually lies within 15 to 35 C, preferably about 18 to 25 C.
[0067] Within the meaning of this invention, the term "patient" refers to a
subject who has
presented a clinical manifestation of a particular symptom or symptoms
suggesting the need for
treatment, who is treated preventatively or prophylactically for a condition,
or who has been
diagnosed with a condition to be treated.
[0068] Within the meaning of this invention the term "pharmacokinetic
parameters" refers to
parameters describing the blood plasma curve, e.g. Cmaõ, C, and AUC112
obtained in a clinical
study, e.g. by single-dose, multi-dose or steady state administration of the
active agent-
containing TTS, e.g. the guanfacine-containing TTS to healthy human subjects.
The
pharmacokinetic parameters of the individual subjects are summarized using
arithmetic and
geometric means, e.g. a mean Cma,õ a mean AUC, and a mean AUCINF, and
additional statistics
such as the respective standard deviations and standard en-ors, the minimum
value, the maximum
value, and the middle value when the list of values is ranked (Median). In the
context of the
present invention, pharmacokinetic parameters, e.g. the Cõ,õõ, C, and AUC12
refer to geometric
mean values if not indicated otherwise. It cannot be precluded that the
absolute mean values
obtained for a certain TTS in a clinical study vary to a certain extent from
study to study. To
allow a comparison of absolute mean values between studies, a reference
formulation, e.g. in the
future any product based on the invention, may be used as internal standard. A
comparison of the
AUC per area of release of the respective reference product in the earlier and
later study can be
used to obtain a correction factor to take into account differences from study
to study.
[0069] Clinical studies according to the present invention refer to studies
performed in full
compliance with the International Conference for Harmonization of Clinical
Trials (ICH) and all
applicable local Good Clinical Practices (GCP) and regulations.
[0070] Within the meaning of this invention, the term "healthy human subject"
refers to a male
or female subject with a body weight ranging from 55 kg to 100 kg and a body
mass index
(BMI) ranging from 18 to 29.4 and normal physiological parameters, such as
blood pressure, etc.
Healthy human subjects for the purposes of the present invention are selected
according to
inclusion and exclusion criteria, which are based on and in accordance with
recommendations of
the ICH.
[0071] Within the meaning of this invention, the term "subject population"
refers to at least
five, preferably at least ten individual healthy human subjects.
[0072] Within the meaning of this invention, the term "geometric mean" refers
to the mean of
the log transformed data back-transformed to the original scale.
[0073] Within the meaning of this invention, the term "arithmetic mean" refers
to the sum of
all values of observation divided by the total number of observations.
[0074] Within the meaning of this invention, the parameter "AUC" corresponds
to the area
under the plasma concentration-time curve. The AUC value is proportional to
the amount of
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 14 -
active agent absorbed into the blood circulation in total and is hence a
measure for the
bioavailability.
[0075] Within the meaning of this invention, the parameter "AUCt1_t2" is
provided in
(ng / ml) h and relates to the area under the plasma concentration-time curve
from hour ti to t2
and is calculated by the linear trapezoidal method, unless otherwise
indicated. Other calculation
methods arc e.g. the logarithmic and linear log trapezoidal method.
[0076] Within the meaning of this invention, the parameter "Cmax" is provided
in (ng / ml) and
relates to the maximum observed blood plasma concentration of the active
agent.
[0077] Within the meaning of this invention, the parameter "Ct" is provided in
(ng / ml) and
relates to the blood plasma concentration of the active agent observed at hour
t.
[0078] Within the meaning of this invention, the parameter "tmax" is provided
in hours and
relates to the time point at which the Cmax value is reached. In other words,
tmaõ is the time point
of the maximum observed plasma concentration.
[0079] Within the meaning of this invention, the term "mean plasma
concentration" is provided
in (ng / ml) and is a mean of the individual plasma concentrations of active
agent, e.g.
guanfacine, at each point in time.
[0080] Within the meaning of this invention, thc term "coating composition"
refers to a
composition comprising all components of the matrix layer in a solvent, which
may be coated
onto the backing layer or release liner to form the matrix layer upon drying.
[0081] Within the meaning of this invention, the term "pressure sensitive
adhesive
composition" refers to a pressure sensitive adhesive at least in mixture with
a solvent (e.g. n-
heptane or ethyl acetate).
[0082] Within the meaning of this invention, the term "dissolve" refers to the
process of
obtaining a solution, which is clear and does not contain any particles, as
visible to the naked
eye.
[0083] Within the meaning of this invention, the term "solvent" refers to any
liquid substance,
which preferably is a volatile organic liquid such as methanol, ethanol,
isopropanol, acetone,
ethyl acetate, methylene chloride, hexane, n-heptane, toluene and mixtures
thereof
[0084] Within the meaning of this invention, the term "mono-carboxylic acid"
refers to a
carboxylic acid comprising only one ¨COOH group.
[0085] Within the meaning of this invention, the term "equimolar" refers to
the amount in
which two or more ingredients are present. Preferably, "equimolar" means that
the ingredients
are present in a ratio of 1:1.
[0086] Within the meaning of this invention, the term "pre-mixture" refers to
a mixture of
guanfacine and the mono-carboxylic acid. The pre-mixture can be obtained by
different
preparation methods, such as a dry-grinding method or a slurry method. Within
the meaning of
this invention the pre-mixture obtained by the "slurry method" comprises the
process of
weighing in guanfacine free base and a mono-carboxylic acid in equimolar
amounts. Solvent,
e.g. DCM is added and the mixture is stirred with a magnetic stirring bar at
room temperature for
at least 1 day. The white solid was recovered by filtration under vacuum,
washed with solvent
and dried under vacuum at 40 C for 24 hours.
[0087] Within the meaning of this invention, the pre-mixture obtained by the
"dry-grinding
method" refers to guanfacine and the mono-carboxylic acid obtained by the
process comprising
milling of a mixture of guanfacine base, mono-carboxylic acid and methanol
with zirconium
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 15 -
oxide milling beads (e.g. bead size 3 mm, in a Retsch Mixer Mill MM 500) at 35
Hz for approx.
minutes.
BRIEF DESCRIPTION OF THE DRAWINGS
[0088] Fig.1.1 depicts the guanfacine cumulative permeated amounts of TTS
prepared
5 according to comparative Examples lA and 1B.
[0089] Fig.1.2 depicts the guanfacine cumulative permeated amount of a TTS
prepared
according to comparative Example 1D.
[0090] Fig.1.3 depicts the guanfacine cumulative permeated amounts of TTS
prepared
according to Examples 1A-E and comparative Example 1C.
10 [0091] Fig. 2 depicts the guanfacine cumulative permeated amounts of TTS
prepared according
to Examples 2A-C and comparative Examples 2A and 2B.
[0092] Fig.3 depicts the guanfacine cumulative permeated amounts of TTS
prepared according
to Examples 3A-E and comparative Example 3.
[0093] Fig. 4.1 depicts the guanfacine cumulative permeated amounts of TTS
prepared
according to Examples 4A-C and comparative Example 4.
[0094] Fig. 4.2 depicts the guanfacine cumulative permeated amounts of the TTS
prepared
according to Example 4D.
[0095] Fig. 5.1 depicts the guanfacine cumulative permeated amounts of TTS
prepared
according to Examples 5A-E.
[0096] Fig. 5.2 depicts the guanfacine cumulative permeated amounts of the TTS
prepared
according to Example 5F.
[0097] Fig. 6 depicts the guanfacine cumulative permeated amounts of ITS
prepared according
to Example 6 and comparative Example 6.
DETAILED DESCRIPTION
TTS STRUCTURE
[0098] The present invention relates to a transdermal therapeutic system for
the transdermal
administration of guanfacine comprising a guanfacine-containing layer
structure, said
guanfacine-containing layer structure comprising a) a backing layer, and b) a
guanfacine-
containing layer comprising guanfacine and a mono-carboxylic acid. This
guanfacine-containing
layer structure is preferably a guanfacine-containing self-adhesive layer
structure and preferably
does not comprise an additional skin contact layer. Preferably, the guanfacine-
containing layer is
a guanfacine-containing matrix layer comprising guanfacine and a mono-
carboxylic acid, and at
least one polymer. In particular, the at least one polymer present in the
transdermal therapeutic
system preferably provides the adhesive properties. Furthermore, the
guanfacine-containing layer
structure comprises guanfacine and a mono-carboxylic acid. Preferably, the
guanfacine, in
particular the guanfacine free base and the mono-carboxylic acid are pre-mixed
prior to the
addition to the guanfacine-containing layer.
[0099] The TTS according to the present invention may be a matrix-type TTS or
a reservoir-
type TTS, and preferably is a matrix-type TTS.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 16 -
In a matrix-type TTS according to the invention, the pre-mixture of the
guanfacine and the
mono-carboxylic acid are preferably homogeneously dispersed within a polymeric
carrier, i.e.
the matrix, which forms with the guanfacine and the mono-carboxylic acid and
optionally
remaining ingredients a matrix layer. Accordingly, the guanfacine-containing
layer may in one
embodiment of the invention be a guanfacine-containing matrix layer, wherein
the guanfacine
and the mono-carboxylic acid arc homogeneously dispersed within a polymer
matrix. The
polymer matrix preferably comprises the at least one polymer as defined
herein. Thus, it is
preferred according to the invention that the guanfacine-containing matrix
layer comprises
guanfacine, a mono-carboxylic acid and at least one polymer, which is present
in the TTS. The at
least one polymer is selected from the group consisting of acrylic polymers,
silicone-based
polymers, silicone-acrylic hybrid polymers, and mixtures thereof. More
preferably, according to
the invention the guanfacine-containing matrix layer comprises guanfacine, a
mono-carboxylic
acid and at least one polymer selected from a mixture of an acrylic polymer
and at least one
silicone-based polymer, a mixture of two silicone-acrylic hybrid polymers, a
mixture of two
silicone-based polymers, an acrylic polymer, and an acrylic polymer comprising
a ¨OH group. In
this connection, it is also preferred that the guanfacine-containing matrix
layer is self-adhesive,
so that no additional skin contact layer is present. If a guanfacinc-
containing matrix layer is
prepared by laminating together two guanfacine-containing matrix layers, which
are of
substantially the same composition, the resulting double layer is to be
regarded as one
guanfacine-containing matrix layer.
[0100] In a preferred embodiment of the invention, the guanfacine-containing
layer is a
guanfacine-containing matrix layer comprising
i) guanfacine and a mono-carboxylic acid; and
ii) at least one polymer.
[0101] Thus, according to one embodiment, the present invention relates to a
transdermal
therapeutic system for the transdermal administration of guanfacine comprising
a guanfacine-
containing layer structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, which is preferably a guanfacine-
containing matrix
layer, comprising:
i) guanfacine and a mono-carboxylic acid, and
ii) at least one polymer.
[0102] The guanfacine-containing layer structure is preferably a guanfacine-
containing self-
adhesive layer structure. In this connection, it is also preferred that the
guanfacine-containing
layer structure does not comprise an additional skin contact layer. Instead,
it is preferred that the
guanfacine-containing layer, which is preferably a guanfacine-containing
matrix layer, is self-
adhesive. Thus, in a preferred embodiment, the guanfacine-containing layer
structure is a
guanfacine-containing self-adhesive layer structure and preferably does not
comprise an
additional skin contact layer. Alternatively or additionally, it is preferred
that the guanfacine-
containing layer is directly attached to the backing layer, so that there is
no additional layer
between the backing layer and the guanfacine-containing layer. Consequently, a
layer structure
of low complexity is obtained, which is advantageous, e.g., in terms of the
costs for the
manufacture.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 17 -
[0103] In particular, it is preferred that the guanfacine-containing layer
structure comprises not
more than 3, preferably 2 layers, i.e. preferably only the backing layer and
the guanfacine-
containing layer. Sufficient adhesion between the guanfacine-containing self-
adhesive layer
structure and the skin of the patient during administration is then provided
by the guanfacine-
containing layer, which is preferably a guanfacine-containing matrix layer. If
an additional skin
contact layer is present, e.g., as the third layer of the guanfacinc-
containing layer structure, the
adhesive properties may be provided by the additional skin contact layer.
However, it is
preferred according to the invention that no additional skin contact layer is
present.
[0104] The self-adhesive properties of the guanfacine-containing layer
structure are preferably
provided by the at least one polymer, which is present in the TTS, preferably
in the guanfacine-
containing layer, more preferably in the guanfacine-containing matrix layer.
Thus, in a preferred
embodiment of the invention, the at least one polymer is a pressure sensitive
adhesive polymer.
[0105] In a preferred embodiment of the invention, the guanfacine and the mono-
carboxylic
acid in the guanfacine-containing layer are present in the form of a pre-
mixture.
[0106] In a more preferred embodiment of the invention, the guanfacine and the
mono-
carboxylic acid in the guanfacine-containing layer are present in the form of
a pre-mixture,
wherein said pre-mixture is obtainable by a dry-grinding method or a slurry
method.
[0107] In a preferred embodiment of the invention, the at least one polymer is
selected from the
group consisting of acrylic polymers, silicone-based polymers, silicone-
acrylic hybrid polymers,
and mixtures thereof In a more preferred embodiment of the invention, the at
least one polymer
is selected from a mixture of an acrylic polymer and at least one silicone-
based polymer, a
mixture of two silicone-acrylic hybrid polymers, a mixture of two silicone-
based polymers, an
acrylic polymer, and an acrylic polymer comprising a ¨OH group. Further
details regarding the
at least one polymer according to the invention are provided further below.
[0108] It is to be understood that the TTS, preferably the guanfacine-
containing layer, more
preferably the guanfacine-containing matrix layer comprises at least two
polymers, wherein the
at least two polymers are selected from the group consisting of acrylic
polymers, silicone-based
polymers, silicone-acrylic hybrid polymers, and mixtures thereof Preferably,
it is to be
understood that the TTS, preferably the guanfacine-containing layer, more
preferably the
guanfacine-containing matrix layer comprises a polymer selected from a mixture
of an acrylic
polymer and at least one silicone-based polymer, a mixture of two silicone-
acrylic hybrid
polymers and a mixture of two silicone-based polymers. The first polymer may
provide
advantages in terms of for example a high flux, while the second polymer can
be used for
example to reduce and/or optimize the flux in order to obtain a continuous and
constant flux.
Furthermore, the tackiness of the TTS can be modified by using a combination
of at least two
polymers. Further details regarding the specific polymers and the mixtures are
provided below.
[0109] It is to be understood that the TTS according to the invention contains
at least a
therapeutically effective amount of guanfacine. Thus, in a preferred
embodiment of the
invention, the guanfacine-containing layer structure contains a
therapeutically effective amount
of guanfacine. The guanfacine in the guanfacine-containing layer structure
according to the
invention is present together with the mono-carboxylic acid, preferably in the
form of a co-salt as
described in more detail above or below. In a more preferred embodiment of the
invention, the
guanfacine and the mono-carboxylic acid are preferably dispersed in the
guanfacine-containing
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 18 -
layer. Preferred embodiments regarding the guanfacine and the mono-carboxylic
acid in the TTS
according to the invention are provided further below. Further, it is to be
understood that the
presence of guanfacine together with the mono-carboxylic acid enhances and/or
optimizes the
flux. In a particularly preferred embodiment of the invention, guanfacine and
sorbic acid are
present in the guanfacine-containing layer structure.
[0110] It is to be understood that the TTS according to the invention
optionally comprises at
least one additive selected from the group consisting of dispersing agents,
permeation enhancers
and/or solubilizers. The additives are described in further detail below.
[0111] Further, it is to be understood that the additive is present within the
TTS, preferably
within the guanfacine-containing layer structure, more preferably within the
guanfacine-
containing layer, in particular within the guanfacine-containing matrix layer.
[0112] It is preferred according to the invention that the area of release of
the TTS ranges from
1 to 100 cm2, preferably from 2.5 to 50 cm2.
[0113] In a preferred embodiment of the invention, the backing layer is
substantially
impermeable for the pre-mixture of guanfacine and a mono-carboxylic acid. In
particular, in a
preferred embodiment of the invention, the backing layer is substantially
impermeable for
guanfacine and/or the mono-carboxylic acid. Furthermore, it is preferred that
the backing layer is
occlusive as outlined above.
[0114] According to certain embodiments of the invention, the ITS may further
comprise an
adhesive overlay. This adhesive overlay is in particular larger in area than
the guanfacine-
containing layer structure and is attached thereto for enhancing the adhesive
properties of the
overall transdermal therapeutic system. Said adhesive overlay comprises a
backing layer and an
adhesive layer. The adhesive overlay provides additional area adhering to the
skin but does not
add to the area of release of the guanfacine. The adhesive overlay comprises a
self-adhesive
polymer or a self-adhesive polymer mixture selected from the group consisting
of silicone
acrylic hybrid polymers, acrylate polymers, silicone polymers,
polyisobutylenes, styrene-
isoprene-styrene copolymers, and mixtures thereof, which may be identical to
or different from
any polymer or polymer mixture included in the guanfacine-containing layer
structure.
[0115] The guanfacine-containing layer structure according to the invention,
such as a
guanfacine-containing self-adhesive layer structure, is normally located on a
detachable
protective layer (release liner), from which it is removed immediately before
application to the
surface of the patient's skin. Thus, the TTS may further comprise a release
liner. A TTS
protected this way is usually stored in a blister pack or a seam-sealed pouch.
The packaging may
be child resistant and/or senior friendly.
GUANFACINE-CONTAINING LAYER
[0116] As outlined in more detail above, the TTS according to the present
invention comprises
a guanfacine-containing layer structure comprising a guanfacine-containing
layer. Preferably, the
guanfacine-containing layer structure is a guanfacine-containing self-adhesive
layer structure.
Accordingly, it is also preferred that the guanfacine-containing layer is a
self-adhesive
guanfacine-containing layer, more preferably a self-adhesive guanfacine-
containing matrix layer.
In a preferred embodiment, the guanfacine-containing layer comprises a
therapeutically effective
amount of the guanfacine.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 19 -
[0117] In one embodiment of the invention, the guanfacine-containing layer is
a guanfacine-
containing matrix layer. In another embodiment, the guanfacine-containing
layer is a guanfacine-
containing reservoir layer. It is preferred that the guanfacine-containing
layer is a guanfacine-
containing matrix layer.
[0118] In one embodiment, the guanfacine-containing layer comprises:
i) guanfacinc and a mono-carboxylic acid; and
ii) at least one polymer.
It is to be understood that the at least one polymer, which is contained in
the guanfacine-
containing layer, is the at least one polymer, which is contained in the TTS
according to the
invention.
[0119] In a preferred embodiment, the guanfacine-containing layer is a
guanfacine-containing
matrix layer comprising
i) guanfacine and a mono-carboxylic acid; and
ii) at least one polymer.
It is to be understood that the at least one polymer, which is contained in
the guanfacine-
containing layer, is the at least one polymer, which is contained in the TTS
according to the
invention.
[0120] In a preferred embodiment, the guanfacine-containing layer comprises at
least one
polymer selected from the group consisting of acrylic polymers, silicone-based
polymers,
silicone-acrylic hybrid polymers, and mixtures thereof. Preferably, the at
least one polymer is a
pressure-sensitive adhesive. Thus, the guanfacine-containing layer is
preferably a guanfacine-
containing matrix layer, and particularly preferably a guanfacine-containing
pressure sensitive
adhesive matrix layer.
[0121] In one embodiment of the invention, the guanfacine-containing layer
comprises
guanfacine and a mono-carboxylic acid or a salt formed from the guanfacine and
the mono-
carboxylic acid. Preferably, the guanfacine and the mono-carboxylic acid are
present in the form
of a co-salt. Further, it is to be understood that the guanfacine and the mono-
carboxylic acid are
pre-mixed prior to the addition to the guanfacine-containing layer, such that
a co-salt is formed.
[0122] Pre-mixing of the guanfacine and the mono-carboxylic acid according to
the invention
refers to different types of preparation methods for obtaining a guanfacine ¨
mono-carboxylic
acid pre-mixture. In one embodiment according to the present invention the pre-
mixture of
guanfacine and a mono-carboxylic acid is prepared by the dry-grinding method
comprising
milling of a mixture of guanfacine base, mono-carboxylic acid and methanol
with zirconium
oxide milling beads (e.g. bead size 3 mm, in a Retsch Mixer Mill MM 500) at 35
Hz for approx.
10 minutes. In this regard, it is to be understood that the guanfacine base
and the mono-
carboxylic acid are present in equimolar amounts and methanol act as a
catalyst. In another
embodiment according to the present invention the guanfacine / mono-carboxylic
acid pre-
mixture is prepared by the slurry method comprising weighing in guanfacine
free base and a
mono-carboxylic acid in equimolar amounts. Solvent, e.g. DCM is added and the
mixture is
stirred with a magnetic stirring bar at room temperature for at least 1 day.
The white solid was
recovered by filtration under vacuum, washed with solvent and dried under
vacuum at 40 C for
24 hours.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 20 -
[0123] Accordingly, the guanfacine-containing layer is obtainable by
dispersing the guanfacine
mono-carboxylic acid pre-mixture, wherein preferably the guanfacine and the
mono-carboxylic
acid are present in the pre-mixture in the form of a co-salt. It is to be
understood that the
guanfacine - mono-carboxylic acid pre-mixture is obtainable by mixing of the
guanfacine free
base and the mono-carboxylic acid as described above. Preferably, the
guanfacine in the present
invention is present in the form of a "co-salt", meaning that the guanfacine
is present in a pre-
mixture together with at least one mono-carboxylic acid, such that a proton
transfer is possible,
and preferably at least partly a guanfacine salt of the mono-carboxylic acid
is formed. In other
words, the active agent, preferably guanfacine, may at least partly be present
in protonated from.
However, in connection with the active agent, preferably guanfacine and the
mono-carboxylic
acid it is to be understood that any form obtained in the guanfacine-
containing layer based on the
pre-mixture of guanfacine and the mono-carboxylic acid is covered by the
present invention,
including, e.g., the option of the guanfacine and the mono-carboxylic acid co-
existing without
chemical interaction, i.e. proton transfer, as well as the option of the
formation of a co-salt as
described above. Preferably, the guanfacine free base and the mono-carboxylic
acid may form
together a co-salt or any other type of acid addition salt, so that the
guanfacine-containing layer
preferably comprises at least partly a co-salt or any other type of acid
addition salt of guanfacine
free base and the mono-carboxylic acid. In other words, the guanfacine-
containing layer
preferably comprises the guanfacine at least partly in protonated form and the
mono-carboxylic
acid at least partly in deprotonated form.
[0124] Thus, in one embodiment, the guanfacine-containing layer comprises
guanfacine and a
mono-carboxylic acid or a salt formed from the guanfacine and the mono-
carboxylic acid. In a
more preferred embodiment of the present invention, the mono-carboxylic acid
is sorbic acid.
Thus, in a preferred embodiment of the invention, the guanfacine-containing
layer comprises
guanfacine and sorbic acid or a salt formed from the guanfacine and the sorbic
acid. In
connection with the above embodiments, it is surprising that the combination
of guanfacine with
a mono-carboxylic acid, in particular with the mono-carboxylic acid sorbic
acid, enhances the
flux and permeation of the transdermal therapeutic system. In particular, it
has surprisingly been
found by the inventors of the present invention that a TTS comprising a
combination of
guanfacine base and sorbic acid in the guanfacine-containing layer shows an
enhanced
cumulative permeated amount over 88 h in comparison to a ITS comprising only
guanfacine in
the form of the free base in the guanfacine-containing layer.
[0125] In one embodiment of the invention, the guanfacine-containing layer
structure,
preferably the guanfacine-containing layer, more preferably the guanfacine-
containing matrix
layer of a transdermal therapeutic system according to the invention comprises
guanfacine in an
amount of from 1 to 100 mg/TTS, preferably from 3 to 72 mg/TTS. In a preferred
embodiment,
the guanfacine-containing layer structure, preferably the guanfacine-
containing layer, more
preferably the guanfacine-containing matrix layer comprises guanfacine in an
amount of from 3
to 50 mg/TTS. In another preferred embodiment, the guanfacine-containing layer
structure,
preferably the guanfacine-containing layer, more preferably the guanfacine-
containing matrix
layer comprises guanfacine in an amount of from 3 to 30 mg/TTS. In other
words, the total
amount of guanfacine in the guanfacine-containing layer structure ranges from
1 to 100 mg/TTS,
preferably from 3 to 72 mg/TTS, more preferably from 3 to 50 mg/TTS, even more
preferably
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 21 -
from 3 to 30 mg/TTS. In this regard, it is to be understood that it is
referred to the amount of
guanfacine in the TTS and not to the amount of the guanfacine ¨ mono-
carboxylic acid pre-
mixture.
[0126] In another embodiment, the guanfacine loading in the guanfacine-
containing layer
structure ranges from 0.4 to 2 mg/cm2. In another embodiment, the guanfacine
loading in the
guanfacinc-containing layer structure ranges from 0.4 to 0.85 mg/cm2.
Furthermore, it is
preferred that the area of release of the TTS ranges from 1 to 100 cm2,
preferably from 2.5 to 50
cm2. It is to be understood that it is referred to the loading of guanfacine
and not the loading of
the guanfacine ¨ mono-carboxylic acid pre-mixture.
[0127] In one embodiment of the invention, the guanfacine-containing layer
comprises
guanfacine in an amount of from 1 to 20 % by weight, preferably from 2 to 16 %
by weight,
more preferably from 4 to 14 % by weight, most preferably from 5 to 13 % by
weight, based on
the total weight of the guanfacine-containing layer. Particularly preferably,
the guanfacine-
containing layer comprises guanfacine in an amount of from 4 to 8 % by weight,
preferably from
5 to 7 % by weight, or in an amount of from 10 to 14 % by weight, preferably
from 11 to 13 %
by weight, based on the total weight of the guanfacine-containing layer,
depending on the
desired dosing strength of the TTS.
[0128] In one embodiment of the invention, the guanfacine-containing layer
comprises the
mono-carboxylic acid in an amount of from 1% to 20%, more preferably in an
amount of from
2% to 16% by weight, based on the total weight of the guanfacine-containing
layer. A
particularly preferred mono-carboxylic acid, which is comprised together with
the guanfacine in
the guanfacine-containing layer is sorbic acid.
[0129] The guanfacine-containing layer structure, and preferably the
guanfacine-containing
layer comprises at least one polymer. As explained above, the at least one
polymer is selected
from the group consisting of acrylic polymers, silicone-based polymers,
silicone-acrylic hybrid
polymers, and mixtures thereof. Preferably, it is to be understood that the
TTS, preferably the
guanfacine-containing layer, more preferably the guanfacine-containing matrix
layer comprises a
polymer selected from a mixture of an acrylic polymer and at least one
silicone-based polymer, a
mixture of two silicone-acrylic hybrid polymers, a mixture of two silicone-
based polymers, an
acrylic polymer, and an acrylic polymer comprising a ¨OH group.
[0130] In one embodiment of the invention, the guanfacine-containing layer
comprises the at
least one polymer in an amount of from 20% to 99%, preferably from 30% to 97%,
most
preferably from 35% to 94% by weight based on the total weight of the
guanfacine-containing
layer. It is to be understood that the above indicated amounts of the at least
one polymer may
refer to one polymer only, but also to a combination of polymers as defined
herein.
[0131] In one preferred embodiment of the invention, the guanfacine-containing
layer
comprises a mixture of an acrylic polymer and at least one silicone-based
polymer, wherein the
acrylic polymer is present in an amount of from 20 to 55 % and the at least
one silicone-based
polymer is present in an amount of from 20 to 55% by weight, based on the
total weight of the
active pharmaceutical-containing layer. It is to be understood that the amount
of the at least one
silicone-based polymer refers to the amount of only one silicone-based polymer
or to the overall
amount of the silicone-based polymers present, if more than one silicone-based
polymer, e.g. two
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 22 -
silicone-based polymers are present. Further details regarding the acrylic
polymer and the
silicone-based polymers are provided below.
[0132] In another preferred embodiment of the invention, the guanfacine-
containing layer
comprises a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second silicone-
acrylic hybrid polymer is present in an amount of from 1 to 20 % by wcight, in
each case based
on the total weight of the guanfacine-containing layer and wherein preferably
the first silicone-
acrylic hybrid polymer and the second silicone-acrylic hybrid polymer comprise
a silicone phase
and an acrylate phase in a weight ratio of from 60:40 to 40:60.
[0133] The silicone acrylic hybrid polymer as defined above comprises a
silicone phase and an
acrylate phase, preferably in a weight ratio of from 60:40 to 40:60, most
preferably in a weight
ratio of 50:50. The silicone acrylic hybrid polymer typically comprises the
reaction product of
(a) a silicone-containing pressure-sensitive adhesive composition comprising
acrylate or
methacrylate functionality, (b) an ethylenically unsaturated monomer; and (c)
an initiator.
Further details regarding components (a), (b) and (c) are provided further
below. It is to be
understood that component (a) mainly forms the silicone phase, while component
(b) mainly
forms the acrylatc phase of the silicone acrylic hybrid polymer. The acrylatc
phase influences the
tackiness and the viscosity of the silicone acrylic hybrid polymer. It is
therefore preferred that
the ethylenically unsaturated monomer forming the acrylate phase is a
combination of 2-
ethylhexyl acrylate and methyl acrylate, preferably in a ratio of from 40:60
to 70:30. Preferred in
terms of a high tackiness is a ratio of 60:40, although the viscosity is then
lower. Preferred in
terms of a higher viscosity is a ratio of 50:50, although the tackiness is
then reduced. The
silicone acrylic hybrid polymer in the guanfacine-containing layer preferably
contains a
continuous, acrylic external phase and a discontinuous, silicone internal
phase.
[0134] In one embodiment of the invention, the guanfacine-containing layer
comprises the at
least one silicone acrylic hybrid polymer in an amount of from 20 to 99 %,
preferably from 30 to
97 %, most preferably from 35 to 94 % by weight, based on the total weight of
the guanfacine-
containing layer. In a preferred embodiment, the guanfacine-containing layer
comprises the at
least one silicone acrylic hybrid polymer in an amount of from 74 to 94 % by
weight, preferably
74 to 89 % by weight, based on the total weight of the guanfacine-containing
layer. It is to be
understood that the above indicated amounts of the at least one silicone
acrylic hybrid polymer
may refer to one silicone acrylic hybrid polymer, but also to a combination of
silicone acrylic
hybrid polymers. Thus, the given amount refers to the overall amount of
silicone acrylic hybrid
polymers.
[0135] In one preferred embodiment of the invention, the guanfacine-containing
layer
comprises only one silicone acrylic hybrid polymer in an amount of from 60 to
97 % by weight,
preferably in an amount of from 70 to 94 % by weight, based on the total
weight of the
guanfacine-containing layer.
[0136] In another preferred embodiment of the invention, the guanfacine-
containing layer
comprises a first silicone acrylic hybrid polymer and a second silicone
acrylic hybrid polymer,
wherein the overall amount of the at least two silicone acrylic hybrid
polymers is from 35 to
94 % by weight, preferably from 74 to 94 % by weight, based on the total
weight of the
guanfacine-containing layer. Preferably, the guanfacine-containing layer
comprises a first
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 23 -
silicone acrylic hybrid polymer in an amount of from 60 to 90 % by weight, and
a second
silicone acrylic hybrid polymer in an amount of from 1 to 20 % by weight,
based on the total
weight of the guanfacine-containing layer. In one particularly preferred
embodiment, the
guanfacine-containing layer comprises a first silicone acrylic hybrid polymer
in an amount of
from 70 to 85 %, preferably from 70 to 78 % by weight, and a second silicone
acrylic hybrid
polymer in an amount of from 1 to 8 % by weight, preferably from 3 to 5 % by
weight, based on
the total weight of the guanfacine-containing layer.
[0137] It is to be understood that the above-indicated preferences regarding
the silicone acrylic
hybrid polymers, in particular regarding the weight ratio of the acrylate to
the silicone phase,
regarding the components from which the silicone acrylic hybrid polymer is
obtained, regarding
the ethylenically unsaturated monomers from which the silicone acrylic hybrid
polymer is
formed as well as regarding the acrylic external phase and the silicone
internal phase apply to
both, the first and the second silicone acrylic hybrid polymer. In particular,
it is preferred that the
weight ratio of silicone phase to acrylate phase in the first silicone acrylic
hybrid polymer is
from 55:45 to 45:55, and that the ethylenically unsaturated monomers forming
the acrylate
comprise 2-ethylhexyl acrylate and methyl acrylate in a ratio of from 55:45 to
45:55. It is more
preferred that the weight ratio of silicone phase to acrylate phase in the
first silicone acrylic
hybrid polymer is 50:50, and that the ethylenically unsaturated monomers
forming the acrylate
comprise 2-ethylhexyl acrylate and methyl acrylate in a ratio of 50:50. On the
other hand, it is
preferred that the weight ratio of silicone phase to acrylate phase in the
second silicone acrylic
hybrid polymer is from 55:45 to 45:55, and that the ethylenically unsaturated
monomers forming
the acrylate comprise 2-ethylhexyl acrylate and methyl acrylate in a ratio of
from 65:35 to 55:45.
It is more preferred that the weight ratio of silicone phase to acrylate phase
in the second silicone
acrylic hybrid polymer is 50:50, and that the ethylenically unsaturated
monomers forming the
acrylate comprise 2-ethylhexyl acrylate and methyl acrylate in a ratio of
60:40. Furthermore, it is
for both silicone acrylic hybrid polymers preferred that the silicone phase is
the internal phase
and the acrylate phase is the external phase.
[0138] In another preferred embodiment of the invention, the guanfacine-
containing layer
comprises a mixture of two silicone-based polymers, wherein the first silicone-
based polymer is
present in an amount of from 20 to 55 % by weight, and the second silicone-
based polymer is
present in an amount of from 20 to 55 % by weight, based on the total weight
of the guanfacine-
containing layer. Further details regarding the silicone-based polymer are
provided below.
[0139] In one embodiment of the invention, the TTS according to the invention,
and in
particular the guanfacine-containing layer, comprises at least one additive.
Suitable additives are
described in further detail below and are preferably each present in an amount
of from 0.5 to 10
% by weight, based on the total weight of the guanfacine-containing layer.
[0140] In a preferred embodiment, the guanfacine-containing layer comprises at
least one
additive selected from the group consisting of dispersing agents, permeation
enhancers, and
solubilizers. In one preferred embodiment, the at least one additive is a
dispersing agent. In
another preferred embodiment, the at least one additive is a permeation
enhancer. In yet another
preferred embodiment, the at least one additive is a solubilizer. In certain
preferred
embodiments, also combinations of the afore-mentioned additives are preferred.
The afore-
mentioned additives are of particular advantage for providing the guanfacine
in homogeneously
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 24 -
dispersed and releasable form. It is to be understood that a dispersing agent
may also act as
permeation enhancer and vice versa. Similarly, also a solubilizer may
additionally act as
dispersing agent or permeation enhancer. Furthermore, the solubilizer may
stabilize the
guanfacine dispersion in the TTS and avoid crystallization. Moreover, the
solubilizer can be
helpful in optimizing the cohesion of the TTS. In certain preferred
embodiments, the guanfacine-
containing layer comprises at least one dispersing agent and at least one
permeation enhancer,
and optionally also at least one solubilizer.
[0141] In one preferred embodiment, the at least one additive is a dispersing
agent, which is
present in an amount of from 1 to 10 % by weight, based on the total weight of
the guanfacine-
containing layer. Preferably, the dispersing agent is present in an amount of
from 2 to 6 % by
weight, more preferably 3 to 5 % by weight, based on the total weight of the
guanfacine-
containing layer.
[0142] In another preferred embodiment, the at least one additive is a
permeation enhancer,
which is present in an amount of from 1 to 10 % by weight, based on the total
weight of the
guanfacine-containing layer. Preferably, the permeation enhancer is present in
an amount of
from 2 to 9 % by weight, more preferably in an amount of from 2 to 6 % by
weight, even more
preferably 3 to 5 % by weight, based on the total weight of the guanfacinc-
containing layer.
[0143] In another embodiment, the at least one additive is a solubilizer,
which is present in an
amount of from 0.5 to 10 % by weight, based on the total weight of the
guanfacine-containing
layer. Preferably, the solubilizer is present in an amount of from 0.5 to 5 %
by weight, based on
the total weight of the guanfacine-containing layer.
[0144] In one embodiment, the TTS according to the invention, and in
particular the
guanfacine-containing layer, more particularly the guanfacine-containing
matrix layer, comprises
at least two additives selected from the group consisting of dispersing
agents, permeation
enhancers, and solubilizers.
[0145] In one preferred embodiment, the transdermal therapeutic system, and in
particular the
guanfacine-containing layer, more particularly the guanfacine-containing
matrix layer, comprises
at least two additives, wherein the first additive is a dispersing agent,
which is present in an
amount of from 1 to 10 % by weight based on the total weight of the guanfacine-
containing
layer, and the second additive is a permeation enhancer, which is present in
an amount of from 1
to 10 % by weight based on the total weight of the guanfacine-containing
layer. Preferably, the
dispersing agent is present in an amount of from 1 to 6 % by weight, and the
permeation
enhancer is present in an amount of from 2 to 9 % by weight. More preferably,
the dispersing
agent is present in an amount of from 2 to 6 % by weight, and the permeation
enhancer is present
in an amount of from 2 to 6 % by weight. Even more preferably, the dispersing
agent is present
in an amount of from 3 to 5 % by weight, and the permeation enhancer is
present in an amount of
from 3 to 5 % by weight, based on the total weight of the guanfacine-
containing layer.
[0146] In another preferred embodiment, the transdermal therapeutic system,
and in particular
the guanfacine-containing layer, more particularly the guanfacine-containing
matrix layer,
comprises at least two additives, wherein the first additive is a dispersing
agent, which is present
in an amount of from 1 to 10 % by weight based on the total weight of the
guanfacine-containing
layer, and the second additive is a solubilizer, which is present in an amount
of from 0.5 to 10 %
by weight based on the total weight of the guanfacine-containing layer.
Preferably, the dispersing
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 25 -
agent is present in an amount of from 1 to 6 % by weight, and the solubilizer
is present in an
amount of from 0.5 to 5 % by weight. More preferably, the dispersing agent is
present in an
amount of from 2 to 6 % by weight, and the solubilizer is present in an amount
of from 0.5 to
% by weight. Even more preferably, the dispersing agent is present in an
amount of from 3 to 5
5 % by weight, and the solubilizer is present in an amount of from 0.5 to 5
% by weight.
[0147] In another preferred embodiment, the transdermal therapeutic system,
and in particular
the guanfacine-containing layer, more particularly the guanfacine-containing
matrix layer,
comprises at least two additives, wherein the first additive is a permeation
enhancer, which is
present in an amount of from 1 to 10 % by weight based on the total weight of
the guanfacine-
containing layer, and the second additive is a solubilizer, which is present
in an amount of from
0.5 to 10 % by weight based on the total weight of the guanfacine-containing
layer. Preferably,
the permeation enhancer is present in an amount of from 2 to 9 % by weight,
and the solubilizer
is present in an amount of from 0.5 to 5 % by weight. Preferably, the
permeation enhancer is
present in an amount of from 2 to 6 % by weight, and the solubilizer is
present in an amount of
from 0.5 to 5 % by weight. More preferably, the permeation enhancer is present
in an amount of
from 3 to 5 % by weight, and the solubilizer is present in an amount of from
0.5 to 5 % by
weight.
[0148] In a particularly preferred embodiment of the invention, the TTS
according to the
invention, and in particular the guanfacine-containing layer, more preferably
the guanfacine-
containing matrix layer, comprises two additives selected from dispersing
agents and permeation
enhancers.
[0149] Accordingly, the guanfacine-containing layer, preferably the guanfacine-
containing
matrix layer comprises a dispersing agent, which is present in an amount of
from 1 to 10 % by
weight based on the total weight of the guanfacine-containing layer, and a
permeation enhancer,
which is present in an amount of from 1 to 10 % by weight based on the total
weight of the
guanfacine-containing layer. Preferably, the dispersing agent is present in an
amount of from 1 to
6 % by weight, and the permeation enhancer is present in an amount of from 2
to 9 % by weight.
More preferably, the dispersing agent is present in an amount of from 2 to 6 %
by weight, and
the permeation enhancer is present in an amount of from 2 to 6 % by weight.
Even more
preferably, the dispersing agent is present in an amount of from 3 to 5 % by
weight, and the
permeation enhancer is present in an amount of from 3 to 5 % by weight, based
on the total
weight of the guanfacine-containing layer.
[0150] In connection with the above embodiments regarding the number of
additives and the
amounts of additives in the TTS according to the invention, and in particular
the guanfacine-
containing layer, more particularly the guanfacine-containing matrix layer,
the following specific
additives are preferred.
[0151] In a preferred embodiment, the dispersing agent is selected from the
group consisting of
esters of fatty acids with polyols, fatty alcohols, polyethylene glycols
having a number average
molecular weight of from 300 to 400, polyethylene glycol alkyl ethers, and
wherein the
dispersing agent is preferably polyethylene glycol C8-C20-alkyl ether having
from 2 to 10 EO
units, preferably from 2 to 6 E0 units. A particularly preferred dispersing
agent is
polyoxyethylene (4) lauryl ether (C12H25(OCH2CH2)40H). This dispersing agent
is, e.g.,
available from Merck under the tradename Brij L48.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 26 -
[0152] In a preferred embodiment, the permeation enhancer is selected from the
group
consisting of diethylene glycol monoethyl ether (transcutol), oleic acid,
levulinic acid,
caprylic/capric triglyeerides, diisopropyl adipate, isopropyl myristate,
isopropyl palmitate, lauryl
lactate, triacetin, dimethylpropylene urea, oleyl alcohol, oleoyl macrogo1-6
glycerides (labrafil
MS 1944), and lauroglycol, and is preferably oleyl alcohol, lauroglycol or
oleoyl macrogo1-6
glycerides (labrafil MS 1944). Oleylalcohol is, e.g., available from BASF
under the tradename
Kollicreame OA.
[0153] In a preferred embodiment, the solubilizer is selected from the group
consisting of
copolymers derived from esters of acrylic and methacrylic acid,
polyvinylpyrrolidone,
vinylpyrrolidone-vinyl acetate copolymers, and polyvinyl caprolactam-polyvinyl
acetate-
polyethylene glycol graft copolymers and is preferably a polyvinyl eaprolactam-
polyvinyl
acetate-polyethylene glycol graft copolymer. Particularly preferred
solubilizers are polyvinyl
caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers. Suitable
polyvinyl
caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers are, e.g.,
available from
BASF under the tradename Soluplusg, and preferably have the following
structural formula,
wherein 1, m, and n are selected such that an average molecular weight
determined by gel
permcation chromatography is in thc rangc of 90000 to 140000 g/mol.
HO
0
0
0
0/)0
0
110
[0154] In certain preferred embodiments, the guanfacine-containing layer
comprises at least
one dispersing agent in an amount of from 2 to 6 % by weight, at least one
permeation enhancer
in an amount of from 2 to 9 % by weight, and optionally at least one
solubilizer in an amount of
from 0.5 to 5 % by weight, in each case based on the total weight of the
guanfacine-containing
layer. Preferably, the guanfacine-containing layer comprises at least one
dispersing agent in an
amount of from 2 to 6 % by weight, at least one permeation enhancer in an
amount of from 2 to
6 % by weight, and optionally at least one solubilizer in an amount of from
0.5 to 5 % by weight,
in each case based on the total weight of the guanfacine-containing layer.
More preferably, the
guanfacine-containing layer comprises at least one dispersing agent in an
amount of from 3 to 5
% by weight, at least one permeation enhancer in an amount of from 3 to 5 % by
weight, and
optionally at least one solubilizer in an amount of from 0.5 to 5 % by weight,
in each case based
on the total weight of the guanfacine-containing layer. In connection with the
above preferred
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 27 -
weight-% amounts, the above preferred dispersing agents, permeation enhancers
and solubilizers
are preferred.
[0155] Accordingly, in a particularly preferred embodiment, the guanfacine-
containing layer
comprises a polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO
units, preferably
polyoxyethylene (4) lauryl ether, in an amount of from 2 to 6 % by weight,
oleyl alcohol in an
amount of from 2 to 9 % by weight, and optionally a polyvinyl caprolactam-
polyvinyl acetate-
polyethylene glycol graft copolymer, preferably as specified above, in an
amount of from 0.5 to
5 % by weight, in each case based on the total weight of the guanfacine-
containing layer. In a
more particularly preferred embodiment, the guanfacine-containing layer
comprises a
polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units,
preferably polyoxyethylene
(4) lauryl ether, in an amount of from 2 to 6 % by weight, oleyl alcohol in an
amount of from 2
to 6 % by weight, and optionally a polyvinyl caprolactam-polyvinyl acetate-
polyethylene glycol
graft copolymer, preferably as specified above, in an amount of from 0.5 to 5
% by weight, in
each case based on the total weight of the guanfacine-containing layer. Most
preferably, the
guanfacine-containing layer comprises a polyethylene glycol C8-C20-alkyl ether
having from 2 to
10 EO units, preferably polyoxyethylene (4) lauryl ether, in an amount of from
3 to 5 % by
weight, oleyl alcohol in an amount of from 3 to 5 % by weight, and optionally
a polyvinyl
caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, preferably
as specified
above, in an amount of from 0.5 to 5 % by weight, in each case based on the
total weight of the
guanfacine-containing layer.
[0156] Accordingly, in another particularly preferred embodiment, the
guanfacine-containing
layer comprises a polyethylene glycol C8-C20-alkyl ether having from 2 to 10
E0 units,
preferably polyoxyethylene (4) lauryl ether, in an amount of from 2 to 6 % by
weight,
lauroglycol in an amount of from 2 to 9 % by weight, and optionally a
polyvinyl caprolactam-
polyvinyl acetate-polyethylene glycol graft copolymer, preferably as specified
above, in an
amount of from 0.5 to 5 % by weight, in each case based on the total weight of
the guanfacine-
containing layer. In another more particularly preferred embodiment, the
guanfacine-containing
layer comprises a polyethylene glycol C8-C20-alkyl ether having from 2 to 10
EO units,
preferably polyoxyethylene (4) lauryl ether, in an amount of from 2 to 6 % by
weight,
lauroglycol in an amount of from 2 to 6 % by weight, and optionally a
polyvinyl caprolactam-
polyvinyl acetate-polyethylene glycol graft copolymer, preferably as specified
above, in an
amount of from 0.5 to 5 % by weight, in each case based on the total weight of
the guanfacine-
containing layer. Most preferably, the guanfacine-containing layer comprises a
polyethylene
glycol C8-C20-alkyl ether having from 2 to 10 EO units, preferably
polyoxyethylene (4) lauryl
ether, in an amount of from 3 to 5 % by weight, lauroglycol in an amount of
from 3 to 5 % by
weight, and optionally a polyvinyl caprolactam-polyvinyl acetate-polyethylene
glycol graft
copolymer, preferably as specified above, in an amount of from 0.5 to 5 % by
weight, in each
case based on the total weight of the guanfacine-containing layer.
[0157] Accordingly, in another particularly preferred embodiment, the
guanfacine-containing
layer comprises a polyethylene glycol Ca-C20-alkyl ether having from 2 to 10
EO units,
preferably polyoxyethylene (4) lauryl ether, in an amount of from 2 to 6 % by
weight, oleoyl
macrogo1-6 glycerides (labrafil MS 1944) in an amount of from 2 to 9 % by
weight, and
optionally a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft
copolymer,
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 28 -
preferably as specified above, in an amount of from 0.5 to 5 % by weight, in
each case based on
the total weight of the guanfacine-containing layer. In another more
particularly preferred
embodiment, the guanfacine-containing layer comprises a polyethylene glycol C8-
C20-alkyl ether
having from 2 to 10 EO units, preferably polyoxyethylene (4) lauryl ether, in
an amount of from
2 to 6 % by weight, oleoyl macrogo1-6 glycerides (labrafil MS 1944) in an
amount of from 2 to 6
% by weight, and optionally a polyvinyl caprolactam-polyvinyl acetate-
polyethylene glycol graft
copolymer, preferably as specified above, in an amount of from 0.5 to 5 % by
weight, in each
case based on the total weight of the guanfacine-containing layer. Most
preferably, the
guanfacine-containing layer comprises a polyethylene glycol C8-C20-alkyl ether
having from 2 to
10 EO units, preferably polyoxyethylene (4) lauryl ether, in an amount of from
3 to 5 % by
weight, oleoyl macrogo1-6 glycerides (labrafil MS 1944) in an amount of from 3
to 5 % by
weight, and optionally a polyvinyl caprolactam-polyvinyl acetate-polyethylene
glycol graft
copolymer, preferably as specified above, in an amount of from 0.5 to 5 % by
weight, in each
case based on the total weight of the guanfacine-containing layer.
[0158] In one embodiment of the invention, the area weight of the guanfacine-
containing layer
ranges from 40 to 250 g/m2, preferably from 50 to 180 g/m2, more preferably
from 70 to
180 g/m2, e.g. from 75 to 150 g/m2 or from 100 to 150 g/m2. In certain
preferred embodiments,
the area weight ranges from 80 to 120 g/m2, preferably from 90 to 100 g/m2.
[0159] In view of the above, the present invention relates in one embodiment
to a transdermal
therapeutic system for the transdermal administration of guanfacine comprising
a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of an acrylic polymer and at least one silicone-based polymer,
wherein the
acrylic polymer is present in an amount of from 20 to 55 % by weight and the
at least one
silicone-based polymer is present in an amount of from 20 to 55 % by weight,
based on
the total weight of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is a
mixture of an acrylic polymer and at least one silicone-based polymer.
In a preferred embodiment, the present invention relates in one embodiment to
a transdermal
therapeutic system for the transdermal administration of guanfacine,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 29 -
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of an acrylic polymer and at least one silicone-based polymer,
wherein the
acrylic polymer is present in an amount of from 20 to 55 % by weight and the
at least one
silicone-based polymer is present in an amount of from 20 to 55 % by weight,
based on
the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleoyl macrogo1-6 glycerides in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is a
mixture of an acrylic polymer and at least one silicone-based polymer.
[0160] In a preferred embodiment, the present invention relates in one
embodiment to a
transdcrmal therapeutic system for the transdcrmal administration of
guanfacinc comprising a
guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is a
mixture of two silicone-acrylic hybrid polymers.
[0161] In a preferred embodiment, the present invention relates in one
embodiment to a
transdermal therapeutic system for the transdermal administration of
guanfacine comprising a
guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 30 -
ii) a mixture of two silicone-based polymers, wherein the first silicone-based
polymer is
present in an amount of from 20 to 55 % by weight, and the second silicone-
based
polymer is present in an amount of from 20 to 55 % by weight, based on the
total weight
of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacinc-containing layer; and
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is a
mixture of two silicone-based polymers.
[0162] In a preferred embodiment, the present invention relates in one
embodiment to a
transdermal therapeutic system for the transdermal administration of
guanfacine comprising a
guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer in an amount of from 65 to 95 % by weight, based on the
total
weight of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is an
acrylic polymer.
10163] In a preferred embodiment, the present invention relates in one
embodiment to a
transdermal therapeutic system for the transdermal administration of
guanfacine comprising a
guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer comprising a ¨OH group in an amount of from 65 to 95 %
by
weight, based on the total weight of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
-31 -
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is an
acrylic polymer comprising a ¨OH group.
[0164] In a more preferred embodiment, the present invention relates in one
embodiment to a
transdermal therapeutic system for the transdermal administration of
guanfacine, comprising a
guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of an acrylic polymer and at least one silicone-based polymer,
wherein the
acrylic polymer is present in an amount of from 20 to 55 % by weight and the
at least one
silicone-based polymer is present in an amount of from 20 to 55 % by weight,
bascd on
the total weight of the guanfacine-containing layer;
iii) polyethylene glycol Cs-C20-alkyl ether having from 2 to 10 E0 units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) ()ley] alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is a
mixture of an acrylic polymer and at least one silicone-based polymer.
[0165] In another more preferred embodiment, the present invention relates in
one embodiment
to a transdermal therapeutic system for the transdermal administration of
guanfacine, comprising
a guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 32 -
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is a
mixture of two silicone-acrylic hybrid polymers.
[0166] In another more preferred embodiment, the present invention relates in
one embodiment
to a transdermal therapeutic system for the transdermal administration of
guanfacine, comprising
a guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-based polymers, wherein the first silicone-based
polymer is
present in an amount of from 20 to 55 % by weight, and the second silicone-
based
polymer is present in an amount of from 20 to 55 % by weight, based on the
total weight
of the guanfacine-containing layer;
iii) polyethylene glycol Cs-C20-alkyl ether having from 2 to 10 E0 units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) ()ley] alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is a
mixture of two silicone-based polymers.
In an even more preferred embodiment, the present invention relates in one
embodiment to a
transdermal therapeutic system for the transdermal administration of
guanfacine, comprising a
guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-based polymers, wherein the first silicone-based
polymer is
present in an amount of from 20 to 55 % by weight, and the second silicone-
based
polymer is present in an amount of from 20 to 55 % by weight, based on the
total weight
of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 33 -
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is a
mixture of two silicone-based polymers.
[0167] In another more preferred embodiment, the present invention relates in
one embodiment
to a transdermal therapeutic system for the transdermal administration of
guanfacine, comprising
a guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer in an amount of from 65 to 95 % by weight, based on the
total
weight of the guanfacine-containing layer;
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacinc-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is an
acrylic polymer.
In an even more preferred embodiment, the present invention relates in one
embodiment to a
transdermal therapeutic system for the transdermal administration of
guanfacine, comprising a
guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) an acrylic polymer in an amount of from 65 to 95 % by weight, based on the
total
weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is an
acrylic polymer.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 34 -
[0168] In another more preferred embodiment, the present invention relates in
one embodiment
to a transdermal therapeutic system for the transdermal administration of
guanfacine, comprising
a guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacinc in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer comprising a ¨OH group in an amount of from 65 to 95 %
by
weight, based on the weight of the guanfacine-containing layer;
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacinc-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is an
acrylic polymer comprising a ¨OH group.
In an even more preferred embodiment, the present invention relates in one
embodiment to a
transdermal therapeutic system for the transdermal administration of
guanfacine, comprising a
guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) an acrylic polymer comprising a ¨OH group in an amount of from 65 to 95 %
by
weight, based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
In connection with this embodiment, it is further preferred that the
guanfacine-containing layer
structure does not comprise an additional skin-contact layer. Thus, the
guanfacine-containing
layer, preferably the guanfacine-containing matrix layer, preferably
represents the skin contact
layer and has pressure sensitive adhesive properties due to the at least one
polymer, which is an
acrylic polymer comprising a ¨OH group.
[0169] In particularly preferred embodiment, the present invention relates in
one embodiment
to a transdermal therapeutic system for the transdermal administration of
guanfacine, comprising
a guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid;
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 35 -
ii) a mixture of two silicone-acrylic hybrid polymers;
iii) polyoxyethylene (4) lauryl ether; and
iv) a permeation enhancer selected from oleyl alcohol, lauroglycol and oleoyl
macrogo1-6
glycerides.
[0170] In particularly preferred embodiment, the present invention relates in
one embodiment
to a transdermal therapeutic system for the transdermal administration of
guanfacine, comprising
a guanfacine-containing layer structure, said guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid;
ii) a mixture of two silicone-acrylic hybrid polymers;
iii) polyoxyethylene (4) lauryl ether; and
iv) oleyl alcohol.
[0171] In another particularly preferred embodiment, the present invention
relates in one
embodiment to a transdermal therapeutic system for the transdermal
administration of
guanfacine, comprising a guanfacine-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid;
ii) a mixture of two silicone-acrylic hybrid polymers;
iii) polyoxyethylene (4) lauryl ether; and
iv) lauroglycol.
[0172] In another particularly preferred embodiment, the present invention
relates in one
embodiment to a transdermal therapeutic system for the transdermal
administration of
guanfacine, comprising a guanfacinc-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacinc and sorbic acid;
ii) a mixture of two silicone-acrylic hybrid polymers;
iii) polyoxyethylene (4) lauryl ether; and
iv) oleoyl macrogo1-6 glycerides.
[0173] In an even more particularly preferred embodiment, the present
invention relates in one
embodiment to a transdermal therapeutic system for the transdermal
administration of
guanfacine, comprising a guanfacine-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 36 -
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) a permeation enhancer selected from ley' alcohol, lauroglycol and oleoyl
macrogo1-6
glycerides in an amount of from 2 to 6 % by weight, based on the total weight
of the
guanfacine-containing layer.
[0174] In another even more particularly preferred embodiment, the present
invention relates in
one embodiment to a transdermal therapeutic system for the transdermal
administration of
guanfacine, comprising a guanfacine-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by wcight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) a permeation enhancer selected from oleyl alcohol, lauroglycol and oleoyl
macrogo1-6
glycerides in an amount of from 2 to 6 % by weight, based on the total weight
of the
guanfacine-containing layer.
[0175] In an even more particularly preferred embodiment, the present
invention relates in one
embodiment to a transdermal therapeutic system for the transdermal
administration of
guanfacine, comprising a guanfacine-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
13) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) leyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
[0176] In another even more particularly preferred embodiment, the present
invention relates in
one embodiment to a transdermal therapeutic system for the transdermal
administration of
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 37 -
guanfacine, comprising a guanfacine-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
[0177] In another even more particularly preferred embodiment, the present
invention relates in
one embodiment to a transdermal therapeutic system for the transdermal
administration of
guanfacinc, comprising a guanfacine-containing layer structure, said
guanfacinc-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) lauroglycol in an amount of from 2 to 6 % by weight, based on the total
weight of the
guanfacine-containing layer.
[0178] In another even more particularly preferred embodiment, the present
invention relates in
one embodiment to a transdermal therapeutic system for the transdermal
administration of
guanfacine, comprising a guanfacine-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 38 -
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) lauroglycol in an amount of from 2 to 6 % by weight, based on the total
weight of the
guanfacine-containing layer.
[0179] In another even more particularly preferred embodiment, the present
invention relates in
one embodiment to a transdermal therapeutic system for the transdermal
administration of
guanfacine, comprising a guanfacine-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxycthylenc (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleoyl macrogo1-6 glycerides in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer.
[0180] In another even more particularly preferred embodiment, the present
invention relates in
one embodiment to a transden-nal therapeutic system for the transdermal
administration of
guanfacine, comprising a guanfacine-containing layer structure, said
guanfacine-containing layer
structure comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleoyl macrogo1-6 glycerides in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer.
[0181] For the above preferred and more preferred embodiments it is further
preferred that the
area weight of the guanfacine-containing layer ranges from 50 to 180 g/m2,
preferably from 75 to
150 g/m2, more preferably from 80 to 120 g/m2.
GUANFACINE
[0182] The TTS according to the invention comprises a guanfacine-containing
layer structure,
said guanfacine-containing layer structure comprising A) a backing layer; and
B) a guanfacine-
containing layer comprising guanfacine and a mono-carboxylic acid. The
guanfacine-containing
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 39 -
layer, which is preferably a guanfacine-containing matrix layer, has been
described in detail
above.
[0183] In one embodiment of the invention, the guanfacine in the guanfacine-
containing layer,
preferably the guanfacine-containing matrix layer, is present in a pre-mixture
with a mono-
carboxylic acid. In one embodiment of the invention, the guanfacine-containing
layer, preferably
the guanfacinc-containing matrix layer comprises guanfacinc and a mono-
carboxylic acid or a
salt formed from the guanfacine and the mono-carboxylic acid. Preferably, the
guanfacine and
the mono-carboxylic acid are present in the form of a co-salt. Further, it is
to be understood that
the guanfacine and the mono-carboxylic acid are pre-mixed prior to the
addition to the
guanfacine-containing layer, such that a co-salt is formed.
[0184] Preferably, the guanfacine in the present invention is present in the
form of a "co-salt",
meaning that the guanfacine is present in a pre-mixture together with at least
one mono-
carboxylic acid, such that a proton transfer is possible, and preferably at
least partly a guanfacine
salt of the mono-carboxylic acid is formed. In other words, the active agent,
preferably
guanfacine, may at least partly be present in protonated from. However, in
connection with the
active agent, preferably guanfacine, and the mono-carboxylic acid it is to be
understood that any
form obtaincd in the guanfacinc-containing layer bascd on thc prc-mixturc of
guanfacinc and thc
mono-carboxylic acid is covered by the present invention, including, e.g., the
option of the
guanfacine and the mono-carboxylic acid co-existing without chemical
interaction, i.e. proton
transfer, as well as the option of the formation of a co-salt as described
above. Preferably, the
guanfacine free base and the mono-carboxylic acid may form together a co-salt
or any other type
of acid addition salt, so that the guanfacine-containing layer preferably
comprises at least partly a
co-salt or any other type of acid addition salt of guanfacine free base and
the mono-carboxylic
acid. In other words, the guanfacine-containing layer preferably comprises the
guanfacine at
least partly in protonated form and the mono-carboxylic acid at least partly
in deprotonated form.
[0185] In a preferred embodiment of the invention, the guanfacine and the mono-
carboxylic
acid in the guanfacine-containing layer are present in the form of a pre-
mixture as described
above.
[0186] In a more preferred embodiment of the invention, the guanfacine and the
mono-
carboxylic acid in the guanfacine-containing layer are present in the form of
a pre-mixture,
wherein said pre-mixture is obtainable by a dry-grinding method or a slurry
method.
[0187] In one preferred embodiment of the invention, the guanfacine and the
mono-carboxylic
acid are present in the guanfacine-containing layer in equimolar amounts. In
this cormection, it is
to be understood that the guanfacine free base as added to the pre-mixture and
the mono-
carboxylic acid as added to the pre-mixture are also present in equimolar
amounts.
[0188] In a preferred embodiment of the invention, the guanfacine-containing
layer comprises
the mono-carboxylic acid in an amount of from 1% to 20%, more preferably in an
amount of
from 2% to 16% by weight, based on the total weight of the guanfacine-
containing layer. A
particularly preferred mono-carboxylic acid, which is comprised together with
the guanfacine in
the guanfacine-containing layer is sorbic acid.
[0189] In connection with the above embodiments, it is surprising that the
combination of
guanfacine with a mono-carboxylic acid, in particular with the mono-carboxylic
acid sorbic acid,
enhances the flux and permeation of the transdermal therapeutic system. In
particular, it has
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 40 -
surprisingly been found by the inventors of the present invention that a TTS
comprising a
combination of guanfacine base and sorbic acid in the guanfacine-containing
layer shows an
enhanced cumulative permeated amount over 88 h in comparison to a TTS
comprising only
guanfacine in the form of the free base in the guanfacine-containing layer.
[0190] In one preferred embodiment of the invention, the guanfacine-containing
layer structure
preferably contains a therapeutically effective amount of guanfacine. More
preferably, the
therapeutically effective amount of guanfacine is present in the guanfacine-
containing layer of
the guanfacine-containing layer structure.
[0191] In certain embodiments, the amount of guanfacine in the guanfacine-
containing layer
ranges from 1 to 20 % by weight, preferably from 2 to 16 % by weight, most
preferably from 5
to 13 % by weight, e.g. from 11 to 13 % by weight or from 5 to 7 % by weight,
based on the total
weight of the guanfacine-containing layer.
[0192] In one embodiment of the invention, the guanfacine-containing layer is
obtainable by
dispersing the guanfacine ¨ mono-carboxylic acid pre-mixture. If the
guanfacine-containing
layer is a guanfacine-containing matrix layer, said layer is preferably
obtainable by dispersing
the guanfacine ¨ mono-carboxylic acid pre-mixture in the polymeric carrier,
which particularly
preferably comprises at least one polymer selected from the group consisting
of acrylic
polymers, silicone-based polymers, silicone-acrylic hybrid polymers, and
mixtures thereof, and
optionally at least one additive as defined above, in particular at least one
dispersing agent and at
least one permeation enhancer.
[0193] In certain embodiments, the guanfacine has a purity of at least 95 %,
preferably of at
least 98 %, and more preferably of at least 99 % as determined by quantitative
HPLC.
Quantitative HPLC may be performed with Reversed-Phase-HPLC with UV detection.
POLYMERS
SILICONE ACRYLIC HYBRID POLYMER
[0194] The TTS according to the present invention comprises at least one
polymer, wherein the
at least polymer is selected from the group consisting of acrylic polymers,
silicone-based
polymers, silicone-acrylic hybrid polymers, and mixtures thereof. Further
details regarding the
mixtures of the polymers are provided below.
[0195] In one embodiment of the present invention the TTS according to the
present invention
comprises a silicone acrylic hybrid polymer. The silicone acrylic hybrid
polymer comprises a
polymerized hybrid species that includes silicone-based sub-species and
acrylate-based sub-
species that have been polymerized together. The silicone acrylic hybrid
polymer thus comprises
a silicone phase and an acrylic phase. Preferably, the silicone acrylic hybrid
polymer is a silicone
acrylic hybrid pressure-sensitive adhesive.
[0196] The silicone acrylic hybrid pressure-sensitive adhesives are usually
supplied and used in
solvents like n-heptane and ethyl acetate. The solids content of the pressure-
sensitive adhesives
is usually between 30 % and 80 %. The skilled person is aware that the solids
content may be
modified by adding a suitable amount of solvent.
[0197] Preferably, the weight ratio of silicone to acrylate in the silicone
acrylic hybrid
pressure-sensitive adhesive is from 5:95 to 95:5, or from 20:80 to 80:20, more
preferably from
40:60 to 60:40, and most preferably the ratio of silicone to acrylate is about
50:50. Suitable
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
-41 -
silicone acrylic hybrid pressure-sensitive adhesives having a weight ratio of
silicone to acrylate
of 50:50 are, for example, the commercially available silicone acrylic hybrid
pressure-sensitive
adhesives 7-6102, Silicone/Acrylate Ratio 50/50, and 7-6302, Silicone/Acrylate
Ratio 50/50,
supplied in ethyl acetate by DuPontTM.
[0198] The preferred silicone acrylic hybrid pressure-sensitive adhesives in
accordance with
the invention arc characterized by a solution viscosity at 25 C and about 50
% solids content in
ethyl acetate of more than about 400 cP, or from about 500 cP to about 3,500
cP, in particular
from about 1,000 cP to about 3,000 cP, more preferred from about 1,200 cP to
about 1,800, or
most preferred of about 1,500 cP or alternatively more preferred from about
2,200 cP to about
2,800 cP, or most preferred of about 2,500 cP, preferably as measured using a
Brookfield RVT
viscometer equipped with a spindle number 5 at 50 RPM.
101991 These silicone acrylic hybrid pressure-sensitive adhesives may also be
characterized by
a complex viscosity at 0.1 rad/s at 30 C of less than about 1.0e9 Poise, or
from about 1.0e5
Poise to about 9.0e8 Poise, or more preferred from about 9.0e5 Poise to about
1.0e7 Poise, or
most preferred about 4.0e6 Poise, or alternatively more preferred from about
2.0e6 Poise to
about 9.0e7 Poise, or most preferred about 1.0e7 Poise, preferably as measured
using a
Rheometrics ARES rheometer, wherein the rheometer is equipped with 8mm plates
and the gap
zeroed.
[0200] To prepare samples for measuring the rheological behavior using a
Rheometrics ARES
rheometer, between 2 and 3 grams of adhesive solution can be poured onto a
SCOTCH-PAK
1022 Iluoropolymer release liner and allow to sit for 60 minutes under ambient
conditions. To
achieve essentially solvent-free films of the adhesive, they can be placed in
an oven at 110 C +/-
10 C for 60 minutes. After removing from the oven and letting equilibrate to
room temperature.
The films can be removed from the release liner and folded over to form a
square. To eliminate
air bubbles the films can be compressed using a Carver press. The samples can
then be loaded
between the plates and are compressed to 1.5 +/-0.1 mm at 30 C. The excess
adhesive is
trimmed, and the final gap recorded. A frequency sweep between 0.01 to 100
rad/s can be
performed with the following settings: Temperature = 30 C; strain = 0.5-1% and
data collected
at 3 points/decade.
[0201] Suitable silicone acrylic hybrid pressure-sensitive adhesives which are
commercially
available include the PSA series 7-6100 and 7-6300 manufactured and supplied
in n-heptane or
ethyl acetate by DuPoritTM (7-610X and 7-630X; X=1 n-heptane-based / X=2 ethyl
acetate-
based). For example, the 7-6102 silicone acrylic hybrid PSA having a
silicone/acrylate ratio of
50/50 is characterized by a solution viscosity at 25 C and about 50% solids
content in ethyl
acetate of 2,500 cP and a complex viscosity at 0.1 rad/s at 30 C of 1.0e7
Poise. The 7-6302
silicone acrylic hybrid PSA having a silicone/acrylate ratio of 50/50 has a
solution viscosity at
25 C and about 50% solids content in ethyl acetate of 1,500 cP and a complex
viscosity at 0.1
rad/s at 30 C of 4.0e6 Poise.
[0202] Depending on the solvent in which the silicone acrylic hybrid pressure-
sensitive
adhesive is supplied, the arrangement of the silicone phase and the acrylic
phase providing a
silicone or acrylic continuous external phase and a corresponding
discontinuous internal phase is
different. If the silicone acrylic hybrid pressure-sensitive adhesive is
provided in n-heptane, the
composition contains a continuous, silicone external phase and a
discontinuous, acrylic internal
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 42 -
phase. If the silicone acrylic hybrid pressure-sensitive adhesive is provided
in ethyl acetate, the
composition contains a continuous, acrylic external phase and a discontinuous,
silicone internal
phase. After evaporating the solvent in which the silicone acrylic hybrid
pressure-sensitive
adhesive is provided, the phase arrangement of the resulting pressure-
sensitive adhesive film or
layer corresponds to the phase arrangement of the solvent-containing adhesive
coating
composition. For example, in the absence of any substance that may induce an
inversion of the
phase arrangement in a silicone acrylic hybrid pressure sensitive adhesive
composition, a
pressure-sensitive adhesive layer prepared from a silicone acrylic hybrid
pressure-sensitive
adhesive in n-heptane provides a continuous, silicone external phase and a
discontinuous, acrylic
internal phase, a pressure-sensitive adhesive layer prepared from a silicone
acrylic hybrid
pressure-sensitive adhesive in ethyl acetate provides a continuous, acrylic
external phase and a
discontinuous, silicone internal phase. The phase arrangement of the
compositions can, for
example, be determined in peel force tests with pressure-sensitive adhesive
films or layers
prepared from the silicone acrylic hybrid PSA compositions which are attached
to a siliconized
release liner. The pressure-sensitive adhesive film contains a continuous,
silicone external phase
if the siliconized release liner cannot or can only hardly be removed from the
pressure-sensitive
adhesive film (laminated to a backing film) duc to thc blocking of the two
silicone surfaces.
Blocking results from the adherence of two silicone layers which comprise a
similar surface
energy. The silicone adhesive shows a good spreading on the siliconized liner
and therefore can
create a good adhesion to the liner. If the siliconized release liner can
easily be removed the
pressure-sensitive adhesive film contains a continuous, acrylic external
phase. The acrylic
adhesive has no good spreading due to the different surface energies and thus
has a low or almost
no adhesion to the siliconized liner. Preferably, according to the present
invention the silicone
acrylic hybrid pressure-sensitive adhesive is provided in ethyl acetate and
the composition
contains a continuous, acrylic external phase and a discontinuous, silicone
internal phase.
[0203] According to a preferred embodiment of the invention the silicone
acrylic hybrid
polymer is a silicone acrylic hybrid pressure-sensitive adhesive obtainable
from a silicon-
containing pressure-sensitive adhesive composition comprising acrylate or
methacrylate
functionality. It is to be understood that the silicon-containing pressure-
sensitive adhesive
composition comprising acrylate or methacrylate functionality can include only
acrylate
functionality, only methacrylate functionality, or both acrylate functionality
and methacrylate
functionality.
[0204] According to certain embodiments of the invention the silicone acrylic
hybrid pressure-
sensitive adhesive comprises the reaction product of (a) a silicon-containing
pressure-sensitive
adhesive composition comprising acrylate or methacrylate functionality, (b) an
ethylenically
unsaturated monomer, and (c) an initiator. That is, the silicone acrylic
hybrid pressure-sensitive
adhesive is the product of the chemical reaction between these reactants ((a),
(b), and (c)). In
particular, the silicone acrylic hybrid pressure-sensitive adhesive includes
the reaction product of
(a) a silicon-containing pressure-sensitive adhesive composition comprising
acrylate or
methacrylate functionality, (b) a (meth)acrylate monomer, and (c) an initiator
(i.e., in the
presence of the initiator). That is, the silicone acrylic hybrid pressure-
sensitive adhesive includes
the product of the chemical reaction between these reactants ((a), (b), and
(c)).
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 43 -
[0205] The reaction product of (a) a silicon-containing pressure-sensitive
adhesive composition
comprising acrylate or methacrylate functionality, (b) an ethylenically
unsaturated monomer, and
(c) an initiator may contain a continuous, silicone external phase and a
discontinuous, acrylic
internal phase or the reaction product of (a), (b), and (c) may contain a
continuous, acrylic
external phase and a discontinuous, silicone internal phase.
[0206] The silicon-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality (a) is typically present in the silicone acrylic
hybrid pressure-sensitive
adhesive in an amount of from 5 to 95, more typically 25 to 75, parts by
weight based on 100
parts by weight of the hybrid pressure-sensitive adhesive.
[0207] The ethylenically unsaturated monomer (b) is typically present in the
silicone acrylic
hybrid pressure-sensitive adhesive in an amount of from 5 to 95, more
typically 25 to 75, parts
by weight based on 100 parts by weight of the hybrid pressure-sensitive
adhesive.
[0208] The initiator (c) is typically present in the silicone acrylic hybrid
pressure-sensitive
adhesive in an amount of from 0.005 to 3, more typically from 0.01 to 2, parts
by weight based
on 100 parts by weight of the hybrid pressure-sensitive adhesive.
[0209] According to certain embodiments of the invention the silicon-
containing pressure-
sensitive adhesive composition comprising acrylatc or methacrylate
functionality (a) comprises
the condensation reaction product of (al) a silicone resin, (a2) a silicone
polymer, and (a3) a
silicon-containing capping agent which provides said acrylate or methacrylate
functionality.
[0210] According to certain embodiments of the invention the silicon-
containing pressure-
sensitive adhesive composition comprising acrylate or methacrylate
functionality (a) comprises
the condensation reaction product of:
(al) a silicone resin,
(a2) a silicone polymer, and
(a3) a silicon-containing capping agent which provides said acrylate or
methacrylate
functionality, wherein said silicon-containing capping agent is of the general
formula
XYRibSiZ3_b, wherein
X is a monovalent radical of the general formula AE-
where E is -0- or -NH- and A is an acryl group or a methacryl group,
Y is a divalent alkylene radical having from 1 to 6 carbon atoms,
R' is a methyl or a phenyl radical,
Z is a monovalent hydrolyzable organic radical or a halogen, and
b is 0 or 1;
wherein the silicone resin and silicone polymer are reacted to form a pressure-
sensitive
adhesive, wherein the silicon-containing capping agent is introduced prior to,
during, or
after the silicone resin and silicone polymer are reacted, and wherein:
the silicon-containing capping agent reacts with the pressure-sensitive
adhesive after
the silicone resin and silicone polymer have been condensation reacted to form
the
pressure-sensitive adhesive; or
the silicon-containing capping agent reacts in-situ with the silicone resin
and silicone
polymer.
[0211] According to certain embodiments of the invention the silicon-
containing pressure-
sensitive adhesive composition comprising acrylate or methacrylate
functionality comprises the
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 44 -
condensation reaction product of a pressure sensitive adhesive and a silicon-
containing capping
agent which provides said acrylate or methacrylate functionality. That is, the
silicon-containing
pressure sensitive adhesive composition comprising acrylate or methacrylate
functionality is
essentially a pressure sensitive adhesive that has been capped or endblocked
with the silicon-
containing capping agent which provides said acrylate or methacrylate
functionality, wherein the
pressure sensitive adhesive comprises the condensation reaction product of the
silicone resin and
the silicone polymer. Preferably, the silicone resin reacts in an amount of
from 30 to 80 parts by
weight to form the pressure sensitive adhesive, and the silicone polymer
reacts in an amount of
from 20 to 70 parts by weight to form the pressure sensitive adhesive. Both of
these parts by
weight are based on 100 parts by weight of the pressure sensitive adhesive.
Although not
required, the pressure sensitive adhesive may comprise a catalytic amount of a
condensation
catalyst. A wide array of silicone resins and silicone polymers are suitable
to make up the
pressure sensitive adhesive.
[0212] According to certain embodiments of the invention the silicone acrylic
hybrid pressure-
sensitive adhesive is the reaction product of:
(a) a silicon-containing pressure-sensitive adhesive composition comprising
acrylate or
methacrylate functionality that comprises the condensation reaction product
of:
(al) a silicone resin,
(a2) a silicone polymer, and
(a3) a silicon-containing capping agent which provides said acrylate or
methacrylate
functionality, wherein said silicon-containing capping agent is of the general
formula
XYR'bSiZ3_b, wherein
X is a monovalent radical of the general formula AE-
where E is -0- or -NH- and A is an acryl group or a methacryl group,
Y is a divalent alkylene radical having from 1 to 6 carbon atoms,
R' is a methyl or a phenyl radical,
Z is a monovalent hydrolyzable organic radical or a halogen, and
b is 0 or 1;
wherein the silicone resin and silicone polymer are reacted to form a pressure-
sensitive
adhesive, wherein the silicon-containing capping agent is introduced prior to,
during, or
alter the silicone resin and silicone polymer are reacted, and wherein:
the silicon-containing capping agent reacts with the pressure-sensitive
adhesive after
the silicone resin and silicone polymer have been condensation reacted to form
the
pressure-sensitive adhesive; or
the silicon-containing capping agent reacts in-situ with the silicone resin
and silicone
polymer;
(b) an ethylenically unsaturated monomer; and
(c) an initiator.
[0213] The silicone acrylic hybrid composition used in the present invention
may be described
by being prepared by a method comprising the steps of:
(i) providing a silicon-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality that comprises the condensation reaction product
of:
a silicone resin,
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 45 -
a silicone polymer, and
a silicon-containing capping agent which provides said acrylate or
methacrylate
functionality, wherein said silicon-containing capping agent is of the general
formula
XYltibSiZ3_b, wherein
X is a monovalent radical of the general formula AE-
where E is -0- or -NH- and A is an acryl group or a methacryl group,
Y is a divalent alkylene radical having from 1 to 6 carbon atoms,
R' is a methyl or a phenyl radical,
Z is a monovalent hydrolyzable organic radical or a halogen, and
b is 0 or 1;
wherein the silicone resin and silicone polymer are reacted to form a pressure-
sensitive
adhesive, wherein the silicon-containing capping agent is introduced prior to,
during, or
after the silicone resin and silicone polymer are reacted, and wherein:
the silicon-containing capping agent reacts with the pressure-sensitive
adhesive after
the silicone resin and silicone polymer have been condensation reacted to form
the
pressure-sensitive adhesive; or
thc silicon-containing capping agent reacts in-situ with the silicone resin
and silicone
polymer;
(ii) polymerizing an ethylenically unsaturated monomer and the silicon-
containing pressure-
sensitive adhesive composition comprising acrylate or methacrylate
functionality of step (i) in
the presence of an initiator to form a silicone acrylic hybrid composition,
optionally at a
temperature of from 50 C to 100 C, or from 65 C to 90 C.
[0214] During the polymerization of the ethylenically unsaturated monomer and
the silicon-
containing pressure-sensitive adhesive composition comprising acrylate or
methacrylate
functionality, the silicone to acrylic ratio can be controlled and optimized
as desired. The
silicone to acrylic ratio can be controlled by a wide variety of mechanisms in
and during the
method. An illustrative example of one such mechanism is the rate controlled
addition of the
ethylenically unsaturated monomer or monomers to the silicon-containing
pressure-sensitive
adhesive composition comprising acrylate or methacrylate functionality. In
certain applications,
it may be desirable to have the silicone-based sub-species, or the overall
silicone content, to
exceed the acrylate-based sub-species, or the overall acrylic content. In
other applications, it may
be desirable for the opposite to be true. Independent of the end application,
it is generally
preferred, as already described above, that the silicon-containing pressure-
sensitive adhesive
composition comprising acrylate or methacrylate functionality is preferably
present in the
silicone acrylic hybrid composition in an amount of from about 5 to about 95,
more preferably
from about 25 to about 75, and still more preferably from about 40 to about 60
parts by weight
based on 100 parts by weight of the silicone acrylic hybrid composition.
[0215] According to a certain embodiment of the invention, the silicone
acrylic hybrid
composition used in the present invention may be described by being prepared
by a method
comprising the steps of:
(i) providing a silicon-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality that comprises the condensation reaction product
of:
a silicone resin,
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 46 -
a silicone polymer, and
a silicon-containing capping agent which provides said acrylate or
methacrylate
functionality, wherein said silicon-containing capping agent is of the general
formula
XYR1bSiZ3_b, wherein
X is a monovalent radical of the general formula AE-
where E is -0- or -NH- and A is an acryl group or a methacryl group,
Y is a divalent alkylene radical having from 1 to 6 carbon atoms,
R' is a methyl or a phenyl radical,
Z is a monovalent hydrolyzable organic radical or a halogen, and
b is 0 or 1;
wherein the silicone resin and silicone polymer are reacted to form a pressure-
sensitive
adhesive, wherein the silicon-containing capping agent is introduced prior to,
during, or
after the silicone resin and silicone polymer are reacted, and wherein:
the silicon-containing capping agent reacts with the pressure-sensitive
adhesive after
the silicone resin and silicone polymer have been condensation reacted to form
the
pressure-sensitive adhesive; or
thc silicon-containing capping agent reacts in-situ with the silicone resin
and silicone
polymer;
(ii) polymerizing an ethylenically unsaturated monomer and the silicon-
containing pressure-
sensitive adhesive composition comprising acrylate or methacrylate
functionality of step (i) in a
first solvent in the presence of an initiator at a temperature of from 50 C to
100 C to form a
silicone acrylic hybrid composition;
(iii) removing the first solvent; and
(iv) adding a second solvent to form the silicone acrylic hybrid composition,
wherein the phase
arrangement of the silicone acrylic hybrid composition is selectively
controlled by selection of
the second solvent.
[0216] The silicone acrylic hybrid PSA composition used in the present
invention may also be
described by being prepared by a method comprising the steps of
(i) providing a silicon-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality that comprises the condensation reaction product
of:
a silicone resin,
a silicone polymer, and
a silicon-containing capping agent which provides said acrylate or
methacrylate
functionality, wherein said silicon-containing capping agent is of the general
formula
XYR'bSiZ3_b, wherein
X is a monovalent radical of the general formula AE-
where E is -0- or -NH- and A is an acryl group or a methacryl group,
Y is a divalent alkylene radical having from 1 to 6 carbon atoms,
R' is a methyl or a phenyl radical,
Z is a monovalent hydrolyzable organic radical or a halogen, and
b is 0 or 1;
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 47 -
wherein the silicone resin and silicone polymer are reacted to form a pressure-
sensitive
adhesive, wherein the silicon-containing capping agent is introduced prior to,
during, or
after the silicone resin and silicone polymer are reacted, and wherein:
the silicon-containing capping agent reacts with the pressure-sensitive
adhesive after
the silicone resin and silicone polymer have been condensation reacted to form
the
pressure-sensitive adhesive; or
the silicon-containing capping agent reacts in-situ with the silicone resin
and silicone
polymer;
(ii) polymerizing an ethylenically unsaturated monomer and the silicon-
containing pressure-
sensitive adhesive composition comprising acrylate or methacrylate
functionality of step (i) in a
first solvent in the presence of an initiator at a temperature of from 50 C to
100 C to form a
silicone acrylic hybrid composition;
(iii) adding a processing solvent, wherein the processing solvent has a higher
boiling point than
the first solvent, and
(iv) applying heat at a temperature of from 70 C to 150 C such that a majority
of the first solvent
is selectively removed;
(v) removing the processing solvent; and.
(vi) adding a second solvent to form the silicone acrylic hybrid composition,
wherein the phase
arrangement of the silicone acrylic hybrid composition is selectively
controlled by selection of
the second solvent.
[0217] The silicone resin according to the previous paragraphs may contain a
copolymer
comprising triorganosiloxy units of the formula RX3S101/2 and tetrafunctional
siloxy units of the
formula SiO4/2 in a ratio of from 0.1 to 0.9, preferably of about 0.6 to 0.9,
triorganosiloxy units
for each tetrafunctional siloxy unit. Preferably, each Rx independently
denotes a monovalent
hydrocarbon radical having from 1 to 6 carbon atoms, vinyl, hydroxyl, or
phenyl groups.
[0218] The silicone polymer according to the previous paragraphs may comprise
at least one
polydiorganosiloxane and is preferably end-capped (end-blocked) with a
functional group
selected from the group consisting of hydroxyl groups, alkoxy groups, hydride
groups, vinyl
groups, or mixtures thereof. The diorganosubstituent may be selected from the
group consisting
of dimethyl, methylvinyl, methylphenyl, diphenyl, methylethyl, (3,3,3-
trifluoropropyl)methyl
and mixtures thereof. Preferably, the diorganosubstituents contain only methyl
groups. The
molecular weight of polydiorganosiloxane will typically range from about
50,000 to about
1,000,000, preferably, from about 80,000 to about 300,000. Preferably, the
polydiorganosiloxane
comprises ARxSiO units terminated with endblocking TRxASi01/2 units, wherein
the poly-
diorganosiloxane has a viscosity of from about 100 centipoise to about
30,000,000 centipoise at
25 C, each A radical is independently selected from Rx or halohydrocarbon
radicals having from
1 to 6 carbon atoms, each T radical is independently selected from the group
consisting of Rx,
OH, H or OR, and each RY is independently an alkyl radical having from 1 to 4
carbon atoms.
[0219] As an example, using forms of the preferred silicone resin and the
preferred silicone
polymer, one type of pressure sensitive adhesive is made by:
mixing (i) from 30 to 80 inclusive parts by weight of at least one resin
copolymer containing
silicon-bonded hydroxyl radicals and consisting essentially of Rx3Si01/2 units
and SiO4/2 units in
a mole ratio of 0.6 to 0.9 Rx3Si01/2 units for each Si.04/2 unit present, (ii)
between about 20 and
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 48 -
about 70 parts by weight of at least one polydiorganosiloxane comprising
ARxSiO units
terminated with endblocking TRxASi01/2 units, wherein the polydiorganosiloxane
has a
viscosity of from about 100 centipoise to about 30,000,000 centipoise at 25 C
and each Rx is a
monovalent organic radical selected from the group consisting of hydrocarbon
radicals of from 1
to 6 inclusive carbon atoms, each A radical is independently selected from Rx
or
halohydrocarbon radicals having from 1 to 6 inclusive carbon atoms, each T
radical is
independently selected from the group consisting of Rx, OH, H or OR, and each
RY is
independently an alkyl radical of from 1 to 4 inclusive carbon atoms; a
sufficient amount of (iii)
at least one of the silicon-containing capping agents, also referred to
throughout as endblocking
agents, described below and capable of providing a silanol content, or
concentration, in the range
of 5,000 to 15,000, more typically 8,000 to 13,000, ppm, when desirable an
additional catalytic
amount of (iv) a mild silanol condensation catalyst in the event that none is
provided by (ii), and
when necessary, an effective amount of (v) an organic solvent which is inert
with respect to (i),
(ii), (iii) and (iv) to reduce the viscosity of a mixture of (i), (ii), (iii),
and (iv), and condensing the
mixture of (i), (ii), (iii) and (iv) at least until a substantial amount of
the silicon-containing
capping agent or agents have reacted with the silicon-bonded hydroxyl radicals
and T radicals of
(i) and (ii). Additional organosilicon cndblocking agents can be uscd in
conjunction with the
silicon-containing capping agent or agents (iii) of the present invention.
[0220] The silicon-containing capping agent according to the previous
paragraphs may be
selected from the group of acrylate functional silanes, acrylate functional
silazanes, acrylate
functional disilazanes, acrylate functional disiloxanes, methacrylate
functional silanes,
methacryl ate functional silazanes, rnethacrylate functional di silazanes,
meth-acryl ate functional
disiloxanes, and combinations thereof and may be described as to be of the
general formula
XYR1bSiZ3_b, wherein X is a monovalent radical of the general formula AE-
where E is -0- or -
NII- and A is an acryl group or a methacryl group, Y is a divalent alkylene
radical having from 1
to 6 carbon atoms, R' is a methyl or a phenyl radical, Z is a monovalent
hydrolyzable organic
radical or a halogen, and b is 0, 1 or 2. Preferably, the monovalent
hydrolyzable organic radical
is of the general formula R"O - where R" is an alkylene radical. Most
preferably, this particular
endblocking agent is selected from the group of 3-
methacryloxypropyldimethylchlorosilane, 3-
methacryloxypropyldichlorosilane, 3-methacryloxypropyltrichlorosilane, 3-
methacryloxypropyldimethylmethoxysilane, 3-
methacryloxypropylmethyldimethoxysilane, 3-
meth-acryloxypropyltrimethoxysilane, 3-methacryloxypropyldimethylethoxysilane,
3-
methacryloxypropylmethyldiethoxysilane, 3-methacryloxypropyltriethoxysilane,
(methacryloxymethyl)dimethylmethoxysilane,
(methacryloxymethyl)methyldimethoxysilane,
(methacryloxymethyl)trimethoxysilane,
(methacryloxymethyl)dimethylethoxysilane,
(methacryloxymethyl)methyldiethoxysilane, methacryloxymethyltriethoxysilane,
methacryloxy-
propyltriisopropoxysilane, 3-methacryloxypropyldimethylsilazane, 3-acryloxy-
propyldimethylchlorosilane, 3-acryloxypropyldichlorosilane, 3-acryloxypropyl-
trichlorosilane,
3-acryloxypropyldimethylmethoxysilane, 3-acryloxy-propylmethyldimethoxysilane,
3-
acryloxypropyltrimethoxysilane, 3-acryloxypropyl-dimethylsilazane, and
combinations thereof
[0221] The ethylenically unsaturated monomer according to the previous
paragraphs can be
any monomer having at least one carbon-carbon double bond. Preferably, the
ethylenically
unsaturated monomer according to the previous paragraphs may be a compound
selected from
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 49 -
the group consisting of aliphatic acrylates, aliphatic methacrylates,
cycloaliphatic acrylates,
cycloaliphatic methacrylates, and combinations thereof. It is to be understood
that each of the
compounds, the aliphatic acrylates, the aliphatic methacrylates, the
cycloaliphatic acrylates, and
the cycloaliphatic methacrylates, include an alkyl radical. The alkyl radicals
of these compounds
can include up to 20 carbon atoms. The aliphatic acrylates that may be
selected as one of the
ethylenically unsaturated monomers are selected from the group consisting of
methyl acrylate,
ethyl acrylate, propyl acrylate, n-butyl acrylate, iso-butyl acrylate, tert-
butyl acrylate, hexyl
acrylate, 2-ethylhexyl acrylate, iso-octyl acrylate, iso-nonyl acrylate, iso-
pentyl acrylate, tridecyl
acrylate, stearyl acrylate, lauryl acrylate, and mixtures thereof. The
aliphatic methacrylates that
may be selected as one of the ethylenically unsaturated monomers are selected
from the group
consisting of methyl methacrylate, ethyl methacrylate, propyl methacrylate, n-
butyl
methacrylate, iso-butyl methacrylate, tert-butyl methacrylate, hexyl
methacrylate, 2-eth-ylhexyl
methacrylate, iso-octyl methacrylate, iso-nonyl methacrylate, iso-pentyl
methacrylate, tridecyl
methacrylate, stearyl methacrylate, lauryl methacrylate, and mixtures thereof.
The cycloaliphatic
acrylate that may be selected as one of the ethylenically unsaturated monomers
is cyclohexyl
acrylate, and the cycloaliphatic methacrylate that may be selected as one of
the ethylenically
unsaturated monomers is cyclohcxyl methacrylate.
[0222] It is to be understood that the ethylenically unsaturated monomer used
for preparing the
silicone acrylic hybrid pressure sensitive adhesive may be more than one
ethylenically
unsaturated monomer. That is, a combination of ethylenically unsaturated
monomers may be
polymerized, more specifically co-polymerized, along with the silicon-
containing pressure
sensitive adhesive composition comprising acrylate or methacrylate
functionality and the
initiator. According to a certain embodiment of the invention, the silicone
acrylic hybrid
pressure-sensitive adhesive is prepared by using at least two different
ethylenically unsaturated
monomers, preferably selected from the group of 2-ethylhexyl acrylate and
methyl acrylate,
more preferably in a ratio of 50% 2-ethylhexyl acrylate and 50% methyl
acrylate, or in a ratio of
60% 2-ethylhexyl acrylate and 40% methyl acrylate as the acrylic monomer.
[0223] The initiator according to the previous paragraphs may be any substance
that is suitable
to initiate the polymerization of the silicon-containing pressure sensitive
adhesive composition
comprising acrylate or methacrylate functionality and the ethylenically
unsaturated monomer to
form the silicone acrylic hybrid. For example, free radical initiators
selected from the group of
peroxides, azo compounds, redox initiators, and photo-initiators may be used.
[0224] Further suitable silicone resins, silicone polymers, silicon-containing
capping agents,
ethylenically unsaturated monomers, and initiators that can be used in
accordance with the
previous paragraphs are detailed in WO 2007/145996, EP 2 599 847 Al, and WO
2016/130408.
[0225] According to a certain embodiment of the invention, the silicone
acrylic hybrid polymer
comprises a reaction product of a silicone polymer, a silicone resin and an
acrylic polymer,
wherein the acrylic polymer is covalently self-crosslinked and covalently
bound to the silicone
polymer and/or the silicone resin.
[0226] According to a certain other embodiment of the invention, the silicone
acrylic hybrid
polymer comprises a reaction product of a silicone polymer, a silicone resin
and an acrylic
polymer, wherein the silicone resin contains triorganosiloxy units R3SiO in
where R is an organic
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 50 -
group, and tetrafunctional siloxy units SiO4/2 in a mole ratio of from 0.1 to
0.9 R3Si01/2 units for
each SiO4/2.
[0227] The acrylic polymer may comprise at least an alkoxysilyl functional
monomer,
polysiloxane-containing monomer, halosilyl functional monomer or alkoxy
halosilyl functional
monomer. Preferably, the acrylic polymer is prepared from alkoxysilyl
functional monomers
selected from the group consisting of trialkoxylsilyl (meth)acrylates,
dialkoxyalkylsilyl
(meth)acrylates, and mixtures thereof; or comprises end-capped alkoxysilyl
functional groups.
The alkoxysilyl functional groups may preferably be selected from the group
consisting of
trimethoxylsilyl groups, dimethoxymethylsilyl groups, triethoxylsilyl,
diethoxymethylsilyl
groups and mixtures thereof.
[0228] The acrylic polymer may also be prepared from a mixture comprising
polysiloxane-
containing monomers, preferably from a mixture comprising polydimethylsiloxane
mono
(meth)acrylate.
[0229] The silyl functional monomers will typically be used in amounts of from
0.2 to 20
weight percent of the acrylic polymer, more preferably the amount of silyl
functional monomers
will range from about 1.5 to about 5 weight percent of the acrylic polymer.
[0230] The polysiloxanc-containing monomer will typically be used in amounts
of from 1.5 to
50 weight percent of the acrylic polymer, more preferably the amount of
polysiloxane-containing
monomers will range from 5 to 15 weight percent of the acrylic polymer.
[0231] Alternatively, the acrylic polymer comprises a block or grafted
copolymer of acrylic
and polysiloxane. An example of a polysiloxane block copolymer is
polydimethylsiloxane-
acrylic block copolymer. The preferred amount of siloxane block is 10 to 50
weight percent of
the whole block polymer.
[0232] The acrylic polymer comprises alkyl (meth)acrylate monomers. Preferred
alkyl
(meth)acrylates which may be used have up to about 18 carbon atoms in the
alkyl group,
preferably from 1 to about 12 carbon atoms in the alkyl group. Preferred low
glass transition
temperature (Tg) alkyl acrylate with a homopolymer Tg of less than about 0 C
have from about
4 to about 10 carbon atoms in the alkyl group and include butyl acrylate, amyl
acrylate, hexyl
acrylate, 2-ethylhexyl acrylate, octyl acrylate, isooctyl acrylate, decyl
acrylate, isomers thereof;
and combinations thereof. Particularly preferred are butyl acrylate, 2-
ethylhexyl acrylate and
isooctyl acrylate. The acrylic polymer components may further comprise
(meth)acrylate
monomers having a high Tg such as methyl acrylate, ethyl acrylate, methyl
methacrylate and
isobutyl methacrylate.
[0233] The acrylic polymer component may further comprise a polyisobutylene
group to
improve cold flow properties of the resultant adhesive.
[0234] The acrylic polymer components may comprise nitrogen-containing polar
monomers.
Examples include N-vinyl pyrrolidone, N-vinyl caprolactam, N-tertiary octyl
acrylamide,
dimethyl acrylamide, diacetone acrylamide, N-tertiary butyl acrylamide, N-
isopropyl
acrylamide, cyanoethylacrylate, N-vinyl acetamide and N-vinyl formamide.
[0235] The acrylic polymer component may comprise one or more hydroxyl
containing
monomers such as 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate,
hydroxypropyl
acrylate and/or hydroxypropyl methacrylate.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
-51 -
[0236] The acrylic polymer components may, if desired, comprise carboxylic
acid containing
monomers. Useful carboxylic acids preferably contain from about 3 to about 6
carbon atoms and
include, among others, acrylic acid, methacrylic acid, itaconic acid, 13-
carboxyethyl acrylate and
the like. Acrylic acid is particularly preferred.
[0237] Other useful, well known co-monomers include vinyl acetate, styrene,
cyclohexyl
acrylate, alkyl di(meth)acrylates, glycidyl methacrylate and allyl glycidyl
ether, as well as
macromers such as, for example, poly(styryl)methacrylate.
[0238] One acrylic polymer component that can be used in the practice of the
invention is an
acrylic polymer that comprises from about 90 to about 99.5 wt% of butyl
acrylate and from
about 0.5 to about 10 wt % dimethoxymethylsilyl methacrylate.
[0239] According to a certain embodiment of the invention the silicone acrylic
hybrid polymer
may be prepared by a) reacting silicone polymer with silicone resin to form a
resultant product,
b) reacting the resultant product of a) with an acrylic polymer containing
reactive functionality,
wherein the components are reacted in an organic solvent.
[0240] According to a certain embodiment of the invention the silicone acrylic
hybrid polymer
may be prepared by a) reacting a silicone resin with an acrylic polymer
containing reactive
functionality to form a resultant product, b) reacting the resultant product
of a) with silicone
polymer, wherein the components are reacted in an organic solvent.
[0241] According to a certain embodiment of the invention the silicone acrylic
hybrid polymer
may be prepared by a) reacting a silicone polymer with an acrylic polymer
containing reactive
functionality to form a resultant product, b) reacting the resultant product
of a) with silicone
resin, wherein the components are reacted in an organic solvent.
[0242] Further suitable acrylic polymers, silicone resins, and silicone
polymers that can be used
for chemically reacting together a silicone polymer, a silicone resin and an
acrylic polymer to
provide a silicone acrylic hybrid polymer in accordance with the previous
paragraphs are
detailed in WO 2010/124187.
ACRYLIC POLYMER (NON-HYBRID)
[0243] As indicated above, the TTS according to the present invention
comprises at least one
polymer in the guanfacine-containing layer. According to the present
invention, the at least one
polymer is selected from the group consisting of acrylic polymers, silicone-
based polymers,
silicone-acrylic hybrid polymers, and mixtures thereof. Thus, in one
embodiment of the present
invention, the TTS according to the present invention comprises an acrylic
polymer in the
guanfacine-containing layer.
[0244] As used herein, the terms acrylic polymer and acrylate polymer are
synonymously used.
Preferably, the acrylic polymers are pressure-sensitive adhesives based on
acrylates. Pressure-
sensitive adhesives based on acrylates may also be referred to as acrylate-
based pressure-
sensitive adhesives, or acrylate pressure-sensitive adhesives.
[0245] Pressure-sensitive adhesives based on acrylates may be provided in the
form of a
solution with a solids content preferably between 30 % and 60 %.
[0246] Acrylate-based pressure-sensitive adhesives may or may not comprise
functional groups
such as hydroxy groups, carboxylic acid groups, neutralized carboxylic acid
groups and mixtures
thereof. Thus, the term "functional groups" in particular refers to hydroxy-
and carboxylic acid
groups, and deprotonated carboxylic acid groups.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 52 -
[0247] Corresponding commercial products are available e.g. from Henkel under
the tradename
Duro Tak . Such acrylate-based pressure-sensitive adhesives are based on
monomers selected
from one or more of acrylic acid, butylacrylate, 2-ethylhexylacrylate,
glycidylmethacrylate, 2-
hydroxyethylacrylate, methylacrylate, methylmethacrylate, butylmethacrylate, t-
octylacrylamide
and vinylacetate, and are provided in ethyl acetate, heptane, n-heptane,
hexane, methanol,
ethanol, isopropanol, 2,4-pentanedione, toluene or xylem or mixtures thereof.
[0248] Specific acrylate-based pressure-sensitive adhesives are available as:
- Duro-TakTm 387-2287 or Duro-TakTm 87-2287 (a copolymer based on vinyl
acetate,
2-ethylhexyl-acrylate, 2-hydroxyethyl-acrylate and glycidyl-methacrylate
provided as a
solution in ethyl acetate without cross-linking agent),
- Duro-TakTm 387-2516 or Duro-TakTm 87-2516 (a copolymer based on vinyl
acetate,
2-ethylhexyl-acrylate, 2-hydroxyethyl-acrylate and glycidyl-methacrylate
provided as a
solution in ethyl acetate, ethanol, n-heptane, and methanol with a titanium
cross-linking
agent),
- Duro-TakTm 387-2051 or Duro-TakTm 87-2051 (a copolymer based on acrylic
acid,
butylacrylate, 2-ethylhexylacrylate and vinyl acetate, provided as a solution
in ethyl acetate
or heptanc without cross-linking agent),
- Duro-Takim 387-2353 or Duro-Takim 87-2353 (a copolymer based on acrylic
acid,
2-ethylhexylacrylate, glycidylmethacrylate and methylacrylate, provided as a
solution in
ethyl acetate and hexane),
- Duro-TakTm 87-4098 (a copolymer based on 2-ethylhexyl-acrylate and vinyl
acetate,
provided as a solution in ethyl acetate).
- Duro-TakTm 387-2287 or Duro-TakTm 87-2054 (a copolymer based on acrylic
acid,
butylacrylate, 2-ethylhexylacrylate and vinyl acetate, provided as a solution
in ethyl acetate
or heptane with cross-linking agent).
[0249] Preferred acrylate-based pressure sensitive adhesives according to the
present invention
are Duro-TakTm 387-2516 or Duro-TakTm 87-2516 (a copolymer based on vinyl
acetate, 2-
ethylhexyl-acrylate, 2-hydroxyethyl-acrylate and glycidyl-methacrylate
provided as a solution in
ethyl acetate, ethanol, n-heptane and methanol with a titanium cross-linking
agent) and Duro-
TakTm 87-4098 (a copolymer based on 2-ethylhexyl-acrylate and vinyl acetate,
provided as a
solution in ethyl acetate).
[0250] Additional polymers may also be added to enhance cohesion and/or
adhesion.
SILICONE-BASED POLYMER (NON HYBRID)
[0251] As indicated above, the TTS according to the present invention
comprises at least one
polymer in the guanfacine-containing layer. According to the present
invention, the at least one
polymer is selected from the group consisting of acrylic polymers, silicone-
based polymers,
silicone-acrylic hybrid polymers, and mixtures thereof. Thus, in one
embodiment of the present
invention, the TTS according to the present invention comprises at least one
silicone-based
polymer in the guanfacine-containing layer, preferably in the guanfacine-
containing matrix layer.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 53 -
[0252] As used herein, the silicone-based polymer is a non-hybrid polymer,
i.e. a polymer,
which does not include a hybrid species. Silicone-based polymers are based on
polysiloxanes.
They may therefore also be referred to as polymers based on polysiloxanes.
Preferably, the
silicone-based polymers are silicone-based pressure sensitive adhesives, i.e.
pressure sensitive
adhesives based on polysiloxanes.
[0253] As the silicone-based polymer is preferably a non-curing polymer, it is
typically
supplied and used in solvents, such as n-heptane and ethyl acetate. The solids
content is usually
between 30 % and 80 %.
[0254] Suitable silicone-based polymers are commercially available under the
brand names
BIO-PSAs (pressure sensitive adhesives based on polysiloxanes).
[0255] Pressure-sensitive adhesives based on polysiloxanes provide for
suitable tack and for
quick bonding to various skin types, including wet skin, suitable adhesive and
cohesive qualities,
long lasting adhesion to the skin, a high degree of flexibility, a
permeability to moisture, and
compatibility to many actives and film-substrates. It is possible to provide
the pressure-sensitive
adhesives based on polysiloxanes with sufficient amine resistance and
therefore enhanced
stability in the presence of amines. Such pressure-sensitive adhesives are
based on a resin-in-
polymer concept wherein, by condensation reaction of silanol end blocked
polydimethylsiloxane
with a silica resin (also referred to as silicate resin), a pressure-sensitive
adhesive based on
polysiloxane is prepared wherein for amine stability the residual silanol
functionality is
additionally capped with trimethylsiloxy groups. The silanol end blocked
polydimethylsiloxane
content contributes to the viscous component of the visco-elastic behavior and
impacts the
wetting and the spreadability properties of the adhesive. The resin acts as a
tackifying and
reinforcing agent and participates in the elastic component. The correct
balance between silanol
end blocked polydimethylsiloxane and resin provides for the correct adhesive
properties.
[0256] In view of the above, silicone-based polymers, and in particular
silicone-based pressure
sensitive adhesives, are generally obtainable by polycondensation of silanol
endblocked
polydimethylsiloxane with a silicate resin. Amine-compatible silicone-based
polymers, and in
particular amine-compatible silicone-based pressure sensitive adhesives, can
be obtained by
reacting the silicone-based polymer, in particular the silicone-based pressure
sensitive adhesive,
with trimethylsilyl (e.g. hexamethyldisilazane) in order to reduce the silanol
content of the
polymer. As a result, the residual silanol functionality is at least partly,
preferably mostly or fully
capped with trimethylsiloxy groups.
[0257] As indicated above, the tackiness of the silicone-based polymer may be
modified by the
resin-to-polymer ratio, i.e. the ratio of the silanol endblocked
polydimethylsiloxane to the silicate
resin, which is preferably in the range of from 70:30 to 50:50, preferably
from 65:35 to 55:45.
The tackiness will be increased with increasing amounts of the
polydimethylsiloxane relative to
the resin. High tack silicone-based polymers preferably have a resin-to-
polymer ratio of 55:45,
medium tack silicone-based polymers preferably have a resin-to-polymer ratio
of 60:40, and low
tack silicone-based polymers preferably have a resin-to-polymer ratio of
65:35. High tack
silicone-based polymers preferably have a complex viscosity at 0.01 rad/s and
30 C of about 5 x
106 Poise, medium tack silicone-based polymers preferably have a complex
viscosity at 0.01
rad/s and 30 C of about 5 x 107 Poise, and low tack silicone-based polymers
preferably have a
complex viscosity at 0.01 rad/s and 30 C of about 5 x 108 Poise. High tack
amine-compatible
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 54 -
silicone-based polymers preferably have a complex viscosity at 0.01 rad/s and
30 C of about 5 x
106 Poise, medium tack amine-compatible silicone-based polymers preferably
have a complex
viscosity at 0.01 rad/s and 30 C of about 5 x 108 Poise, and low tack amine-
compatible silicone-
based polymers preferably have a complex viscosity at 0.01 rad/s and 30 C of
about 5 x 109
Poise.
[0258] Examples of silicone-based PSA compositions which arc commercially
available
include the standard BIO-PSA series (7-4400,7-4500 and 7-4600 series) and the
amine
compatible (endcapped) BIO-PSA series (7-4100, 7-4200 and 7-4300 series)
manufactured and
typically supplied in n-heptane or ethyl acetate by DuPontTM. For example, BIO-
PSA 7-4201 is
characterized by a solution viscosity at 25 C and about 60 % solids content
in heptane of 450
mPa s and a complex viscosity at 0.01 rad/s at 30 C of lx108 Poise. BIO-PSA
7-4301 has a solution viscosity at 25 C and about 60 % solids content in
heptane of 500 mPa s
and a complex viscosity at 0.01 radis at 30 C of 5x106 Poise. BIO-PSA 7-4202
is characterized
by a solution viscosity at 25 C and about 60 % solids content in ethyl
acetate of 800 mPa s and
a complex viscosity at 0.01 rad/s at 30 C of lx108 Poise. BIO-PSA 7-4302 has
a solution
viscosity at 25 C and about 60 % solids content in ethyl acetate of 1200 mPa
s and a complex
viscosity at 0.01 rad/s at 30 C of 5x106 Poisc.
[0259] The pressure-sensitive adhesives based on polysiloxanes are supplied
and used in
solvents like n-heptane, ethyl acetate or other volatile silicone fluids. The
solids content of
pressure-sensitive adhesives based on polysiloxanes in solvents is usually
between 60 and 85 %,
preferably between 70 and 80 % or between 60 and 75 %. The skilled person is
aware that the
solids content may be modified by adding a suitable amount of solvent.
[0260] Pressure-sensitive adhesives based on polysiloxanes, which are, e.g.,
available from
DuPontTM, may be obtained according to the following scheme:
OH
OH 11T HO OH
+NH3
Silanol endblocked PDMS Heat HO
1120 Soluble silcate resin
; 'olycondensation
OH
HO 0 OH
O
H
Such pressure-sensitive adhesives based on polysiloxanes are available from
DuPontTM, e.g.,
under the tradenames FITO-PSA 7-4401, 17110-PSA-7-4501, or FITO-PSA 7-4601,
which are
provided in the solvent n-heptane (indicated by the code "01"), or under the
tradenames BIO-
PSA 7-4402, BIO-PSA 7-4502, and BIO 7-4602, which are provided in the solvent
ethyl acetate
(indicated by the code "02"). Typical solids contents in the solvent are in
the range of from 60 to
75 %. The code "44" indicates a resin-to-polymer ratio of 65:35 resulting in a
low tackiness, the
code "45" indicates a resin-to-polymer ratio of 60:40 resulting in medium
tackiness, the code
"46" indicates a resin-to-polymer ratio of 55:45 resulting in high tackiness.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 55 -
[0261] Amine-compatible pressure-sensitive adhesives based on polysiloxanes,
which are, e.g.,
available from DUPOfltTM may be obtained according to the following scheme:
GU.
OH
+NH3 HO OH
Silanol endblockcal PDMS Heat HO
H .0 Soluble silicate resin
Polycondensation
OH
.......".........,,N.õ."..........0 a........,.."......õ..N......... OH
HO
O = OH......,./Nõ/'
Trimethylsilylar II!
OSi(CH3) 3
(CH3) 3S i0 ....../ ====%,/,'N,../. 0
.,õ,.....,..................õ........,PSi(CH3) 3
CoSCH
O i( 3)3 "`,.....,"
Such amine-compatible pressure-sensitive adhesives based on polysiloxanes are
available from
DuPontTm, e.g., under the tradenames BIO-PSA 7-4101, BIO-PSA-7-4201, or BIO-
PSA 7-4301,
which are provided in the solvent n-heptane (indicated by the code "01"), or
under the
tradenames BIO-PSA 7-4102, BIO-PSA 7-4202, and BIO 7-4302, which are provided
in the
solvent ethyl acetate (indicated by the code "02"). Typical solids contents in
the solvent are in
the range of from 60 to 75 %. The code "41" indicates a resin-to-polymer ratio
of 65:35 resulting
in a low tackiness, the code "42" indicates a resin-to-polymer ratio of 60:40
resulting in medium
tackiness, the code "43" indicates a resin-to-polymer ratio of 55:45 resulting
in high tackiness.
[0262] The preferred pressure-sensitive adhesives based on polysiloxanes in
accordance with
the invention arc characterized by a solution viscosity at 25 C and 60 %
solids content in n-
heptane of more than about 150 mPa s, or from about 200 mPa s to about 700 mPa
s, preferably
as measured using a Brookfield RVT viscometer equipped with a spindle number 5
at 50 rpm.
These may also be characterized by a complex viscosity at 0.01 rad/s at 30 C
of less than about
1 x 109 Poise or from about 1 x 105 to about 9 x 108 Poise.
POLYMER MIXTURES
[0263] The TTS according to the invention, and in particular the guanfacine-
containing layer,
comprises at least one polymer selected from the group consisting of acrylic
polymers, silicone-
based polymers, silicone-acrylic hybrid polymers, and mixtures thereof.
In one embodiment of the present invention, the guanfacine-containing layer
comprises at least
one polymer, wherein the at least one polymer is
- a mixture of an acrylic polymer and at least one silicone-based polymer;
or
- a mixture of two silicone-acrylic hybrid polymers; or
- a mixture of two silicone-based polymers; or
- an acrylic polymer; or
- an acrylic polymer comprising a ¨OH group.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 56 -
[0264] In this connection it is to be understood that the acrylic polymers,
silicone-based
polymers, and silicone-acrylic hybrid polymers are as defined above.
[0265] In one preferred embodiment of the present invention, the at least one
polymer is
present in an amount of from 20% to 99%, preferably from 30% to 97%, most
preferably from
35% to 94% by weight based on the total weight of the guanfacine-containing
layer.
[0266] In a more preferred embodiment of the present invention, the guanfacinc-
containing
layer comprises a mixture of an acrylic polymer and at least one silicone-
based polymer, wherein
the acrylic polymer is present in an amount of from 20 to 55 % and the at
least one silicone-
based polymer is present in an amount of from 20 to 55% by weight, based on
the total weight of
the guanfacine-containing layer.
[0267] In another more preferred embodiment of the present invention, the
guanfacine-
containing layer comprises a mixture of two silicone-acrylic hybrid polymers,
wherein the first
silicone-acrylic hybrid polymer is present in an amount of from 60 to 90 % by
weight, and the
second silicone-acrylic hybrid polymer is present in an amount of from 1 to 20
% by weight, in
each case based on the total weight of guanfacine-containing layer and wherein
preferably the
first silicone-acrylic hybrid polymer and the second silicone-acrylic hybrid
polymer comprise a
silicone phasc and an acrylatc phase in a weight ratio of from 60:40 to 40:60.
[0268] In a further more preferred embodiment of the present invention, the
guanfacine-
containing layer comprises a mixture of two silicone-based polymers, wherein
the first silicone-
based polymer is present in an amount of from 20 to 55 % by weight, and the
second silicone-
based polymer is present in an amount of from 20 to 55 % by weight, based on
the total weight
of the guanfacine-containing layer.
[0269] In an even more preferred embodiment of the present invention, the
guanfacine-
containing layer comprises a mixture of an acrylic polymer, wherein the
acrylic polymer is a
copolymer based on vinyl acetate, 2-ethylhexyl-acrylate, 2-hydroxyethyl-
acrylate and glycidyl-
methacrylate, and at least one silicone-based polymer, wherein the at least
one silicone-based
polymer refers to two silicone-based polymers, wherein the first silicone-
based polymer is BIO-
PSA 7-4202 and the second silicone-based polymer is BIO-PSA 7-4302. In
connection with the
above more preferred embodiment, it is to be understood that the acrylic
polymer is present in an
amount of from 20 to 55 % and the two silicone-based polymers are present in
an overall amount
of from 20 to 55% by weight, based on the total weight of the guanfacine-
containing layer.
Furthermore, in connection with the above preferred embodiment it is to be
understood that the
two silicone-based polymers are preferably present in the guanfacine-
containing layer in a ratio
of 1:1.
[0270] In an even more preferred embodiment of the present invention, the
guanfacine-
containing layer comprises a mixture of an acrylic polymer, wherein the
acrylic polymer is a
copolymer based on 2-ethylhexyl-acrylate and vinyl acetate, and at least one
silicone-based
polymer, wherein the at least one silicone-based polymer refers to two
silicone-based polymers,
wherein the first silicone-based polymer is BIO-PSA 7-4202 and the second
silicone-based
polymer is BIO-PSA 7-4302. In connection with the above more preferred
embodiment, it is to
be understood that the acrylic polymer is present in an amount of from 20 to
55 % and the two
silicone-based polymers are present in an overall amount of from 20 to 55% by
weight, based on
the total weight of the guanfacine-containing layer. Furthermore, in
connection with the above
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 57 -
preferred embodiment it is to be understood that the two silicone-based
polymers are preferably
present in the guanfacine-containing layer in a ratio of 1:1.
[0271] In connection with the above embodiments, it is to be understood that
the amount of the
at least one silicone-based polymer refers to the overall amount of silicone-
based polymers
present in the guanfacine-containing layer based on the total weight of the
guanfacine-containing
layer. In particular, it is to be understood that if it is referred to two
silicone-based polymers, the
two silicone-based polymers are present in an overall amount as defined above.
[0272] In another even more preferred embodiment of the present invention, the
guanfacine-
containing layer comprises a mixture of two silicone-acrylic hybrid polymers,
wherein the first
silicone-acrylic hybrid polymer is preferably a 7-6102 silicone acrylic hybrid
PSA as defined
above and is present in an amount of from 60 to 90 % by weight, and the second
silicone-acrylic
hybrid polymer is preferably a 7-6302 silicone acrylic hybrid PSA as defined
above and is
present in an amount of from 1 to 20 % by weight, in each case based on the
total weight of
guanfacine-containing layer and wherein preferably the first silicone-acrylic
hybrid polymer and
the second silicone-acrylic hybrid polymer comprise a silicone phase and an
acrylate phase in a
weight ratio of from 60:40 to 40:60.
[0273] In a further even more preferred embodiment of the present invention,
the guanfacinc-
containing layer comprises a mixture of two silicone-based polymers, wherein
the first silicone-
based polymer is BIO-PSA 7-4202 and is present in an amount of from 20 to 55 %
by weight,
and the second silicone-based polymer is BIO-PSA 7-4302 and is present in an
amount of from
20 to 55 % by weight, based on the total weight of the guanfacine-containing
layer. In
connection with the above preferred embodiment, it is to be understood that
the two silicone-
based polymers are preferably present in the guanfacine-containing layer in a
ratio of 1:1.
FURTHER ADDITIVES
[0274] The TTS according to the invention, and in particular the guanfacine-
containing layer,
may further comprise at least one additive or excipient. Particularly
preferred additives according
to the invention include dispersing agents, permeation enhancers, and
solubilizers. Details in this
regard are provided above. However, the TTS according to the invention, and in
particular the
guanfacine-containing layer, may also include further additives or excipients.
[0275] In general, additives or excipients are preferably selected from the
group consisting of
dispersing agents, solubilizers, permeation enhancers, film-forming agents,
softeners/plasticizers,
tackifiers, substances for skincare, pH regulators, preservatives, stabilizing
agents, and fillers.
Such additives may be present in the guanfacine-containing layer in an amount
of from 0.001 %
to 15 % by weight, e.g. from 0.5 to 10 % by weight or from 1 to 10 % by weight
or from 0.01 to
6 % by weight, based on the total weight of the guanfacine-containing layer,
and wherein the
weight % amounts refer to a single additive.
[0276] It should be noted that in pharmaceutical formulations, the formulation
components are
categorized according to their physicochemical and physiological properties,
and in accordance
with their function. This means in particular that a substance or a compound
falling into one
category is not excluded from falling into another category of formulation
component. E.g a
certain polymer can be a film-forming agent, but also a tackifier. Some
substances may e.g. be a
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 58 -
typical softener but at the same time act as a permeation enhancer. The
skilled person is able to
determine based on his general knowledge in which category or categories of
formulation
components a certain substance or compound belongs to. In the following,
details on the
excipients and additives are provided which are, however, not to be understood
as being
exclusive. Other substances not explicitly listed in the present description
may be as well used in
accordance with the present invention, and substances and/or compounds
explicitly listed for one
category of formulation component are not excluded from being used as another
formulation
component in the sense of the present invention.
[0277] In one embodiment, the guanfacine-containing layer comprises a
dispersing agent as
defined above, preferably a dispersing agent selected from the group
consisting of esters of fatty
acids with polyols, fatty alcohols, polyethylene glycols having a number
average molecular
weight of from 300 to 400, polyethylene glycol alkyl ethers. As explained
above, the dispersing
agent is preferably polyethylene glycol C8-C20-alkyl ether having from 2 to 10
EO units, in
particular polyoxyethylene (4) lauryl ether. Alternatively or additionally,
silicone polyethers may
be used as dispersing agents. The dispersing agent is helpful in order to
homogeneously disperse
the guanfacine within the guanfacine-containing layer, in particular the
guanfacine-containing
matrix layer, thereby improving the release properties of the TTS.
[0278] In one embodiment, the guanfacine-containing layer comprises a
solubilizer. The
solubilizer preferably improves the dispersibility of the guanfacine in the
guanfacine-containing
layer and stabilizes the guanfacine-containing layer. Furthermore, the
solubilizer may positively
influence cohesion. Preferred solubilizers include, e.g., glycerol-,
polyglycerol-, propylene
glycol- and polyoxyethylene-esters of medium chain and/or long chain fatty
acids, such as
glyceryl monolinoleate, medium chain glycerides and medium chain
triglycerides, non-ionic
solubilizers made by reacting castor oil with ethylene oxide, and any mixtures
thereof which may
further contain fatty acids or fatty alcohols; cellulose and methylcellulose
and derivatives thereof
such as hydroxypropylcellulose and hypromellose acetate succinate; various
cyclodextrins and
derivatives thereof; non-ionic tri-block copolymers having a central
hydrophobic chain of
polyoxypropylene flanked by two hydrophilic chains of polyoxyethylene known as
poloxamers;
water-soluble derivatives of vitamin E; pharmaceutical graded or agglomerated
spherical
isomalt; a polyethylene glycol, polyvinyl acetate and polyvinylcaprolactame-
based graft
copolymer, also abbreviated as PVAc-PVCap- PEG and known as Soluplus8;
vinylpyrrolidone-
vinyl acetate copolymers such as Kollidon VA64; purified grades of naturally
derived castor
oil, of polyethylene glycol 400, of polyoxyethylene sorbitan monooleate (such
as polysorbate 80)
or of propylene glycols; diethylene glycol monoethyl ether; glucono-delta-
lactone; maize and
potato starch; as well as any of the below mentioned soluble
polyvinylpyrrolidones, but also
insoluble / cross-linked polyvinylpyrrolidones such as crospovidones.
[0279] However, also the permeation enhancers mentioned below can act as
solubilizers.
Furthermore, also the film-forming agents described below may act at the same
time as
solubilizers and vice versa.
[0280] In one embodiment, the guanfacine-containing layer comprises a
permeation enhancer.
Preferences in this regard are provided above. Permeation enhancers are
substances, which
influence the barrier properties of the stratum corneum in the sense of
increasing the active agent
permeability. Some examples of permeation enhancers are polyhydric alcohols
such as
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 59 -
dipropylene glycol, propylene glycol, and polyethylene glycol; oils such as
olive oil, squalene,
and lanolin; fatty ethers such as eetyl ether and oleyl ether; fatty acid
esters such as isopropyl
myristate; urea and urea derivatives such as allantoin; polar solvents such as
dimethyldecylphosphoxide, methylcetylsulfoxide, dimethylaurylamine, dodecyl
pyrrolidone,
isosorbitol, dimethylacetonide, dimethylsulfoxide, decylmethylsulfoxide, and
dimethylformamide; salicylic acid; amino acids; benzyl nicotinatc; and highcr
molecular weight
aliphatic surfactants such as lauryl sulfate salts. Other agents include oleic
and linoleic acids,
ascorbic acid, panthenol, butylated hydroxytoluene, tocopherol, tocopheryl
acetate, tocopheryl
linoleate, propyl oleate, and isopropyl palmitate. If the guanfacine-
containing layer comprises a
permeation enhancer, the permeation enhancer is preferably selected from the
group consisting
of diethylene glycol monoethyl ether (transcutol), oleic acid, levulinic acid,
caprylic/capric
triglycerides, diisopropyl adipate, isopropyl myristate, isopropyl palmitate,
lauryl lactate,
triacetin, dimethylpropylene urea, oleyl alcohol, oleoyl macrogo1-6 glycerides
(labrafil MS
1944), and lauroglycol, and is preferably oleyl alcohol, lauroglycol or oleoyl
macrogo1-6
glycerides (labrafil MS 1944).
[0281] In one embodiment, the guanfacine-containing layer further comprises a
film-forming
agent. It is to be understood that the above mentioned solubilizers, such as
Soluplus , may also
act as film-forming agents and control cohesion. Suitable examples of further
film-forming
agents include polyvinylpyrrolidone, vinyl acetate/vinylpyn-olidone copolymers
and cellulose
derivatives, preferably polyvinylpyrrolidone, more preferably soluble
polyvinylpyrrolidone.
[0282] If the guanfacine-containing layer is required to have self-adhesive
properties and one
or more polymers is/are selected, which does/do not provide sufficient self-
adhesive properties, a
tackifier is added. Preferred tackifiers include Miglyol, which is a liquid
wax ester based on
long-chain, unsaturated, even-numbered fatty acids and long-chain,
unsaturated, even-numbered
fatty alcohols of vegetable origin, and polyethylene glycols. In particular,
the tackifier may be
selected from polyvinylpyrrolidone (which, due to its ability to absorb water,
is able to maintain
the adhesive properties of the matrix layer and thus can be regarded as a
tackifier in a broad
sense), triglycerides, polyethylene glycols, dipropylene glycol, resins, resin
esters, terpenes and
derivatives thereof, ethylene vinyl acetate adhesives, dimethylpolysiloxanes
and polybutenes,
preferably polyvinylpyrrolidone and more preferably soluble
polyvinylpyrrolidone. Preferably,
the tackifier may be selected from polyvinylpyrrolidone, triglycerides,
dipropylene glycol,
resins, resin esters, terpenes and derivatives thereof, ethylene vinyl acetate
adhesives,
dimethylpolysiloxanes and polybutenes, preferably polyvinylpyrrolidone and
more preferably
soluble polyvinylpyrrolidone.
[0283] The term "soluble polyvinylpyrrolidone" refers to polyvinylpyrrolidone,
also known as
povidone, which is soluble with more than 10 % in at least ethanol, preferably
also in water,
diethylene glycol, methanol, n-propanol, 2 propanol, n-butanol, chloroform,
methylene chloride,
2-pyrrolidone, macrogol 400, 1,2 propylene glycol, 1,4 butanediol, glycerol,
triethanolamine,
propionic acid and acetic acid. Examples of polyvinylpyrrolidones which are
commercially
available include Kollidon 12 PF, Kollidon 17 PF, Kollidon 25, Kollidon 30
and
Kollidon 90 F supplied by BASF, or povidone K9OF. The different grades of
Kollidon are
defined in terms of the K-Value reflecting the average molecular weight of the
polyvinylpyrrolidone grades. Kollidon 12 PF is characterized by a K-Value
range of 10.2 to
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 60 -
13.8, corresponding to a nominal K-Value of 12. Kollidon 17 PF is
characterized by a K-Value
range of 15.3 to 18.4, corresponding to a nominal K-Value of 17. Kollidon 25
is characterized
by a K-Value range of 22.5 to 27.0, corresponding to a nominal K-Value of 25,
Kollidon 30 is
characterized by a K-Value range of 27.0 to 32.4, corresponding to a nominal K-
Value of 30.
Kollidon 90 F is characterized by a K-Value range of 81.0 to 97.2,
corresponding to a nominal
K-Value of 90. Preferred Kollidon grades arc Kollidon 12 PF, Kollidon 30
and Kollidon
90 F. Within the meaning of this invention, the term "K-Value" refers to a
value calculated from
the relative viscosity of polyvinylpyrrolidone in water according to the
European Pharmacopoeia
(Ph.Eur.) and USP monographs for "Povidone".
[0284] In one embodiment, the guanfacine-containing layer further comprises a
softener/
plasticizer. Exemplary softeners/plasticizers include linear or branched,
saturated or unsaturated
alcohols having 6 to 20 carbon atoms, triglycerides and polyethylene glycols.
[0285] In one embodiment, the guanfacine-containing layer further comprises a
stabilizing
agent. Stabilizing agents include tocopherol and ester derivatives thereof and
ascorbic acid and
ester derivatives thereof. Further stabilizing agents include sodium
metabisulfite, ascorbyl esters
of fatty acids such as ascorbyl palmitate, ascorbic acid, butylated
hydroxytoluene, tocopherol,
tocopheryl acetate and tocophcryl linolcatc.
[0286] In one embodiment, the guanfacine-containing layer further comprises a
pH regulator.
Suitable pH regulators include mild acids and bases including amine
derivatives, inorganic alkali
derivatives, and polymers with basic or acidic functionality.
[0287] In one embodiment, the guanfacine-containing layer further comprises a
preservative.
Suitable preservatives include parabens, formaldehyde releasers,
isothiazolinones, and
phenoxyethanol.
[0288] In one embodiment, the guanfacine-containing layer further comprises a
substance for
skincare. Such substances may be used to avoid or reduce skin irritation as
detectable by the
dermal response score. Suitable substances for skincare include sterol
compounds such as
cholesterol, dexpanthenol, alpha-bisabolol, and antihistamines.
[0289] In one embodiment, the guanfacine-containing layer further comprises a
filler. Fillers
such as silica gels, titanium dioxide and zinc oxide may be used in
conjunction with the polymer
in order to influence certain physical parameters, such as cohesion and bond
strength, in the
desired way.
RELEASE CHARACTERISTICS
[0290] The TTS in accordance with the invention are designed for transdermally
administering
guanfacine to the systemic circulation for a predefined extended period of
time, preferably for at
least 24 hours, more preferably at least 72 hours, in particular for about 84
hours.
[0291] In one embodiment, the TTS according to the invention provides by
transdermal
delivery at steady state a mean plasma concentration of guanfacine of from 1
to 20 ng/ml,
preferably from 1 to 15 ng/ml, more preferably 1 to 10 ng/ml.
[0292] Preferably, the TTS provides therapeutically effective plasma
concentrations of
guanfacine within less than 8 hours, preferably less than 6 hours, more
preferably less than 4
hours after application of the TTS to the skin. Furthermore, the
therapeutically effective plasma
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 61 -
concentrations are preferably maintained over the whole administration period
of at least 24
hours, preferably at least 72 hours, more preferably about 84 hours.
[0293] In one embodiment, the TTS according to the invention provides an
AUC0_241, of 10 to
600 ng*h/ml, preferably of 20 to 400 ng*h/ml. In another embodiment, the TTS
according to the
invention provides an AUC0_72h of 30 to 1800 ng*h/ml, preferably of 60 to 1200
ng*h/ml. In
another embodiment, the TTS according to the invention provides an AUC0_84h of
35 to 2100
ng*h/ml, preferably of 70 to 1400 ng*h/ml. It is to be understood that the AUC
values preferably
refer to the AUC values obtained at steady state.
[0294] In one embodiment, the TTS according to the invention provides a Cmax
to C84 ratio of
less than 3.5. In another embodiment, the TTS according to the invention
provides a Cmax to C22
ratio of less than 3Ø In another embodiment, the TTS according to the
invention provides a Cilia?,
to C24 ratio of less than 2Ø These ratios indicate a flat blood plasma
curve, which is
advantageous in terms of a continuous treatment of the patient.
[0295] In one embodiment, the TTS according to the invention provides a skin
permeation rate
of guanfacine as measured in a Franz diffusion cell with dermatomed human skin
of
0.01 iug/(cm2*h) to 8 g/(cm2*h) in the first 24 hours,
0.05 pg/(cm2*h) to 1011g/(cm2*h) from hour 24 to hour 88.
In another embodiment, the TTS according to the invention provides a skin
permeation rate of
guanfacine as measured in a Franz diffusion cell with dermatomed human skin of
0.01 gg/(cm2*h) to 8 ug/(cm2*h) in the first 24 hours,
0.05 i_rg/(cm2*h) to 8 .g/(em2*h) from hour 24 to hour 88.
[0296] In one embodiment, the TTS according to the invention provides a skin
permeation rate
of guanfacine as measured in a Franz diffusion cell with dermatomed Gottinger
minipig skin of
0.01 fig/(cm2*h) to 8 lag/(cm2*h) in the first 24 hours, 0.05 p.g/(cm2*h) to
10 ug/(cm2*h) from
hour 24 to hour 88.
[0297] In another embodiment, the TTS according to the invention provides a
cumulative
permeated amount of guanfacine as measured in a Franz diffusion cell with
dermatomed
Gottinger minipig skin of 0.01 mg/cm2 to 0.7 mg/cm2, preferably 0.05 mg/cm2 to
0.6 mg/cm2,
more preferably 0.10 mg/cm2 to 0.5 mg/cm2 over a time period of 88 hours.
[0298] In view of the above, the present invention relates in one aspect also
to a transdermal
therapeutic system for the transdermal administration of guanfacine comprising
a guanfacine-
containing layer structure,
wherein the transdermal therapeutic system provides by transdermal delivery
one or more
pharmacokinetic parameter(s) selected from the group consisting of
an AUC0_24 from 10 to 600 (ng / mL) h,
an AUC0_72 from 30 to 1800 (ng / mL) h,
an AUC0_84 from 35 to 2100 (ng / mL) h,
a Cmax to C24 ratio of less than 2.0,
a Cmax to C22 ratio of less than 3.0, and
a Cmax to C84 ratio of less than 3.5.
[0299] In a preferred embodiment, the present invention relates to a
transdermal therapeutic
system for the transdermal administration of guanfacine comprising a
guanfacine-containing
layer structure,
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 62 -
wherein the transdermal therapeutic system provides by transdermal delivery
one or more
pharmacokinetic parameter(s) selected from the group consisting of
an AUC0_24 from 20 to 400 (ng / mL) h,
an AUC0_72 from 60 to 1200 (ng / mL) h,
an AUC0_84 from 70 to 1400 (ng / mL) h,
a C. to C24 ratio of less than 1.5,
a C. to C72 ratio of less than 2.5, and
a C. to C84 ratio of less than 3Ø
[0300] In one particularly preferred embodiment, the present invention relates
to a transdermal
therapeutic system for the transdermal administration of guanfacine comprising
a guanfacine-
containing layer structure, wherein the transdermal therapeutic system
provides by transdermal
delivery an AUC0_84 of from 70 to 1400 (ng / mL) h.
METHOD OF TREATMENT / MEDICAL USE
[0301] In one embodiment of the present invention, the TTS according to the
invention are
suitable for use in a method of treating a human patient, preferably a patient
at the age of from 6
to 17. In particular, the TTS according to the invention are suitable for use
in a method of
treating hypertension or attention deficit hyperactivity disorder (ADHD)
and/or as adjunctive
therapy to stimulant medications in a human patient, preferably in a human
patient at the age of
from 6 to 17.
[0302] In a preferred embodiment in connection with the above medical use, the
TTS is applied
to the skin of the patient for at least 24 hours, preferably at least 72
hours, more preferably about
84 hours.
[0303] In one embodiment, the present invention relates to a method of
treating a human
patient, preferably a human patient at the age of from 6 to 17, by applying a
transdermal
therapeutic system as defined above to the skin of the patient. In particular,
the present invention
relates to a method of treating hypertension or attention deficit
hyperactivity disorder (ADHD) in
a human patient, preferably a human patient at the age of from 6 to 17, by
applying a transdermal
therapeutic system according to the invention to the skin of the patient.
[0304] In a preferred embodiment of the above methods of treatment, the
transdermal
therapeutic system is applied to the skin of the patient for at least 24
hours, preferably at least 72
hours, more preferably about 84 hours.
[0305] In view of the above, the present invention relates in one aspect to a
transdermal
therapeutic system comprising guanfacine and a mono-carboxylic acid for use in
a method of
treating a human patient, preferably a human patient at the age of from 6 to
17, by transdermal
administration of guanfacine, wherein the transdermal therapeutic system is
applied to the skin
of a patient for at least 24 hours, preferably at least 72 hours, more
preferably about 84 hours. In
a preferred embodiment, the transdermal therapeutic system is for use in a
method of treating
hypertension or attention deficit hyperactivity disorder (ADHD) and/or as
adjunctive therapy to
stimulant medications in a human patient. In a more preferred embodiment, the
transdermal
therapeutic system is a transdermal therapeutic system according to the
invention, in particular a
transdermal therapeutic system providing one or more of the pharmacokinetic
parameter(s)
selected from the group consisting of
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 63 -
an AUC0_24 from 10 to 600 (ng / mL) h,
an AUC0_72 from 30 to 1800 (ng / mL) h,
an AUC0_84 from 35 to 2100 (ng / mL) h,
a Cmax to C24 ratio of less than 2.0,
a Cmax to C72 ratio of less than 3.0, and
a Cmax to C84 ratio of less than 3.5;
and preferably selected from the group consisting of
an AUC0_24 from 20 to 400 (ng / mL) h,
an AUC0_72 from 60 to 1200 (ng / mL) h,
an AUC0_84 from 70 to 1400 (ng / mL) h,
a Crnax to C24 ratio of less than 1.5,
a Crnax to C72 ratio of less than 2.5, and
a C to C84 ratio of less than 3Ø
[0306] In connection with the above uses and methods of treatment, the TTS
according to the
invention is preferably applied to at least one body surface on the subject
selected from the upper
outer art, upper chest, upper back or the side of the chest for the defined
dosing intervals.
[0307] The preferred application time of a TTS according to the invention is
at least 24 hours
(1 day), preferably at least 72 hours (3 days), more preferably about 84 hours
(3.5 days). After
this time, the TTS may be removed, and optionally a new TTS may be applied, so
as to allow an
around-the-clock treatment.
PROCESS OF MANUFACTURE
[0308] The invention further relates to a process for manufacturing an active
pharmaceutical-
containing layer, preferably an active pharmaceutical-containing matrix layer
for use in a
transdermal therapeutic system.
[0309] In accordance with the invention, the process for manufacturing an
active
pharmaceutical-containing layer for use in a transdermal therapeutic system
according to the
invention comprises
1) combining at least the components
(i) a pharmaceutically active agent; and
(ii) at least one mono-carboxylic acid;
to obtain a pre-mixture;
2) combining
(i) the pre-mixture of step 1); and
(ii) at least one polymer;
to obtain a coating composition
3) coating the coating composition onto a backing layer or a
release liner to obtain a coated
coating composition; and
4) drying the coated coating composition to form the active
pharmaceutical-containing
layer.
[0310] In one embodiment of the present invention, the pre-mixture according
to step 1) of the
process is obtained by combining (i) and (ii) in a dry-grinding method and/or
in a slurry method.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 64 -
[0311] In one embodiment of the present invention, the slurry method of the
above process
comprises
- weighing in pharmaceutically active agent (i) and the mono-carboxylic
acid (ii) in
equimolar amounts;
- adding a solvent, which is selected from the group consisting of
dichloromethane,
methanol and ethyl acetate;
- stirring the obtained mixture for at least 24 hours, preferably from 24
to 36 hours with a
magnetic stirring bar.
[0312] Thus, the slurry method of step 1) of the process of manufacture
comprises combining
equimolar amounts of the components (i) and (ii) in at least one solvent
selected from the group
consisting of dichloromethane, methanol and ethyl acetate.
[0313] In order to obtain the pre-mixture of the pharmaceutically active agent
and the mono-
carboxylic acid in the slurry method from step 1) the solvent is removed from
the above-obtained
mixture under reduced pressure and the residue is dried for at least 24 hours
under vacuum.
[0314] In step 2) of the above process of manufacture, the pre-mixture
obtained in step 1) is
preferably dispersed in the at least one polymer to obtain a homogenous
coating composition. In
this regard it is to be understood that the pre-mixture obtained in step 1)
can be obtained by the
dry-grinding method and/or by the slurry method.
[0315] It is to be understood that in step 2), also further ingredients,
preferably at least one
additive as defined above, may be added.
[0316] Preferably, a solvent is added in step 2) of the process, and/or a
solvent is present
because the one or more polymer(s) are provided in the form of a solution. The
solvent is
preferably selected from alcoholic solvents, in particular methanol, ethanol,
isopropanol and
mixtures thereof, and from non-alcoholic solvents, in particular ethyl
acetate, hexane, heptane,
petroleum ether, toluene, and mixtures thereof. Preferably, the solvent is
selected from non-
alcoholic solvents and is most preferably ethyl acetate or n-heptane. In a
particularly preferred
embodiment, the solvent is ethyl acetate.
[0317] In a preferred embodiment, the at least on polymer as defined above, in
particular the
mixtures of polymers as defined above, is provided as a solution, wherein the
solvent is ethyl
acetate or n-heptane, and is preferably ethyl acetate.
[0318] In a preferred embodiment, the at least one polymer as defined above,
has a solids
content of from 40 % to 70 % by weight.
[0319] In step 3) of the process the coating composition is applied to a
backing layer or a
release liner. As a result, a coated coating composition, i.e. a coating
composition being coated
on a backing layer or a release liner is obtained.
[0320] After the active-pharmaceutical-containing layer is formed in step 4),
the process may
thus further comprise a step, wherein a release liner or backing layer is
applied to the other side
of the active-pharmaceutical-containing layer.
[0321] In step 4) of the above process of manufacture, drying is performed
preferably at a
temperature of from 20 to 90 C, more preferably from 30 to 70 C.
[0322] In a preferred embodiment of the process of manufacture as defined in
the above
embodiments, the pharmaceutically active agent (i) in the active-
pharmaceutical-containing layer
is guanfacine.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 65 -
[0323] In another preferred embodiment of the process of manufacture as
defined above, the
mono-carboxylic acid (ii) is sorbic acid.
[0324] In connection with the above embodiments of the process of manufacture
it is to be
understood that the at least one polymer, the further additives, and the
active-pharmaceutical-
containing layer, preferably the guanfacine-containing layer are as defined
above with regard to
the TTS.
EXAMPLES
[0325] The present invention will now be more fully described with reference
to the
accompanying examples. It should be understood, however, that the following
description is
illustrative only and should not be taken in any way as a restriction of the
invention. Numerical
values provided in the examples regarding the amount of ingredients in the
composition or the
area weight may vary slightly due to manufacturing variability.
COMPARATIVE EXAMPLE 1A, 1B, 1C AND 111
Coating composition
[0326] The formulations of the guanfacine-containing coating compositions of
comparative
Examples 1A, 1B, 1C and 1C are summarized in Table 1.1 and 1.2 below. The
solids %-values
refer to the amounts (Amt) in % by weight.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 66 -
10327] Table 1.1
Comp. Ex. lA Comp. Ex. 1B
Ingredient (Trade Name) Amt Solids Amt
Solids
Igl [vol [g]
[%]
Guanfacine Base 0.81 6.03
Guanfacine Base / Polyoxyethylene (4) lauryl
1.10 8.11
ether (Brij L4) in a ratio of 1:1
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 45.8 % by weight 23.23 79.17
24.68 83.32
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTM)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 55.3 % by weight 1.01 4.16 1.09
4.44
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTM)
Oleylalcohol 0.54 4.02 0.56
4.13
Polyoxyethylene (4) lauryl ether (Brij L4) 0.53 3.94
Sorbic acid 0.36 2.68
Total 26.48 100.0
27.43 100.0
Area Weight [g/m2] 95
96
Loading API [p.g/cm2] 573
389
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 67 -
[0328] Table 1.2
Comp. Ex. IC Comp. Ex. ID
Ingredient (Trade Name) Amt Solids
Solids
[g] Amt [g]
Guanfacine base 1.63 6.12
Guanfacine base plus sorbic acid (grinded) 1.19
8.82
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 45.8 or 50.5 % by weight 42.84 81.18
23.31 79.17
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTM)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50.3 or 55.3 % by weight 2.32 4.39 1.01
4.15
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTM)
Oleylalcohol 1.11 4.17 0.53
3.93
Polyoxyethylene (4) lauryl ether (Brij L4) 1.11 4.17 0.53
3.93
Total 49.01 100.0
26.57 100.0
Area Weight [g/m2] 95
89
Loading API [i.tg/cm2] 581
541
Preparation of the coating composition
[0329] Drug substance, sorbic acid if present and used enhancers were
dispersed in the solvent
ethyl acetate and optionally ultrasonic treated for approx. 5 min. Then the
adhesives were added.
These two steps can be done also in reverse order. With a dissolver stirrer
the mixture was
homogenized at 2000 rpm for 10 minutes.
[0330] In case of comparative Example 1B a pre-mixture of guanfacine base and
polyoxyethylene (4) lauryl ether (Brij L4) in a ratio of 1:1 was prepared. The
pre-mixture was
prepared according to the dry-grinding method by milling of a mixture of
guanfacine base and
polyoxyethylene (4) lauryl ether with zirconium oxide milling beads (bead size
1 mm, in a
Retsch Mixer Mill MM 500) at 35 Hz for approx. 1.5 hours to achieve a particle
size of approx.
5 um. For preparing the coating composition the pre-mixture was stirred and
the used enhancers
and adhesives were added. With a dissolver stirrer the mixture was homogenized
at 2000 rpm for
approx. 10 minutes.
[0331] In case of comparative Example 1D guanfacine base and sorbic acid in
equimolar
amounts were grinded in a mortar for 15 minutes. For preparing the coating
composition to the
guanfacine base and sorbic acid dry grinded and the used enhancers were
dissolved in the solvent
ethyl acetate and ultrasonic treated for 5 minutes. Then the adhesives were
added. With a
dissolver stirrer the mixture was homogenized at 2000 rpm for 10 minutes.
Coating of the coating composition
[0332] The resulting guanfacine-containing coating composition was coated on a
polyethylene
terephthalate film (Scotchpak 9755, which may function as a release liner)
using for example a
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 68 -
film applicator from the company Erichsen according to the solid content of
the mixture under
consideration of the desired coating dry weight and dried at approx. 50 C for
approx. 10 min.
Depending on the target area weight the corresponding film applicator gap is
between 325 - 350
pm.
[0333] The coating thickness was chosen such that removal of the solution
results in an area
weight of the guanfacinc-containing layer of approx. 95 (Comp. Ex. 1A) g/m2,
96 (Comp. Ex.
1B) g/m2, 95 (Comp. Ex. 1C) g/m2 and 89 (Comp. Ex. 1D) g/m2. The dried film
was then
laminated with a backing layer (PET 15 pm [tsp]) to provide a guanfacine-
containing self-
adhesive layer structure.
Preparation of the TTS (concerning all examples)
[0334] The individual systems (TTS) were then punched out from the guanfacine-
containing
self-adhesive layer structure obtained as described above. Then, the TTS were
sealed into
pouches of the primary packaging material.
Measurement of skin permeation
[0335] The permeated amount of ITS prepared according to comparative Examples
1A-D was
determined in accordance with the OECD Guideline (adopted April 13, 2004)
carried out with a
7.0 mL Franz diffusion cell. Split thickness Goettinger minipig skin (female)
was used. A
dermatome was used to prepare skin to a thickness of 800 p.m, with an intact
epidermis for all
TTS. Diecuts with an area of release of 1.17 cm2 were punched from the TTS.
The guanfacine
permeated amount in the receptor medium of the Franz diffusion cell (0.9%
sodium chloride
solution with 0.1 % sodium azide as antibacteriological agent) at a
temperature of 32 1 C was
measured and the corresponding cumulative permeated amount was calculated.
[0336] The results are shown in Table 1.3 and 1.4 and Figure 1.1, 1.2 and 1.3.
[0337] Table 1.3
Cumulative permeated amount with SD Ittg/cm2]
Comp. Ex. 1A Comp. Ex. 1B Comp. Ex. 1C
Elapsed
(n=3) (n=3) (n=3)
time [h]
Amount SD Amount SD Amount SD
4 0.64 0.38 0.25 0.08 0.17 0.15
8 1.15 0.42 0.90 0.22 0.95 0.49
16 6.37 0.87 5.36 0.82 5.02 1.82
24 19.72 1.77 13.38 1.25 12.42 3.74
32 39.07 2.95 23.06 1.42 21.46 5.5
40 62.67 4.08 33.52 1.54 31.68 6.97
48 86.15 5.00 44.05 1.77 42.3 8.08
56 110.65 5.92 54.74 1.96 52.94 8.98
64 134.24 7.91 65.75 2.42 64.29 9.95
72 156.65 7.14 76.56 2.76 74.89 11.66
88 193.84 6.37 95.78 3.54 95.08 13.08
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 69 -
[0338] Table 1.4
Cumulative permeated amount with
SD [pg/cm2]
Elapsed Comp. Ex. 1D (n=3)
time [h] Amount SD
4 0.87 0.68
8 5.59 3.03
16 24.35 7.97
24 50.57 11.32
32 78.69 13.65
40 106.61 15.51
48 133.06 16.41
56 157.73 15.43
64 180.4 13.88
72 201.69 13.51
88 234.12 12.35
EXAMPLES 1A, 1B, 1C, 1D AND 1E
Coating composition
[0339] The formulations of the guanfacine-containing coating compositions of
Examples 1A,
1B, 1C, 1D and lEare summarized in Table 1.4, Table 1.5 and Table 1.6 below.
The solids %-
values refer to the amounts (Amt) in % by weight.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 70 -
[0340] Table 1.4
Ex. 1A Ex. 1B
Ingredient (Trade Name) Amt Solids Amt
Solids
Igl rid [gl
Guanfacine base / Sorbic acid / Methanol 1.96 8.68 0.98
8.67
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 45.8 % by weight 38.92 78.93
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTM)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 55.3 % by weight 1.77 4.33
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTM)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondcnsed with a silicate resin and reacted
7.82
41.53
with trimethylsily1) in ethyl acetate
Solids content of 60 % by weight (LiVeoTM
BIO-PSA Q7-4302 from DUPofltTM)
Amine-compatible silicone adhesive (silanol
cndblockcd polydimethylsiloxanc
polycondensed with a silicate resin and reacted
7.83
41.65
with trimethylsily1) in ethyl acetate
Solids content of 60.1 % by weight (LiveoTM
BIO-PSA Q7-4202 from DuPontTM)
Olcylalcohol 0.91 4.03 0.46
4.07
Polyoxyethylene (4) lauryl ether (Brij L4) 0.91 4.03 0.46
4.07
Total 44.47 100.0 17.55 100.0
Area Weight [g/m2] 100
94
Loading API [1.1g/cm2] 600
540
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 71 -
[0341] Table 1.5
Ex. IC Ex. ID
Ingredient (Trade Name) Amt Solids Amt
Solids
Igl rid [gl
Guanfacine Base / Sorbic Acid / Methanol 0.92 8.63 0.87
8.60
Acrylate-vinylacetate adhesive in ethyl acetate
Solids content of 38.6 % by weight (DURO- 22.97 83.21 11.83
45.25
TAM) 87-4098)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
3.88
23.07
with trimethylsily1) in ethyl acetate
Solids content of 60 % by weight (LivcoTM
BIO-PSA Q7-4302 from DuPontTM)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
3.87
23.07
with trimethylsily1) in ethyl acetate
Solids content of 60.1 % by weight (LiVCOTM
BIO-PSA Q7-4202 from DuPontTM)
Oleylalcohol 0.42 3.94
Polyoxyethylene (4) lauryl ether (Brij L4) 0.45 4.22
Total 24.76 100.0 20.45 100.0
Area Weight [g/m2] 91
98
Loading API [i.tg/cm2] 542
581
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 72 -
[0342] Table 1.6
Ex. lE
Ingredient (Trade Name) Amt Solids
[g] rid
Guanfacine Base / Sorbic Acid / Methanol 0.98 8.70
Acrylate-vinylacetate adhesive in ethyl acetate
/ ethanol / heptane / methanol
22.32 83.22
Solids content of 42 % by weight (DURO-
TAM) 387-2516)
Oley'alcohol 0.45 3.99
Polyoxyethylene (4) lauryl ether (Brij L4) 0.46 4.08
Total 24.21 100.0
Area Weight [g/m2] 81
Loading API [ps/cm2] 486
Preparation of the coating composition
[0343] A pre-mixture of guanfacine base, sorbic acid and methanol was
prepared. The pre-
mixture was prepared according to the dry-grinding method by milling of a
mixture of
guanfacine base, sorbic acid and methanol as a catalyst with zirconium oxide
milling beads (bead
size 3 mm, in a Rctsch Mixer Mill MM 500) at 35 Hz for approx. 10 minutcs.
Guanfacinc base
and sorbic acid were present in a ratio of 1:1. For preparing the coating
composition the pre-
mixture and the used enhancers were dispersed in the solvent ethyl acetate and
ultrasonic treated
for approx. 5 mm. Then the adhesives were added. These two steps can be done
also in reverse
order. With a dissolver stirrer the mixture was homogenized at 2000 rpm for 10
minutes.
Coating of the coating composition
[0344] The resulting guanfacine-containing coating composition was coated on a
polyethylene
terephthalate film (Scotchpak 9755, which may function as a release liner)
using for example a
film applicator from the company Erichsen according to the solid content of
the mixture under
consideration of the desired coating dry weight and dried at approx. 50 C for
approx. 10 mm.
Depending on the target area weight the corresponding film applicator gap is
between 300 - 400
p.m.
[0345] The coating thickness was chosen such that removal of the solution
results in an area
weight of the guanfacinc-containing layer of approx. 100 (Ex. 1A) g/m2, 94
(Ex. 1B) g/m2, 91
(Ex. 1C) g/m2, 98 (Ex. 1D) g/m2 and 81 (Ex. 1E) g/m2. The dried film was then
laminated with a
backing layer (PET 15 pm [tsp] or MN 19 AB I) to provide a guanfacinc-
containing self-
adhesive layer structure.
Preparation of the TTS
[0346] See comparative Examples 1A-1D.
Measurement of skin permeation
[0347] The permeated amount of TTS prepared according to Examples 1A-E was
determined
in accordance with the OECD Guideline (adopted April 13, 2004) carried out
with a 7.0 mL
Franz diffusion cell. Split thickness Goettinger minipig skin (female) was
used. A dermatome
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 73 -
was used to prepare skin to a thickness of 800 pm, with an intact epidermis
for all TTS. Diecuts
with an area of release of 1.17 cm2 were punched from the TTS. The guanfacine
permeated
amount in the receptor medium of the Franz diffusion cell (0.9 % sodium
chloride solution with
0.1 % sodium azide as antibacteriological agent) at a temperature of 32 1 C
was measured and
the corresponding cumulative permeated amount was calculated.
[0348] The results are shown in Tables 1.7 and 1.8 and Figure 1.3.
[0349] Table 1.7
Cumulative permeated amount with SD bag/cm2]
Elapsed Ex. 1A (n=3) Ex. 1B (n=3)
time [h] Amount SD Amount SD
4 0.2 0.13 0.67 0.55
8 0.83 0.44 2.56 2.24
16 6.08 1.41 11.79 7.71
24 18.24 2.46 29.06 14.43
32 34.96 3.2 51.06 20.74
40 54.22 3.59 75.78 26.22
48 74.24 3.81 100.55 29.75
56 94.13 4.75 123.96 31.35
64 113.8 5.02 145.85 31.83
72 132.41 5.86 163.99 32.16
88 163 6.65 191.64 31.5
[0350] Table 1.8
Cumulative permeated amount with SD 1ug/cm2]
Elapsed Ex. 1C (n=3) Ex. 1D (n=3) Ex. 1E
(n=3)
time [h] Amount SD Amount SD Amount SD
4 0.32 0.52 0 0 0.3 0.49
8 1.62 1.99 0.02 0.02 1.22 1.75
16 7.86 7.5 0.31 0.05 6.24 6.41
24 18.9 15.44 0.99 0.08 17.02 13.11
32 32.92 23.73 2.3 0.3 32.64 19.87
40 49.09 31.86 4.11 0.71 52.73 27.02
48 65.36 38.49 6.7 1.18 74.77 32.89
56 81.15 43.37 9.98 1.55 97.93 37.87
64 96.54 46.86 13.65 2.13 121.53
40.76
72 110.5 48.85 17.51 3.21 145.16
44.41
88 134.41 51.1 26.26 4.93 186.01
45.28
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 74 -
EXAMPLE 2A, 2B, 2C AND COMPARATIVE EXAMPLE 2A AND 2B
Coating composition
[0351] The formulations of the guanfacine-containing coating compositions of
Examples 2A,
2B and 2C and comparative Example 2A and 2B are summarized in Table 2.1, 2.2
and 2.3
below. The solids %-values refer to the amounts (Amt) in % by weight.
[0352] Table 2.1
Ex. 2A
Ex.2B
Ingredient (Trade Name) Amt Solids Amt
Solids
lgl lgl
Guanfacine / Sorbic acid 0.21 8.74
0.20 8.46
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
1.68 41.85
with trimethylsily1) in ethyl acetate
Solids content of 60 % by weight (LiveoTm
BIO-PSA Q7-4302 from DuPontim )
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
1.68 41.92
with trimethylsily1) in ethyl acetate
Solids content of 60.1 % by weight (Liveolm
BIO-PSA Q7-4202 from DuPontTM)
Acrylate-vinylacetate adhesive in ethyl acetate
Solids content of 38.6 % by weight (DURO-
5.06 82.65
TAK 87-4098)
Oleylalcohol 0.09 3.75
0.09 3.81
Polyoxyethylene (4) lauryl ether (Brij L4) 0.09 3.75
0.12 5.08
Total 3.74 100.0
5.47 100.0
Area Weight [g/m2] 137
104
Loading API [gg/cm2] 826
607
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 75 -
[0353] Table 2.2
Ex. 2C
Ingredient (Trade Name) Amt Solids
Igl [%1
Guanfacine / Sorbic acid 0.2 8.60
Acrylate-vinylacetate adhesive in ethyl acetate
Solids content of 38.6 % by weight (DURO- 2.55 42.33
TAM) 87-4098)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
0.8 20.64
with trimethylsily1) in ethyl acetate
Solids content of 60 % by weight (LjVCOTM
BIO-PSA Q7-4302 from DuPontTM)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
0.8 20.68
with trimethylsily1) in ethyl acetate
Solids content of 60.1 % by weight (LiVCOTM
BIO-PSA Q7-4202 from DuPontTM)
Labrafil M1994 0.09 3.87
Polyoxyethylene (4) lauryl ether (Brij L4) 0.09 3.87
Total 4.53 100.0
Area Weight [g/m2] 102
Loading API [1.tg/cm2] 606
[0354] Table 2.3
Comp. Ex. 2A
Comp. Ex. 2B
Ingredient (Trade Name) Amt Solids Amt
Solids
Igl [%] Igl
Guanfacine base 1.63 6.12 4.28
5.88
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50.5 or 45.8 % by weight 42.84 81.18 139.73
87.86
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTM)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50.3 or 55.3 % by weight 2.32 4.39 8.24
6.26
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTM)
Oleylacohol 1.11 4.17
Polyoxyethylene (4) lauryl ether (Brij L4) 1.11 4.17
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 76 -
Total 49.01 100.0 152.25
100.0
Area Weight [g/m2] 95
95
Loading API [i_tg/cm2] 581
559
Preparation of the coating composition
[0355] The guanfacine / sorbic acid pre-mixture was prepared according to the
slurry method,
i.e. according to the following general procedure.
Guanfacine free base and sorbic acid were weighed in in equimolar amounts.
Solvent, e.g. DCM
lmL was added and the mixture was stirred with a magnetic stirring bar at room
temperature for
at least 1 day. The white solid was recovered by filtration under vacuum,
washed with solvent (at
least 4 mL) and dried under vacuum at 40 C for 24 hours. In case of
comparative Example 2 no
pre-mixture was prepared, but the guanfacine was used in the form of the free
base.
[0356] For preparing the coating composition the guanfacine / sorbic acid pre-
mixture or the
guanfacine free base and the used enhancers were dispersed in the solvent
ethyl acetate and
ultrasonic treated for approx. 5 min. Then the adhesives were added. These two
steps can be
done also in reverse order. With a dissolver stirrer the mixture was
homogenized at 2000 rpm for
10 minutes.
[0357] For preparing Comparative Examples 2A and 2B guanfacine free base and
the used
enhancers if present, were dispersed in the solvent ethyl acetate and if
necessary ultrasonic
treated for approx. 5 min. Then the adhesives were added. These two steps can
be done also in
reverse order. With a dissolver stirrer the mixture was homogenized at around
1500 rpm for 15
minutes.
Coating of the coating composition
[0358] The resulting guanfacine-containing coating composition was coated on a
polyethylene
terephthalate film (Scotchpak 9755, which may function as a release liner)
using for example a
film applicator from the company Erichsen according to the solid content of
the mixture under
consideration of the desired coating dry weight and dried at approx. 50 C for
approx. 10 min.
Depending on the target area weight the corresponding film applicator gap is
between 325 - 450
p.m.
[0359] The coating thickness was chosen such that removal of the solution
results in an area
weight of the guanfacine-containing layer of approx. 137 (Ex. 2A) g/m2, 104
(Ex. 2B) g/m2, 102
(Ex. 2C) g/m2, 95 (Comp. Ex. 2A) g/m2, and 95 (Comp. Ex. 2B) g/m2. The dried
film was then
laminated with a backing layer (MN 19 SIL, PET RN15 or PET 15 p.m) to provide
a guanfacine-
containing self-adhesive layer structure.
Preparation of the TTS
[0360] See comparative Examples 1A-1D.
Measurement of skin permeation
[0361] The permeated amount of TTS prepared according to Examples 2A-C and
Comparative
Examples 2A and 2B was determined in accordance with the OECD Guideline
(adopted April
13, 2004) carried out with a 7.0 mL Franz diffusion cell. Split thickness
Gocttingcr minipig skin
(female) was used. A dermatome was used to prepare skin to a thickness of 800
1.1m, with an
intact epidermis for all TTS. Diecuts with an area of release of 1.17 cm2 were
punched from the
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 77 -
TTS. The guanfacine permeated amount in the receptor medium of the Franz
diffusion cell (0.9
% sodium chloride solution with 0.1 % sodium azide as antibacteriological
agent) at a
temperature of 32 1 C was measured and the corresponding cumulative
permeated amount
was calculated.
[0362] The results are shown in Tables 2.4 and 2.5 and Figure 2.
[0363] Table 2.4
Cumulative permeated amount with SD [pg/cm2]
Elapsed Ex. 2A (n=3) Ex. 2B (n=3) Ex. 2C (n=3)
time [h] Amount SD Amount SD Amount SD
4 1.16 0.8 0.78 0.68 0.19 0.05
8 3.52 2.28 2.7 2.34 0.74 0.25
16 11.94 6.8 11.45 7.47 5.01 1.14
24 23.32 10.4 27.64 13.2
32 37.87 16.79 49.26 18.22 31.89 6.04
40 51.81 21.41 73.09 22.44 53.01 7.67
48 64.21 26.28 97.82 25.38 75.75 12.23
56 78.08 30.97 121.73 27.05 99.3 15.73
64 89.93 37.04 145.65 28.54 122.58 22.53
72 101.56 41.05 168.61 29.84 147.39 24.61
88 120.77 46.36 207.8 30.97 194.65 27.42
[0364] Table 2.5
Cumulative permeated amount with SD big/em21
Elapsed Comp. Ex. 2A (n=3) Comp. Ex. 2B
time [h] Amount SD Amount SD
4 0.18 0.12 0.09 0.05
8 0.81 0.58 0.18 0.09
16 4.98 2.31 0.28 0.11
24 12.36 3.73 0.53 0.2
32 21.9 4.39 1.13 0.62
40 32.38 5.24 2.16 1.35
48 43.72 6.71 3.49 2.2
56 54.85 8.19 5.24 3.14
64 66.51 9.21 7.38 4.07
72 77.59 11.23 9.82 5
88 99.51 13.49 15.13 6.42
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 78 -
EXAMPLES 3A, 3B, 3C, 3D, 3E AND COMPARATIVE EXAMPLE 3
Coating composition
[0365] The formulations of the guanfacine-containing coating compositions of
Examples 3A,
3B, 3C, 3D and 3E and comparative Example 3 are summarized in Table 3.1, 3.2,
3.3 and 3.4
below. The solids %-values refer to the amounts (Amt) in % by weight.
[0366] Table 3.1
Ex. 3A Ex.
3B
Ingredient (Trade Name) Amt Solids Amt
Solids
Igi lgl
rid
Guanfacine / Sorbic acid 0.19 8.70 0.19
7.92
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
1.66 45.69
with trimethylsily1) in ethyl acetate
Solids content of 60.1 % by weight (LiveoTM
BIO-PSA Q7-4202 from DuPontim)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
1.66 45.61
with trimethylsily1) in ethyl acetate
Solids content of 60 % by weight (Liveolm
BIO-PSA Q7-4302 from DuPontTM)
Acrylate-vinylacetate adhesive in ethyl acetate
Solids content of 38.6 % by weight (DURO- 5.72
92.08
TAK 87-4098)
Total 3.51 100.0 5.91
100.0
Area Weight [g/m2] 114
87
Loading API [1.1g/cm2] 684
475
[0367] Table 3.2
Ex. 3C Ex.
3D
Ingredient (Trade Name) Amt Solids Amt
Solids
[%1 [gl
rid
Guanfacinc / Sorbic acid 0.2 8.42 0.2
8.68
Acrylate-vinylacetate adhesive in ethyl acetate
/ ethanol / heptane / methanol
5.18 91.58
Solids content of 42 % by weight (DURO-
TAK 387-2516)
Acrylate-vinylacetate adhesive in ethyl acetate
/ heptane / isopropanol
4.43
91.32
Solids content of 47.5 % by weight (DURO-
TAK 2054)
Total 5.38 100.0 4.63
100.0
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 79 -
Area Weight [g/m2] 102
90
Loading API [pg/cm2] 612
540
[0368] Table 3.3
Ex. 3E
Ingredient (Trade Name) Amt Solids
Igl 1%1
Guanfacine / Sorbic acid 0.2 8.58
Acrylate-vinylacetate adhesive in ethyl acetate
Solids content of 38.6 % by weight (DURO- 2.78 46.06
TAK 87-4098)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
0.88 22.66
with trimethylsily1) in ethyl acetate
Solids content of 60.1 % by weight (LiveoTM
BIO-PSA Q7-4202 from DuPontTM)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
0.88 22.70
with trimethylsily1) in ethyl acetate
Solids content of 60 % by weight (LiveoTM
BIO-PSA Q7-4302 from DuPontTM)
Total 4.74 100.0
Area Weight [g/m2] 96
Loading API [p,g/cm2] 568
[0369] Table 3.4
Comp. Ex. 3
Ingredient (Trade Name) Amt Solids
Igl rYol
Guanfacine base 4.28 5.88
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 45.8 % by weight 139.73 87.87
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTM)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 55.3 % by weight 8.24 6.26
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTM)
Total 152.25 100.0
Area Weight [g/m2] 95
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 80 -
Loading API [gg/cm2] 559
Preparation of the coating composition
[0370] The guanfacine / sorbic acid pre-mixture was prepared according to the
slurry method,
i.e. according to the following general procedure.
Guanfacinc free base and sorbic acid were weighed in in cquimolar amounts.
Solvent, e.g. DCM
lmL was added and the mixture was stirred with a magnetic stirring bar at room
temperature for
at least 1 day. The white solid was recovered by filtration under vacuum,
washed with solvent (at
least 4 mL) and dried under vacuum at 40 C for 24 hours. In case of
comparative Example 3 no
pre-mixture was prepared, but the guanfacine was used in the form of the free
base.
[0371] For preparing the coating composition the guanfacine / sorbic acid pre-
mixture or the
guanfacine free base and the adhesives were dispersed in the solvent ethyl
acetate and the
mixture was homogenized with a dissolver stirrer at 2000 rpm for approx.10
minutes. In case of
Ex. 3A and if BIO-PSA 4202 and BIO-PSA 4302 are used together the adhesives
were prior to
mixing with the guanfacine / sorbic acid pre-mixture mixed together and
stirred at 2000 rpm for
approx. 10 min until homogenized.
Coating of the coating composition
[0372] The resulting guanfacinc-containing coating composition was coated on a
polyethylene
terephthalate film (Scotchpak 9755, which may function as a release liner)
using for example a
film applicator from the company Erichsen according to the solid content of
the mixture under
consideration of the desired coating dry weight and dried at approx. 50 C for
approx. 10 mm.
Depending on the target area weight the corresponding film applicator gap is
between 300 - 400
p.m.
[0373] The coating thickness was chosen such that removal of the solution
results in an area
weight of the guanfacine-containing layer of approx. 114 (Ex. 3A) g/m2, 87
(Ex. 3B) g/m2, 102
(Ex. 3C) g/m2, 90 (Ex. 3D) g/m2, 96 (Ex. 3E) g/m2 and 95 (Comp. Ex. 3) g/m2.
The dried film
was then laminated with a backing layer (MN 19 SIL or PET 15 gm) to provide a
guanfacine-
containing self-adhesive layer structure.
Preparation of the TTS
[0374] See comparative Examples 1A-1D.
Measurement of skin permeation
[0375] The permeated amount of TTS prepared according to Examples 3A-E and
Comparative
Example 3 was determined in accordance with the OECD Guideline (adopted April
13, 2004)
carried out with a 7.0 mL Franz diffusion cell. Split thickness Goettinger
minipig skin (female)
was used. A dermatome was used to prepare skin to a thickness of 800 gm, with
an intact
epidermis for all TTS. Diecuts with an area of release of 1.17 cm2 were
punched from the TTS.
The guanfacine permeated amount in the receptor medium of the Franz diffusion
cell (0.9 %
sodium chloride solution with 0.1 % sodium azide as antibacteriological agent)
at a temperature
of 32 1 C was measured and the corresponding cumulative permeated amount
was calculated.
[0376] The results are shown in Tables 3.5 and 3.6 and Figure 3.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 81 -
[0377] Table 3.5
Cumulative permeated amount with SD hug/cm21
Elapsed Ex. 3A (n=3) Ex. 3B
(n=3) Ex. 3C (n=3)
time [h] Amount SD Amount SD Amount SD
4 0.01 0 0.04 0.05 0.08 0.12
8 0.05 0.02 0.2 0.17 0.25 0.35
16 0.12 0.08 0.66 0.45 0.67 0.91
24 0.38 0.19 1.64 0.78 1.48 1.53
32 1 0.36 3.28 1.21 2.93 2.13
40 2.09 0.59 5.55 1.69 5.2 2.62
48 3.79 0.84 8.5 2.25 8.44 3.03
56 5.95 1.08 12.1 2.92 12.45 3.49
64 8.48 1.27 16.1 3.6 17.02 3.52
72 11.44 1.53 20.6 4.36 22.58 3.95
88 16.58 1.65 28.65 5.52 32.32 4.18
[0378] Table 3.6
Cumulative permeated amount with SD [pg/em21
Elapsed Ex. 3D (n=3) Ex. 3E (n=3)
Comp. Ex. 3 (n=3)
time [h] Amount SD Amount SD Amount SD
4 0.02 0.03 0.16 0.24 0.05 0.04
8 0.08 0.08 0.45 0.63 0.13 0.11
16 0.17 0.16 1.13 1.56 0.39 0.38
24 0.32 0.24 2.12 2.76 1.04 1
32 0.47 0.32 3.59 4.26 2.31 1.95
40 0.65 0.37 5.47 5.79 4.23 3.14
48 0.86 0.4 7.77 7.24 6.79 4.42
56 1.07 0.47 10.59 8.81 9.94 5.65
64 1.28 0.52 13.92 10.55 13.55 6.82
72 1.54 0.57 17.93 12.6 17.78 7.96
88 2.05 0.64 25.03 15.66 25.36 9.33
EXAMPLES 4A, 4B, 4C, 4D AND COMPARATIVE EXAMPLE 4
Coating composition
[0379] The formulations of the guanfacine-containing coating compositions of
Examples 4A,
4B, 4C and 4D and Comparative Example 4 are summarized in Table 4.1, 4.2 and
4.3 below.
The solids %-values refer to the amounts (Amt) in % by weight.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 82 -
[0380] Table 4.1
Ex. 4A Ex.
4B
Ingredient (Trade Name) Amt Solids Amt
Solids
1g1 1%1 1g1
1%1
Guanfacine / Sorbic acid 0.2 8.73
0.20 8.97
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50 % by weight 3.62 79.04
3.48 78.03
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTM)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50 % by weight 0.2 4.37
0.18 4.04
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTM)
Labrafil M1944 0.100 3.93
Oleylalcohol
0.091 4.04
Polyoxyethylene (4) lauryl ether (Brij L4) 0.097 3.93
0.11 4.93
Total 4.22 100.0
4.06 100.0
Area Weight [g/m2] 103
93
Loading API [iig/cm2] 620
575
[0381] Table 4.2
Ex. 4C Ex.
4D
Ingredient (Trade Name) Amt Solids Amt
Solids
1g1 1%1 1g1
1%1
Guanfacine / Sorbic acid 0.22 8.66 0.2
8.47
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50 % by weight 4.00 78.74
3.71 78.39
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTm)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50 % by weight 0.22 4.33
0.19 4.24
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTm)
Transcutol
0.10 4.24
Lauroglycol 90 0.11 4.33
Polyoxyethylene (4) lauryl ether (Brij L4) 0.10 3.94
0.11 4.66
Total 4.65 100.0
4.31 100.0
Area Weight [g/m2] 96
100
Loading API [i_tg/cm2] 573
584
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 83 -
[0382] Table 4.3
Comp. Ex. 4
Ingredient (Trade Name) Amt Solids
Igl [%1
Guanfacine base 1.63 6.12
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50.5% by weight 42.84 81.18
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTM)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50.3 % by weight 2.32 4.38
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTM)
Oleylacohol 1.11 4.16
Polyoxyethylene (4) lauryl ether (Brij L4) 1.11 4.16
Total 49.01 100.0
Area Weight [g/m2] 95
Loading API [1.tg/cm2] 581
Preparation of the coating composition
[0383] The guanfacine / sorbic acid pre-mixture was prepared according to the
slurry method,
i.e. according to the following general procedure.
Guanfacine free base and sorbic acid were weighed in in equimolar amounts.
Solvent, e.g. DCM
lmL was added and the mixture was stirred with a magnetic stirring bar at room
temperature for
at least 1 day. The white solid was recovered by filtration under vacuum,
washed with solvent (at
least 4 mL) and dried under vacuum at 40 C for 24 hours. In case of
comparative Example 4 no
pre-mixture was prepared, but the guanfacine was used in the form of the free
base.
[0384] For preparing the coating composition the guanfacine / sorbic acid pre-
mixture or the
guanfacine free base, the used enhancers and the adhesives were dispersed in
the solvent ethyl
acetate and the mixture was homogenized with a dissolver stirrer at 2000 rpm
for approx.] 0
minutes. The adhesives SilAc 6102 and SilAc 6302 when used together were prior
to mixing
with the guanfacine / sorbic acid pre-mixture mixed together and stirred at
2000 rpm for approx.
10 mm until homogenized.
[0385] For Comparative Example 4 the guanfacine free base and the used
enhancers were
dissolved in the solvent ethyl acetate and the adhesives were added. The
mixture was
homogenized with a dissolver stirrer at 2000 rpm for approx.10 minutes.
Coating of the coating composition
[0386] The resulting guanfacine-containing coating composition was coated on a
polyethylene
terephthalate film (Scotchpak 9755, which may function as a release liner)
using for example a
film applicator from the company Erichsen according to the solid content of
the mixture under
consideration of the desired coating dry weight and dried at approx. 50 C for
approx. 10 mm.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 84 -
Depending on the target area weight the corresponding film applicator gap is
between 325 - 350
m.
[0387] The coating thickness was chosen such that removal of the solution
results in an area
weight of the guanfacine-containing layer of approx. 103 (Ex. 4A) g/m2, 93
(Ex. 4B) g/m2, 96
(Ex. 4C) g/m2, 100 (Ex. 4D) g/m2 and 95 (Comp. Ex. 4) g/m2. The dried film was
then laminated
with a backing layer (PET 15 p.m) to provide a guanfacinc-containing self-
adhesive layer
structure.
Preparation of the TTS
[0388] See comparative Examples 1A-1D.
Measurement of skin permeation
[0389] The permeated amount of TTS prepared according to Examples 4A-D and
Comparative
Example 4 was determined in accordance with the OECD Guideline (adopted April
13, 2004)
carried out with a 7.0 mL Franz diffusion cell. Split thickness Goettinger
minipig skin (female)
was used. A dermatome was used to prepare skin to a thickness of 800 p,m, with
an intact
epidermis for all ITS. Diecuts with an area of release of 1.17 cm2 were
punched from the ITS.
The guanfacine permeated amount in the receptor medium of the Franz diffusion
cell (0.9 %
sodium chloride solution with 0.1 % sodium azide as antibacteriological agent)
at a temperature
of 32 + 1 C was measured and the corresponding cumulative permeated amount
was calculated.
[0390] The results are shown in Tables 4.3 and 4.4 and Figure 4.1 and 4.2.
[0391] Table 4.3
Cumulative permeated amount with SD hug/cm2]
Elapsed Ex. 4A (n=3) Ex. 4B (n=3)
time [h] Amount SD Amount SD
4 0.52 0.39 0.74 0.4
8 2.98 1.81 3.38 1.26
16 16.75 7.24 18.65 3.61
24 38.5 12.71 43.91 5.25
32 64.85 17.02 75.78 6.08
40 93.12 19.42 110.99 5.56
48 120.89 20.26 143.5 7.2
56 147.47 20.02 176.85 5.77
64 174 19.27 207.33 6.26
72 199.51 17.86 236.58 4.8
88 242.24 13.78 281.16 9.25
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 85 -
[0392] Table 4.4
Cumulative permeated amount with SD 1 g/cm21
Elapsed Ex. 4C (n=3) Ex. 4D (n=3)
Comp. Ex. 4 (n=2)
time [h] Amount SD Amount SD Amount SD
4 1.01 0.99 -0.11 0.01 0.6
0.47
8 4.51 2.93 -0.05 0.05 2.76
1.35
16 21.47 8.61 0.44 0.21 10.6
2.84
24 47.17 14.17 1.89 0.34 21.35
3.92
32 78.92 19.57 5.09 0.91 34.08
4.82
40 113.46 23.09 8.94 1.63
48.07 5.86
48 147.86 26.13 13.81 2.09
62.74 7.99
56 181.37 28.56 18.69 2.69
77.03 9.71
64 215.46 31.38 24.28 3.35
91.84 11.07
72 247.41 32.92 28.74 2.97
106.28 12.61
88 302.19 33 36.36 2.94 132.5
14.25
COMPARATIVE EXAMPLES 5A, 5B, 5C, 5D, SE AND 5F
Coating composition
[0393] The formulations of the guanfacine-containing coating compositions of
comparative
Examples 5A, 5B, 5C, 5D, 5E and 5F are summarized in Tables 5.1, 5.2, 5.3 and
5.4 below. The
solids %-values refer to the amounts (Amt) in % by weight.
[0394] Table 5.1
Comp. Ex. 5A
Comp. Ex. 5B
Ingredient (Trade Name) Amt Solids Amt
Solids
IgI 1%l [g]
Guanfacine Base / Pimelic acid (dry grinding) 1.11 9.84
1.12 9.93
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
7.70 41.05
with trimethylsily1) in ethyl acetate
Solids content of 60.1 % by weight (LiveoTM
BIO-PSA Q7-4202 from DuPontTM)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
7.70 40.96
with trimethylsily1) in ethyl acetate
Solids content of 60 % by weight (LiveoTM
BIO-PSA Q7-4302 from DuPontTM)
Acrylate-vinylacetate adhesive in ethyl acetate
/ ethanol / heptane / methanol
22.05 82.09
Solids content of 42 % by weight (DURO-
TAK 387-2516)
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 86 -
Oleylalcohol 0.46 4.08 0.45
3.99
Polyoxyethylene (4) lauryl ether (Brij L4) 0.46 4.08 0.45
3.99
Total 17.43 100.0 24.07
100.0
Area Weight [g/m2] 90
96
Loading API [pg/cm2] 537
578
103951 Table 5.2
Comp. Ex. SC
Comp. Ex. SD
Ingredient (Trade Name) Amt Solids Amt
Solids
Egl 1%1
[%1
Guanfacinc Base / Pimelic Acid (dry grinding) 1.05 9.78 0.99
9.86
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
3.79 22.71
with trimethylsily1) in ethyl acetate
Solids content of 60 % by weight (LiveoTM
BIO-PSA Q7-4302 from DuPontTM)
Amine-compatible silicone adhesive (silanol
endblocked polydimethylsiloxane
polycondensed with a silicate resin and reacted
3.77 22.51
with trimethylsily1) in ethyl acetate
Solids content of 60.1 % by weight (LiveoTM
BIO-PSA Q7-4202 from DuPontTM)
Acrylate-vinylacetate adhesive in ethyl acetate
Solids content of 38.6 % by weight (DURO- 22.87 82.22 11.69
44.92
TAK 87-4098)
Oleylalcohol 0.43 4.00
Polyoxyethylene (4) lauryl ether (Brij L4) 0.43 4.00
Total 24.78 100.0 20.24
100.0
Area Weight [g/m2] 112
107
Loading API [p,g/cm2] 664
639
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 87 -
[0396] Table 5.3
Comp. Ex. 5E
Ingredient (Trade Name) Amt Solids
1g1 1%1
Guanfacine Base / Pimelic Acid (dry grinding) 2.23 9.88
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50 % by weight 38.34 77.77
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTM)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50 % by weight 1.7 4.16
(Dow Corning SilAc Hybrid PSA 7-6302
from DuPontTM)
Oleylalcohol 0.91 4.03
Polyoxyethylene (4) lauryl ether (Brij L4) 0.94 4.16
Total 44.12 100.0
Area Weight [g/m2] 99
Loading API [p,g/cm2] 593
[0397] Table 5.4
Comp. Ex. 5F
Ingredient (Trade Name) Amt Solids
1g1 1%1
Guanfacine Base 0.80 5.99
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50 % by weight 22.70 77.85-
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPont'm)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 50% by weight 1.01 4.19
(Dow Coming SilAc Hybrid PSA 7-6302
from DuPontTm)
Pimelic Acid 0.52 3.89
Oleylalcohol 0.53 3.97
Polyoxyethylene (4) lauryl ether (Brij L4) 0.55 4.12
Total 26.11 100.0
Area Weight [g/m2] 104
Loading API [p,g/cm2] 623
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 88 -
Preparation of the coating composition
[0398] A pre-mixture of guanfacine base and pimelic acid was prepared. The pre-
mixture was
prepared according to the grinding method by milling of a mixture of
guanfacine base and
pimelic acid with zirconium oxide milling beads (bead size 3 mm, in a Retsch
Mixer Mill MM
500) at 35 Hz for approx. 10 minutes. Guanfacine base and pimelic acid were
present in a ratio
of 1:1. For preparing the coating composition the pre-mixture and the used
enhancers were
dispersed in the solvent ethyl acetate and ultrasonic treated for approx. 5
mm. Then the adhesives
were added. These two steps can be done also in reverse order. With a
dissolver stirrer the
mixture was homogenized at 2000 rpm for 10 minutes. In case of comparative Ex.
5F no pre-
mixture of guanfacine base and pimelic acid was prepared. Instead, guanfacine
base, pimelic
acid and the used enhancers were weighed in directly for preparing the coating
composition.
Coating of the coating composition
[0399] The resulting guanfacine-containing coating composition was coated on a
polyethylene
terephthalate film (Scotchpak 9755, which may function as a release liner)
using for example a
film applicator from the company Erichsen according to the solid content of
the mixture under
consideration of the desired coating dry weight and dried at approx. 50 C for
approx. 10 min.
Depending on the target area weight the corresponding film applicator gap is
between 300 - 525
pm.
[0400] The coating thickness was chosen such that removal of the solution
results in an area
weight of the guanfacine-containing layer of approx. 90 (Comp. Ex. 5A) g/m2,
96 (Comp. Ex.
5B) g/m2, 112 (Comp. Ex. 5C) g/m2, 107 (Comp. Ex. 5D) g/m2, 99 (Comp. Ex. 5E)
g/m2 and 104
(Comp. Ex. 5F) g/m2. The dried film was then laminated with a backing layer
(PET MN 19 AB 1
or PET 15 pm [tsp]) to provide a guanfacine-containing self-adhesive layer
structure.
Preparation of the TTS
[0401] See comparative Examples 1A-1D.
Measurement of skin permeation
[0402] The permeated amount of TTS prepared according to comparative Examples
5A-F was
determined in accordance with the OECD Guideline (adopted April 13, 2004)
carried out with a
7.0 mL Franz diffusion cell. Split thickness Goettinger minipig skin (female)
was used. A
dermatome was used to prepare skin to a thickness of 800 um, with an intact
epidermis for all
TTS. Diecuts with an area of release of 1.17 cm2 were punched from the TTS.
The guanfacine
permeated amount in the receptor medium of the Franz diffusion cell (0.9 %
sodium chloride
solution with 0.1 % sodium azide as antibacteriological agent) at a
temperature of 32 1 C was
measured and the corresponding cumulative permeated amount was calculated.
[0403] The results are shown in Tables 5.5 and 5.6 and Figure 5.1 and 5.2.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 89 -
[0404] Table 5.5
Cumulative permeated amount with SD hug/cm9
Comp. Ex. 5A Comp. Ex. 5B Comp. Ex. 5C
Elapsed
(n=3) (n=3) (n=3)
tune [h]
Amount SD Amount SD Amount SD
4 0.04 0.07 0.03 0.05 0.02 0.04
8 0.22 0.32 0.21 0.32 0.18 0.32
16 1.25 0.95 1.31 1.13 0.93 1.17
24 3.74 1.83 3.58 2.53 2.85 2.39
32 7.93 2.99 7.26 4.35 5.91 4.07
40 13.69 4.31 12.15 6.26 9.93 6.04
48 20.55 5.53 18.12 7.88 14.83 8.08
56 27.94 6.48 24.64 9.03 20.13 9.9
64 35.75 7.24 31.61 9.72 25.72 11.37
72 44.14 8.31 38.84 10.22 31.78 12.49
88 59.52 10.13 50.82 10.19 42.27
13.25
[0405] Table 5.6
Cumulative permeated amount with SD [jug/cm2]
El d Comp. Ex. 5D Comp. Ex. 5E
Comp. Ex. 5F
apse
time [h] (n=2) (n=2) (n=3)
Amount SD Amount SD Amount SD
4 0 0 0 0 0.13 0.2
8 0.13 0.18 0.09 0.13 0.36 0.28
16 0.5 0.61 1.19 0.57 1.95 0.33
24 0.98 1.1 4.06 0.9 6.36 0.67
32 1.56 1.71 8.96 1.18 14.23 1.41
40 2.24 2.39 15.69 1.27 25.32 1.83
48 3.05 3.2 24.04 1.41 38.32 1.1
56 3.99 4.09 33.29 1.12 51.71 0.66
64 5.04 5.09 43.3 0.73 65.52 2.75
72 6.27 6.18 53.77 0.19 78.38 4.96
88 8.64 8.17 71.76 0.9 99.47 8.8
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 90 -
EXAMPLE 6 AND COMPARATIVE EXAMPLE 6
Coating composition
[0406] The formulations of the guanfacine-containing coating compositions of
Examples and
Comparative Example 6 are summarized in Tables 6.1 below. The solids %-values
refer to the
amounts (Amt) in % by weight.
[0407] Table 6.1
Ex. 6
Comp. Ex. 6
Ingredient (Trade Name) Amt Solids Amt
Solids
lgl 1%1 lgl
1%1
Guanfacine / Sorbic acid 0.84 8.42
Guanfacine / Glutaric acid 0.96
10.23
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 45.8 % by weight 17.36 79.66 15.72
76.76
(Dow Corning SilAc Hybrid PSA 7-6102
from DuPontTm)
Silicone acrylic hybrid pressure sensitive
adhesive in ethyl acetate
Solids content of 55.3 % by weight 0.78 4.31 0.72
4.26
(Dow Corning SilAc Hybrid 7-6302 from
DuPontTM)
Oleylalcohol 0.37 3.71 0.42
4.48
Polyoxyethylene (4) lauryl ether (Brij L4) 0.39 3.91 0.40
4.26
Total 19.74 100.0 18.22
100.0
Area Weight [g/m2] 89
94
Loading API [ps/cm2] 517
578
Preparation of the coating composition
[0408] The guanfacine / sorbic acid pre-mixture of Example 6 and the
guanfacine / glutaric
acid pre-mixture of Comparative Example 6 were prepared according to the
slurry method, i.e.
according to the following general procedure.
Guanfacine free base and the respective acid were weighed in in equimolar
amounts. Solvent,
e.g. DCM lmL or ethyl acetate 2mL was added and the mixture was stirred with a
magnetic
stirring bar at room temperature for at least 1 day. The white solid was
recovered by filtration
under vacuum, washed with solvent (at least 4 mL) and dried under vacuum at 40
C for 24
hours.
[0409] For preparing the coating composition the guanfacine / sorbic acid pre-
mixture or the
guanfacine / glutaric acid pre-mixture, the used enhancers and the adhesives
were dispersed in
the solvent ethyl acetate and the mixture was homogenized with a dissolver
stirrer at 1400 rpm
for approx.15 minutes.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 91 -
Coating of the coating composition
[0410] The resulting guanfacine-containing coating composition was coated on a
polyethylene
terephthalate film (Scotchpak 9755, which may function as a release liner)
using for example a
film applicator from the company Erichsen according to the solid content of
the mixture under
consideration of the desired coating dry weight and dried at approx. 50 C for
approx. 15 min.
Depending on the target area weight the corresponding film applicator gap is
between 275 - 350
gm.
[0411] The coating thickness was chosen such that removal of the solution
results in an area
weight of the guanfacine-containing layer of approx. 89 (Ex. 6) g/m2 and 94
(Comp. Ex. 6) g/m2.
The dried film was then laminated with a backing layer (PET 15 gm [tsp.]) to
provide a
guanfacine-containing self-adhesive layer structure.
Preparation of the TTS
[0412] See comparative Examples 1A-1D.
Measurement of skin permeation
[0413] The permeated amount of TTS prepared according to Example 6 and
Comparative
Example 6 was determined in accordance with the OECD Guideline (adopted April
13, 2004)
carried out with a 7.0 mL Franz diffusion cell. Split thickness Goettinger
minipig skin was used.
A dermatome was used to prepare skin to a thickness of 800 gm, with an intact
epidermis for all
TTS. Diecuts with an area of release of 1.17 cm2 were punched from the TTS.
The guanfacine
permeated amount in the receptor medium of the Franz diffusion cell (0.9 %
sodium chloride
solution with 0.1 % sodium azide as antibacteriological agent) at a
temperature of 32 1 C was
measured and the corresponding cumulative permeated amount was calculated.
[0414] The results are shown in Table 6.1 and Figure 6.
[0415] Table 6.1
Cumulative permeated amount with SD [p.g/cm2]
Elapsed Ex. 6 (n-3) Comp. Ex. 6 (n-3)
time [h] Amount SD Amount SD
4
8
16 19.39 8.35 8.34 4.77
24 39.82 13.72 18.02 6.81
32 58.96 19.97 24.92 7.7
40 82.32 23.81 34.88 9.14
48 106.66 25.49 42.2 10.16
56 127.34 26.35 50.64 11.19
64 149.24 28.53 59.3 12.8
72 170.43 29.3 67.03 14.52
80 188.66 31.54 74.13 16.55
88 206.52 31.06 80.92 18.23
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 92 -
THE INVENTION RELATES IN PARTICULAR TO THE FOLLOWING FURTHER
ITEMS
1. Transdermal therapeutic system for the transdermal
administration of guanfacine
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer comprising guanfacine and a mono-
carboxylic acid.
2. Transdermal therapeutic system according to item 1,
wherein the guanfacine-containing layer is a guanfacine-containing matrix
layer comprising:
i) guanfacine and a mono-carboxylic acid; and
ii) at least one polymer.
3. Transdennal therapeutic system according to item 1 or 2, wherein the
mono-carboxylic
acid is sorbic acid.
4. Transdermal therapeutic system according to any one of items 1 to 3,
wherein the
guanfacine-containing layer structure is self-adhesive and preferably does not
comprise an
additional skin contact layer.
5. Transdermal therapeutic system according to any one of items 1 to 4,
wherein the at least
one polymer is selected from the group consisting of acrylic polymers,
silicone-based polymers,
silicone-acrylic hybrid polymers, and mixtures thereof.
6. Transdermal therapeutic system according to any one of items 1 to 5,
wherein the at least
one polymer is
- a mixture of an acrylic polymer and at least one silicone-based polymer;
or
- a mixture of two silicone-acrylic hybrid polymers; or
- a mixture of two silicone-based polymers; or
- an acrylic polymer; or
- an acrylic polymer comprising a ¨OH group.
7. Transdermal therapeutic system according to any one of items 5 or 6,
wherein the
silicone-based polymer is obtainable by polycondensation of silanol endblocked
polydimethylsiloxane with a silicate resin.
8. Transdermal therapeutic system according to any one of items 5 to 7,
wherein the acrylic
polymer is selected from a copolymer based on vinyl acetate, 2-ethylhexyl-
acrylate, 2-
hydroxyethyl-acrylate and glycidyl-methacrylate and a copolymer based on 2-
ethylhexyl-
acrylate and vinyl acetate.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 93 -
9. Transdermal therapeutic system according to any one of items 5
to 8, wherein the
silicone-acrylic hybrid polymer is a silicone acrylic hybrid pressure-
sensitive adhesive
comprising the reaction product of
(a) a silicone-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality;
(b) an ethylenically unsaturated monomer; and
(c) an initiator.
10. Transdermal therapeutic system according to item 9,
wherein the silicon-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality comprises the condensation reaction product of
(al) a silicone resin, and
(a2) a silicone polymer, and
(a3) a silicon-containing capping agent comprising acrylate or methacrylate
functionality,
wherein said silicon-containing capping agent is of the general formula
XYR'bSiZ34õ wherein X
is a monovalent radical of the general formula AE, where E is ¨0- or ¨NH- and
A is an acryl
group or methacryl group, Y is a divalent alkylene radical having from 1 to 6
carbon atoms, R' is
a methyl or phenyl radical, Z is a monovalent hydrolysable organic radical or
halogen, and b is 0
or 1;
wherein the silicone resin and silicone polymer are reacted to form a pressure-
sensitive adhesive,
wherein the silicon-containing capping agent is introduced prior to, during,
or after the silicone
resin and silicone polymer are reacted,
and wherein the silicon-containing capping agent reacts with the pressure-
sensitive adhesive
after the silicone resin and silicone polymer have been condensation reacted
to form the
pressure-sensitive adhesive, or the silicon-containing capping agent reacts in
situ with the
silicone resin and silicone polymer.
11. Transdermal therapeutic system according to any one of items 9
or 10, wherein the
ethylenically unsaturated monomer is selected from the group consisting of
aliphatic acrylates,
aliphatic methacrylates, cycloaliphatic acrylates, cycloaliphatic
methacrylates, and combinations
thereof, each of said compounds having up to 20 carbon atoms in the alkyl
radical, and wherein
the ethylenically unsaturated monomer is preferably a combination of 2-
ethylhexyl acrylate and
methyl acrylate, particularly preferably in a ratio of from 40:60 to 70:30.
12. Transdermal therapeutic system according to any one of items 9 to 11,
wherein the reaction product of
(b 1) the silicon-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality;
(b2) the ethylenically unsaturated monomer; and
(b3) the initiator
contains a continuous, acrylic external phase and a discontinuous, silicone
internal phase.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 94 -
13. The transdermal therapeutic system according to any one of
items 1 to 12, wherein the
guanfacine-containing layer structure comprises guanfacine in an amount of
from 1 to 100
mg/TTS, preferably from 3 to 72 mg/TTS.
14. Transdermal therapeutic system according to any one of items 1 to 13,
wherein the
guanfacine-containing layer comprises guanfacine in an amount of from 1% to
20%, more
preferably in an amount of from 2% to 16% by weight, based on the total weight
of the
guanfacine-containing layer.
15. Transdermal therapeutic system according to any one of items 1 to 14,
wherein the
guanfacine-containing layer comprises the mono-carboxylic acid in an amount of
from 1% to
20%, more preferably in an amount of from 2% to 16% by weight, based on the
total weight of
the guanfacine-containing layer.
16. Transdermal therapeutic system according to any one of items 1 to 15
comprising
guanfacine and the mono-carboxylic acid in equimolar amounts.
17. Transdermal therapeutic system according to any one of items 1
to 16, wherein the
guanfacine-containing layer comprises the at least one polymer in an amount of
from 20% to
99%, preferably from 30% to 97%, most preferably from 35% to 94% by weight
based on the
total weight of the guanfacine-containing layer.
1g. Transdermal therapeutic system according to any one of items 1
to 17, wherein the
guanfacine-containing layer comprises a mixture of an acrylic polymer and at
least one silicone-
based polymer, wherein the acrylic polymer is present in an amount of from 20
to 55 % and the
at least one silicone-based polymer is present in an amount of from 20 to 55%
by weight, based
on the total weight of the guanfacine-containing layer.
19. Transdermal therapeutic system according to any one of items 1 to 17,
wherein the
guanfacine-containing layer comprises a mixture of two silicone-acrylic hybrid
polymers,
wherein the first silicone-acrylic hybrid polymer is present in an amount of
from 60 to 90 % by
weight, and the second silicone-acrylic hybrid polymer is present in an amount
of from 1 to 20 %
by weight, in each case based on the total weight of guanfacine-containing
layer and wherein
preferably the first silicone-acrylic hybrid polymer and the second silicone-
acrylic hybrid
polymer comprise a silicone phase and an acrylate phase in a weight ratio of
from 60:40 to
40:60.
20. Transdermal therapeutic system according to any one of items 1 to 17,
wherein the
guanfacine-containing layer comprises a mixture of two silicone-based
polymers, wherein the
first silicone-based polymer is present in an amount of from 20 to 55 % by
weight, and the
second silicone-based polymer is present in an amount of from 20 to 55 % by
weight, based on
the total weight of the guanfacine-containing layer.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 95 -
21. Transdermal therapeutic system according to any one of items 1 to 20,
wherein the
guanfacine-containing layer further comprises at least one additive,
preferably at least two
additives selected from the group consisting of dispersing agents, permeation
enhancers and
solubilizers.
22. Transdermal therapeutic system according to item 21, wherein the
dispersing agent is
selected from the group consisting of esters of fatty acids with polyols,
fatty alcohols,
polyethylene glycols having a number average molecular weight of from 300 to
400,
polyethylene glycol alkyl ethers, and wherein the dispersing agent is
preferably polyethylene
glycol C8-C20-alkyl ether having from 2 to 10 EO units.
23. Transdermal therapeutic system according to item 21 or 22, wherein the
permeation
enhancer is selected from the group consisting of diethylene glycol monoethyl
ether (transcutol),
oleic acid, levulinic acid, caprylic/capric triglycerides, diisopropyl
adipate, isopropyl myristate,
isopropyl palmitate, lauryl lactate, triacetin, dimethylpropylene urea, oleyl
alcohol, oleoyl
macrogo1-6 glycerides (labrafil MS 1944), lauroglycol, and wherein the
permeation enhancer is
preferably olcyl alcohol, lauroglycol or olcoyl macrogo1-6 glycerides
(labrafil MS 1944).
24_ Transdermal therapeutic system according to any one of items
21 to 23, wherein the
solubilizer is selected from the group consisting of copolymers derived from
esters of acrylic and
methacrylic acid, polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate
copolymers, and
polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers
and is preferably
a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
25. Transdermal therapeutic system according to any one of items 21 to 24,
wherein the
guanfacine-containing layer comprises two additives selected from dispersing
agents and
permeation enhancers.
26. Transdermal therapeutic system according to any one of items 1 to 25,
wherein the area
weight of the guanfacine-containing layer ranges from 40 to 250 g/m2,
preferably from 50 to 180
g/m2, and/or wherein the area of release ranges from 1 to 100 cm2, preferably
from 2.5 to 50 cm2.
27. Transdermal therapeutic system according to any one of items 1 to 26,
wherein the
guanfacine loading of the transdermal therapeutic system ranges from 0.4 to 2
mg/cm2,
preferably from 0.4 to 0.85 mg/cm2.
28. Transdermal therapeutic system according to any one of items 1 to 27,
wherein the
transdermal therapeutic system provides by transdermal delivery at steady
state a plasma
concentration of guanfacine of from 1 to 20 ng/mL, preferably from 1 to 15
ng/mL.
29. Transdermal therapeutic system according to any one of items 1 to 28,
having an
AUCo_24h of about 10 to 600 ng*h/mL, preferably of about 20 to 400 ng*h/mL;
and/or having an
AUC0_72h of about 30 to 1800 ng*h/mL, preferably of about 60 to 1200 ng*h/mL;
and/or having
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 96 -
an AUC0_84h of about 35 to 2100 ng*h/mL, preferably of about 70 to 1400
ng*h/mL; and/or
having a Cmax to C84 ratio of less than 3.5; and/or having a Cmax to C72 ratio
of less than 3.0;
and/or having a Cam. to C24 ratio of less than 2Ø
30. Transdermal therapeutic system according to any one of items 1 to 29,
providing a skin
permeation rate of guanfacinc as measured in a Franz diffusion cell with
dermatomcd minipig
skin of 0.01 ,g/(cm2*h) to 8 g/(cm2*h) in the first 24 hours,
0.051.1g/(cm2*h) to 10 g/(cm2*h)
from hour 24 to hour 88.
31. Transdermal therapeutic system according to any one of items 1 to 30,
providing a
cumulative permeated amount of guanfacine as measured in a Franz diffusion
cell with
dermatomed minipig skin of 0.01 mg/cm2 to 0.7 mg/cm2, preferably 0.05 mg/cm2
to 0.6 mg/cm2,
more preferably 0.10 mg/cm2 to 0.5 mg/cm2 over a time period of 88 hours.
32. Transdermal therapeutic system according to any one of items 1 to 31
for use in a method
of treating a human patient, preferably a human patient at the age of from 6
to 17.
33. Transdermal therapeutic system according to any one of items 1 to 31
for use in a method
of treating hypertension or attention deficit hyperactivity disorder (ADHD)
and/or as adjunctive
therapy to stimulant medications in a human patient, preferably in a human
patient at the age of
from 6 to 17.
34. Transdermal therapeutic system for use according to item 32 or 33,
wherein the
transdermal therapeutic system is applied to the skin of the patient for at
least 24 hours,
preferably at least 72 hours, more preferably about 84 hours.
35. Transdermal therapeutic system for the transderrnal administration of
guanfacine
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of an acrylic polymer and at least one silicone-based polymer,
wherein the
acrylic polymer is present in an amount of from 20 to 55 % by weight and the
at least one
silicone-based polymer is present in an amount of from 20 to 55 % by weight,
based on
the total weight of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 97 -
36. Transdermal therapeutic system for the transdermal
administration of guanfacine
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
37. Transdermal therapeutic system for the transdermal
administration of guanfacinc
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-based polymers, wherein the first silicone-based
polymer is
present in an amount of from 20 to 55 % by weight, and the second silicone-
based
polymer is present in an amount of from 20 to 55 % by weight, based on the
total weight
of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
38. Transdermal therapeutic system for the transdermal
administration of guanfacine
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer in an amount of from 65 to 95 % by weight, based on the
total
weight of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 98 -
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
39. Transdermal therapeutic system for the transdermal
administration of guanfacine
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer comprising a ¨OH group in an amount of from 65 to 95 %
by
weight, based on the total weight of the guanfacine-containing layer;
iii) at least one dispersing agent in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer; and
iv) at least one permeation enhancer in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer.
40. Transdermal therapeutic system according to item 35,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of an acrylic polymer and at least one silicone-based polymer,
wherein the
acrylic polymer is present in an amount of from 20 to 55 % by weight and the
at least one
silicone-based polymer is present in an amount of from 20 to 55 % by weight,
based on
the total weight of the guanfacine-containing layer;
iii) polyethylene glycol Cs-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
41. Transdermal therapeutic system according to item 36,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 99 -
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
42. Transdermal therapeutic system according to item 37,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) a mixture of two silicone-based polymers, wherein the first silicone-based
polymer is
present in an amount of from 20 to 55 % by weight, and the second silicone-
based
polymer is present in an amount of from 20 to 55 % by weight, based on the
total weight
of the guanfacine-containing layer;
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
43. Transdermal therapeutic system according to item 38,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
ii) an acrylic polymer in an amount of from 65 to 95 % by weight, based on the
total
weight of the guanfacine-containing layer;
iii) polyethylene glycol Cg-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
44. Transdermal therapeutic system according to item 39,
comprising a guanfacine-
containing layer structure, said guanfacine-containing layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine in an amount of from 3 to 16 % by weight and sorbic acid in an
amount of
from 1 to 7.2 % by weight, based on the total weight of the guanfacine-
containing layer;
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 100 -
ii) an acrylic polymer comprising a ¨OH group in an amount of from 65 to 95 %
by
weight, based on the weight of the guanfacine-containing layer;
iii) polyethylene glycol C8-C20-alkyl ether having from 2 to 10 EO units in an
amount of
from 2 to 6 % by weight, based on the total weight of the guanfacine-
containing layer;
and
iv) oley1 alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
45. Process for manufacturing an active pharmaceutical-containing
layer for use in a
transdermal therapeutic system comprising the steps of:
1) combining at least the components
(i) a pharmaceutically active agent; and
(ii) at least one mono-carboxylic acid;
to obtain a pre-mixture;
2) combining
(i) the pre-mixture of step 1); and
(ii) at least one polymer;
to obtain a coating composition
3) coating the coating composition onto a backing layer or a release liner
to obtain a coated
coating composition; and
4) drying the coated coating composition to form the active pharmaceutical-
containing
layer.
46_ The process according to item 45, wherein the pre-mixture
according to step 1) of the
process is obtained by combining (i) and (ii) in a dry-grinding method and/or
in a slurry method.
47. The process according to item 45 or 46, wherein the slurry
method comprises combining
equimolar amounts of the components (i) and (ii) in at least one solvent
selected from the group
consisting of dichloromethane, methanol, and ethyl acetate.
48. The process according to any one of items 45 to 47, wherein
the slurry method further
comprises stirring the solution obtained in step 1) for 24 to 36 hours.
49. The process according to item 48, wherein the solution is
preferably stirred for 24 hours.
50. The process according to any one of items 45 to 49, wherein
the active pharmaceutical-
containing layer is an active pharmaceutical-containing matrix layer
comprising:
i) the pharmaceutically active agent and the mono-carboxylic acid; and
ii) at least one polymer.
51. The process according to any one of items 45 to 50, wherein
the at least one mono-
carboxylic acid is sorbic acid.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 101 -
52. The process according to any one of items 45 to 51, wherein the
pharmaceutically active
agent is guanfacine.
53. The process according to any one of items 45 to 52, wherein the active
pharmaceutical-
containing layer structure is self-adhesive and preferably does not comprise
an additional skin
contact layer.
54. The process according to any one of items 45 to 53, wherein the at
least one polymer is
selected from the group consisting of acrylic polymers, silicone-based
polymers, silicone-acrylic
hybrid polymers, and mixtures thereof.
55. The process according to any one of items 45 to 54, wherein the at
least one polymer is
- a mixture of an acrylic polymer and at least one silicone-based polymer;
or
- a mixture of two silicone-acrylic hybrid polymers; or
- a mixture of two silicone-based polymers; or
- an acrylic polymer; or
- an acrylic polymer comprising a ¨OH group.
56_ The process according to any one of items 45 to 55, wherein
the silicone-based polymer
is obtainable by polycondensation of silanol endblocked polydimethylsiloxane
with a silicate
resin.
57. The process according to any one of items 45 to 56, wherein the acrylic
polymer is
selected from a copolymer based on vinyl acetate, 2-ethylhexyl-acrylate, 2-
hydroxyethyl-acrylate
and glycidyl-methacrylate and a copolymer based on 2-ethylhexyl-acrylate and
vinyl acetate.
58. The process according to any one of items 45 to 57, wherein the
silicone-acrylic hybrid
polymer is a silicone acrylic hybrid pressure-sensitive adhesive comprising
the reaction product
of
(a) a silicone-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality:
(b) an ethylenically unsaturated monomer; and
(c) an initiator.
59. The process according to item 58, wherein the silicon-containing
pressure-sensitive
adhesive composition comprising acrylate or methacrylate functionality
comprises the
condensation reaction product of
(al) a silicone resin, and
(a2) a silicone polymer, and
(a3) a silicon-containing capping agent comprising acrylate or methacrylate
functionality,
wherein said silicon-containing capping agent is of the general formula
XYR'bSiZ3_b, wherein X
is a monovalent radical of the general formula AE, where E is ¨0- or ¨NH- and
A is an acryl
group or methacryl group, Y is a divalent alkylene radical having from 1 to 6
carbon atoms, R' is
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 102 -
a methyl or phenyl radical, Z is a monovalent hydrolysable organic radical or
halogen, and b is 0
or 1;
wherein the silicone resin and silicone polymer are reacted to form a pressure-
sensitive adhesive,
wherein the silicon-containing capping agent is introduced prior to, during,
or after the silicone
resin and silicone polymer are reacted,
and wherein the silicon-containing capping agent reacts with the pressure-
sensitive adhesive
after the silicone resin and silicone polymer have been condensation reacted
to form the
pressure-sensitive adhesive, or the silicon-containing capping agent reacts in
situ with the
silicone resin and silicone polymer.
60. The process according to item 58 or 59, wherein the ethylenically
unsaturated monomer
is selected from the group consisting of aliphatic acrylates, aliphatic
methacrylates,
cycloaliphatic acrylates, cycloaliphatic methacrylates, and combinations
thereof; each of said
compounds having up to 20 carbon atoms in the alkyl radical, and wherein the
ethylenically
unsaturated monomer is preferably a combination of 2-ethylhexyl acrylate and
methyl acrylate,
particularly preferably in a ratio of from 40:60 to 70:30.
61. The process according to any one of items 58 to 60, wherein the
reaction product of
(hi) the silicon-containing pressure-sensitive adhesive composition comprising
acrylate or
methacrylate functionality;
(b2) the ethylenically unsaturated monomer; and
(b3) the initiator
contains a continuous, acrylic external phase and a discontinuous, silicone
internal phase.
62. The process according to any one of items 45 to 61, wherein the active
pharmaceutical-
containing layer structure comprises the pharmaceutically active agent in an
amount of from 1 to
100 mg/TTS, preferably from 3 to 72 mg/TTS.
63. The process according to any one of items 45 to 62, wherein the active
pharmaceutical-
containing layer comprises the pharmaceutically active agent in an amount of
from 1% to 20%,
more preferably in an amount of from 3% to 16% by weight, based on the total
weight of the
active pharmaceutical-containing layer.
64. The process according to any one of items 45 to 63 comprising the
pharmaceutically
active agent and the mono-carboxylic acid in equimolar amounts.
65. The process according to any one of items 45 to 64, wherein the active
pharmaceutical-
containing layer comprises the at least one polymer in an amount of from 20%
to 99%,
preferably from 30% to 97%, most preferably from 35% to 94% by weight based on
the total
weight of the active pharmaceutical-containing layer.
66. The process according to any one of items 45 to 65, wherein the active
pharmaceutical-
containing layer comprises a mixture of an acrylic polymer and at least one
silicone-based
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 103 -
polymer, wherein the acrylic polymer is present in an amount of from 20 to 55
% and the at least
one silicone-based polymer is present in an amount of from 20 to 55% by
weight, based on the
total weight of the active pharmaceutical-containing layer.
67. The process according to any one of items 45 to 65, wherein the active
pharmaceutical-
containing layer comprises a mixture of two silicone-acrylic hybrid polymers,
wherein the first
silicone-acrylic hybrid polymer is present in an amount of from 60 to 90 % by
weight, and the
second silicone-acrylic hybrid polymer is present in an amount of from 1 to 20
% by weight, in
each case based on the total weight of the active pharmaceutical-containing
layer and wherein
preferably the first silicone-acrylic hybrid polymer and the second silicone-
acrylic hybrid
polymer comprise a silicone phase and an acrylate phase in a weight ratio of
from 60:40 to
40:60.
68. The process according to any one of items 45 to 65, wherein
the active pharmaceutical-
containing layer comprises a mixture of two silicone-based polymers, wherein
the first silicone-
based polymer is present in an amount of from 20 to 55 % by weight, and the
second silicone-
based polymer is present in an amount of from 20 to 55 % by weight, based on
the total weight
of the active pharmaceutical-containing layer.
69. The process according to any one of items 45 to 68, wherein the active
pharmaceutical-
containing layer further comprises at least one additive, preferably at least
two additives selected
from the group consisting of dispersing agents, permeation enhancers and
solubilizers.
70_ The process according to item 69, wherein the dispersing agent
is selected from the group
consisting of esters of fatty acids with polyols, fatty alcohols, polyethylene
glycols having a
number average molecular weight of from 300 to 400, polyethylene glycol alkyl
ethers, and
wherein the dispersing agent is preferably polyethylene glycol Cs-C20-alkyl
ether having from 2
to 10 EO units.
71. The process according to item 69 or 70, wherein the permeation enhancer
is selected from
the group consisting of diethylene glycol monoethyl ether (transcutol), oleic
acid, levulinic acid,
caprylic/capric triglycerides, diisopropyl adipate, isopropyl myristate,
isopropyl palmitate, lauryl
lactate, triacetin, dimethylpropylene urea, oleyl alcohol, oleoyl macrogo1-6
glycerides (labrafil
MS 1944), lauroglycol, and wherein the permeation enhancer is preferably oleyl
alcohol,
lauroglycol or oleoyl macrogo1-6 glycerides (labrafil MS 1944).
72. The process according to any one of items 69 to 71, wherein
the solubilizer is selected
from the group consisting of copolymers derived from esters of acrylic and
methacrylic acid,
polyvinylpyrrolidone, vinylpyrrolidone-vinyl acetate copolymers, and polyvinyl
caprolactam-
polyvinyl acetate-polyethylene glycol graft copolymers and is preferably a
polyvinyl
caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 104 -
73. The process according to any one of items 69 to 72, wherein
the active pharmaceutical-
containing layer comprises two additives selected from dispersing agents and
permeation
enhancers.
74. Transdermal therapeutic system obtainable by a process in accordance
with any one of
items 45 to 73.
75. A transdermal therapeutic system for the transdermal
administration of guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) a permeation enhancer selected from oleyl alcohol, lauroglycol and olcoyl
macrogo1-6
glycerides in an amount of from 2 to 6 % by weight, based on the total weight
of the
guanfacine-containing layer.
76. A transdermal therapeutic system for the transdermal administration of
guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
77. A transdermal therapeutic system for the transdermal
administration of guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 105 -
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by wcight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) lauroglycol in an amount of from 2 to 6 % by weight, based on the total
weight of the
guanfacine-containing layer.
78. A transdermal therapeutic system for the transdermal
administration of guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleoyl macrogo1-6 glycerides in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer.
79. A transdermal therapeutic system for the transdermal administration of
guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-based polymers, wherein the first silicone-based
polymer is
present in an amount of from 20 to 55 % by weight, and the second silicone-
based
polymer is present in an amount of from 20 to 55 % by weight, based on the
total weight
of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 106 -
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
80. A transdermal therapeutic system for the transdermal
administration of guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) an acrylic polymer in an amount of from 65 to 95 % by weight, based on the
total
weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
81. A transdermal therapeutic system for the transdermal
administration of guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) an acrylic polymer comprising a ¨0II group in an amount of from 65 to 95 %
by
weight, based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
82. A transdermal therapeutic system for the transdermal
administration of guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of an acrylic polymer and at least one silicone-based polymer,
wherein the
acrylic polymer is present in an amount of from 20 to 55 % by weight and the
at least one
silicone-based polymer is present in an amount of from 20 to 55 % by weight,
based on
the total weight of the guanfacine-containing layer;
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 107 -
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) oleoyl macrogo1-6 glycerides in an amount of from 2 to 6 % by weight,
based on the
total weight of the guanfacine-containing layer.
Further, the present invention relates to the following items.
1. Transdermal therapeutic system for the transdermal
administration of guanfacine
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer comprising guanfacine and a mono-
carboxylic acid.
2. Transdermal therapeutic system according to item 1,
wherein the guanfacine-containing layer is a guanfacine-containing matrix
layer comprising:
i) guanfacine and a mono-carboxylic acid; and
ii) at least one polymer.
3. Transdermal therapeutic system according to item 1 or 2,
wherein the mono-carboxylic
acid is sorbic acid.
4. Transden-nal therapeutic system according to any one of items
1 to 3, wherein the
guanfacine-containing layer structure is self-adhesive and preferably does not
comprise an
additional skin contact layer.
5. Transdermal therapeutic system according to any one of items 1
to 4, wherein the at least
one polymer is selected from the group consisting of acrylic polymers,
silicone-based polymers,
silicone-acrylic hybrid polymers, and mixtures thereof.
6. Transdermal therapeutic system according to any one of items 1 to 5,
wherein the at least
one polymer is
- a mixture of an acrylic polymer and at least one silicone-based polymer;
- a mixture of two silicone-acrylic hybrid polymers; or
- a mixture of two silicone-based polymers; or
- an acrylic polymer; or
- an acrylic polymer comprising a ¨OH group.
7. Transdermal therapeutic system according to any one of items 5 or 6,
wherein the
silicone-based polymer is obtainable by polycondensation of silanol endblocked
polydimethylsiloxane with a silicate resin.
8. Transdermal therapeutic system according to any one of items 5 to 7,
wherein the acrylic
polymer is selected from a copolymer based on vinyl acetate, 2-ethylhexyl-
acrylate, 2-
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 108 -
hydroxyethyl-acrylate and glycidyl-methacrylate and a copolymer based on 2-
ethylhexyl-
acrylate and vinyl acetate.
9. Transdermal therapeutic system according to any one of items 5
to 8, wherein the
silicone-acrylic hybrid polymer is a silicone acrylic hybrid pressure-
sensitive adhesive
comprising the reaction product of
(a) a silicone-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality:
(b) an ethylenically unsaturated monomer; and
(c) an initiator.
10. Transdermal therapeutic system according to item 9,
wherein the silicon-containing pressure-sensitive adhesive composition
comprising acrylate or
methacrylate functionality comprises the condensation reaction product of
(al) a silicone resin, and
(a2) a silicone polymer, and
(a3) a silicon-containing capping agent comprising acrylatc or mcthacrylatc
functionality,
wherein said silicon-containing capping agent is of the general formula
XYR'bSiZ3_b, wherein X
is a monovalent radical of the general formula AE, where E is ¨0- or ¨NH- and
A is an acryl
group or methacryl group, Y is a divalent alkylene radical having from 1 to 6
carbon atoms, R' is
a methyl or phenyl radical, Z is a monovalent hydrolysable organic radical or
halogen, and b is 0
or 1;
wherein the silicone resin and silicone polymer are reacted to form a pressure-
sensitive adhesive,
wherein the silicon-containing capping agent is introduced prior to, during,
or after the silicone
resin and silicone polymer are reacted,
and wherein the silicon-containing capping agent reacts with the pressure-
sensitive adhesive
after the silicone resin and silicone polymer have been condensation reacted
to form the
pressure-sensitive adhesive, or the silicon-containing capping agent reacts in
situ with the
silicone resin and silicone polymer.
11. Transdermal therapeutic system according to any one of item 9
or 10, wherein the
ethylenically unsaturated monomer is selected from the group consisting of
aliphatic acrylates,
aliphatic methacrylates, cycloaliphatic acrylates, cycloaliphatic
methacrylates, and combinations
thereof, each of said compounds having up to 20 carbon atoms in the alkyl
radical, and wherein
the ethylenically unsaturated monomer is preferably a combination of 2-
ethylhexyl acrylate and
methyl acrylate, particularly preferably in a ratio of from 40:60 to 70:30.
12. The transdermal therapeutic system according to any one of
items 1 to 11, wherein the
guanfacine-containing layer structure comprises guanfacine in an amount of
from 1 to 100
mg/TTS, preferably from 3 to 72 mg/TTS.
13. Transdermal therapeutic system according to any one of items 1
to 12, wherein the
guanfacine-containing layer comprises guanfacine in an amount of from 1% to
20%, more
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 109 -
preferably in an amount of from 3% to 16% by weight, based on the total weight
of the
guanfacine-containing layer.
14. Transdermal therapeutic system according to any one of items 1 to 13
comprising
guanfacine and the mono-carboxylic acid in equimolar amounts.
15. Transdermal therapeutic system according to any one of items 1 to 14,
wherein the
guanfacine-containing layer comprises the at least one polymer in an amount of
from 20% to
99%, preferably from 30% to 97%, most preferably from 35% to 94% by weight
based on the
total weight of the guanfacine-containing layer.
16. Transdermal therapeutic system according to any one of items 1 to 15,
wherein the
guanfacine-containing layer further comprises at least one additive,
preferably at least two
additives selected from the group consisting of dispersing agents, permeation
enhancers and
solubilizers.
17. Transdermal therapeutic system according to any one of items 1 to 16,
wherein the arca
weight of the guanfacine-containing layer ranges from 40 to 250 g/m2,
preferably from 50 to 180
g/m2, and/or wherein the area of release ranges from 1 to 100 cm2, preferably
from 2.5 to 50 cm2.
18. Transdermal therapeutic system according to any one of items 1 to 17
for use in a method
of treating a human patient, preferably a human patient at the age of from 6
to 17.
19_ Transdermal therapeutic system according to any one of items 1
to 17 for use in a method
of treating hypertension or attention deficit hyperactivity disorder (ADIID)
and/or as adjunctive
therapy to stimulant medications in a human patient, preferably in a human
patient at the age of
from 6 to 17.
20. Transdermal therapeutic system for use according to item 18 or 19,
wherein the
transdermal therapeutic system is applied to the skin of the patient for at
least 24 hours,
preferably at least 72 hours, more preferably about 84 hours.
21. Process for manufacturing an active pharmaceutical-containing layer for
use in a
transdermal therapeutic system comprising the steps of:
1) combining at least the components
(i) a pharmaceutically active agent; and
(ii) at least one mono-carboxylic acid;
to obtain a pre-mixture;
2) combining
(i) the pre-mixture of step 1); and
(ii) at least one polymer;
to obtain a coating composition
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 110 -
3) coating the coating composition onto a backing layer or a release liner
to obtain a coated
coating composition; and
4) drying the coated coating composition to form the active pharmaceutical-
containing
layer.
22. The proccss according to item 21, wherein the pharmaceutically active
agent is
guanfacine.
23. The process according to item 21 or 22, wherein the pre-mixture
according to step 1) of
the process is obtained by combining (i) and (ii) in a dry-grinding method
and/or in a slurry
method.
24. A transdermal therapeutic system for the transdermal administration of
guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacinc-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) a permeation enhancer selected from oleyl alcohol, lauroglycol and
macrogo1-6
glycerides in an amount of from 2 to 6 % by weight, based on the total weight
of the
guanfacine-containing layer.
25. A transdermal therapeutic system for the transdermal administration of
guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
CA 03226214 2024- 1- 17
WO 2023/031103
PCT/EP2022/073922
- 111 -
iv) oleyl alcohol in an amount of from 2 to 6 % by weight, based on the total
weight of
the guanfacine-containing layer.
26. A transdermal therapeutic system for the transdermal
administration of guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) lauroglycol in an amount of from 2 to 6 % by weight, based on the total
weight of the
guanfacine-containing layer.
27. A transdermal therapeutic system for the transdermal administration of
guanfacine,
comprising a guanfacine-containing layer structure, said guanfacine-containing
layer structure
comprising:
A) a backing layer; and
B) a guanfacine-containing layer, preferably a guanfacine-containing matrix
layer, comprising
i) guanfacine and sorbic acid in an overall amount of from 6 to 9 % by weight,
based on
the total weight of the guanfacine-containing layer;
ii) a mixture of two silicone-acrylic hybrid polymers, wherein the first
silicone-acrylic
hybrid polymer is present in an amount of from 60 to 90 % by weight, and the
second
silicone-acrylic hybrid polymer is present in an amount of from 1 to 20 % by
weight, in
each case based on the total weight of the guanfacine-containing layer;
iii) polyoxyethylene (4) lauryl ether in an amount of from 2 to 6 % by weight,
based on
the total weight of the guanfacine-containing layer; and
iv) macrogo1-6 glycerides in an amount of from 2 to 6 % by weight, based on
the total
weight of the guanfacine-containing layer.
CA 03226214 2024- 1- 17
